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PART I
GENERAL INTRODUCTION 
Kidney transplantation is the best treatment for patients with end-stage renal disease 
(ESRD). Kidney transplant recipients have a superior quality of life and life expectancy 
compared to patients undergoing maintenance dialysis1-3. In 2018, in the Netherlands, 941 
patients received a kidney transplant and a total of 11,405 kidney transplant recipients were 
alive with a functioning allograft4. However, due to an imbalance between donor kidney 
supply and demand, 1,271 patients are currently on the waiting list for a kidney transplant 
in the Netherlands (1-1-2020)5. 
Kidney transplantation is a very successful therapy with reported five-year kidney transplant 
survival rates currently ranging between 91.8% (for deceased donor kidneys) and 95.6% (for 
living donor kidneys)6. The two main causes of kidney transplant loss are death of a patient 
with a functioning allograft and kidney transplant rejection. When the donor is genetically 
different from the recipient, immune cells of the recipient will recognize the donor kidney 
as foreign because of differences in human leucocyte antigens (HLA)7. This will trigger 
a robust immune response directed against the donor kidney, a process called transplant 
rejection. If left untreated, kidney transplant rejection will ultimately destroy the allograft. 
Despite significant advances in the clinical care of kidney transplant recipients, kidney 
transplant rejection complicates a significant proportion of kidney transplantations8,9. Large 
randomized controlled trials report rejection rates between 8 and 16%. However, most of 
these trials included a highly selected patient population with a low risk of rejection10-13. 
The incidence of acute rejection is likely to be higher in the real world. Reports from major 
registries of kidney transplant recipients show rejection rates ranging between 9% (United 
States)8 and 21.4% (Australia/New Zealand)9,14. In the Erasmus MC, the incidence of 
acute rejection in the first three months after transplantation is approximately 30% (Figure 
1). This difference in acute rejection rates may reflect differences in the use of induction 
immunosuppression, criteria for transplantation acceptance of donor and recipient, changes 
in the definition of rejection, and differences in the ethnicity of patients8,15.
13
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Figure 1. The number of kidney transplantations performed annually and percentage of acute rejection in 
Erasmus MC. The number of kidney transplantations is shown in the grey bars. The black line represents 
the percentage of acute rejection in the first three months after kidney transplantation. These acute rejec-
tions are presumed and/or biopsy proven acute rejections.
Kidney transplant rejection
A rejection can either be hyperacute (occurring within hours after transplantation), acute 
(within days to weeks), late acute (after three months) or chronic. Most rejections occur 
within the first weeks after transplantation7. The immune response to an allograft can 
occur via the direct, indirect and semidirect pathway of allorecognition and involves many 
components or the immune system (Figure 2)7,16. 
In the direct pathway, the T cell receptor (TCR) on naive T cells (both CD4+ and CD8+) 
of the recipient recognizes intact HLA molecules on donor-derived antigen presenting cells 
(APCs; Figure 2A). In the indirect pathway, alloantigens are taken up by the recipient’s 
APCs and presented as processed peptides in the context of an intact HLA molecule to 
recipient naive CD4+ T cells (Figure 2B). In the semidirect pathway, fragments of the donor 
cell membrane which contain HLA molecules, are transferred to the membrane of recipient’s 
APCs. This results in presentation of intact donor HLA molecules by recipient APCs (Figure 
2C)7,16. The direct pathway is the most important pathways directly after transplantation, 
while the indirect pathway is the dominant pathway later after transplantation (Figure 
3)16. The exact role and timing of the semidirect pathway after transplantation remains to 
be elucidated16,17.
1
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Figure 3. The occurrence of the direct and indirect pathway of allorecognition after organ transplantation.
The recognition of antigens by T cells in combination with costimulatory signals and 
cytokines promotes T cell proliferation and the generation of diverse subsets of CD4+ 
and CD8+ T cells which infiltrate the allograft18. CD4+ T cells acquire helper function, 
while CD8+ T cells are usually cytotoxic. Activated CD4+ T cells secrete proinflammatory 
cytokines (i.e. interferon-γ) that allow them to provide help for activation of CD8+ cells, B 
cells and various cells of the innate immune system.
Two types of rejection are distinguished: T cell-mediated rejection (TCMR) and antibody-
mediated rejection (ABMR)19. In TCMR, CD4+ T cells help cytotoxic CD8+ T cells to 
release cytotoxic molecules such as perforin and granzyme that cause apoptosis (cell death) 
of allograft cells. In addition, CD4+ effector cells can activate cells of the innate immune 
system (i.e. monocytes, natural killer [NK] cells, and macrophages), that subsequently 
destroy allograft cells. Infiltration of the above-mentioned mononuclear cells into renal 
tubular cells causes tubulitis, while invasion of these cells into arteries is called arteritis 
(Figure 4)7. 
In ABMR, CD4+ T cells help B lymphocytes to differentiate into plasma cells that 
subsequently produce antibodies directed against HLA- and non-HLA antigens expressed 
in the transplant. These alloantibodies will bind to their target antigens and innate 
1
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immune cells (NK cells, neutrophils, and macrophages) interact with the Fc fragments of 
the alloantibodies. This in turn causes degranulation and release of lytic enzymes, which 
subsequently causes injury and cell death of the endothelial cells in the peritubular and 
glomerular capillaries. The microvascular injury may then lead to platelet aggregation and 
the formation of microthrombi in the capillaries (Figure 4)20.
Figure 4. Histology of ABMR and TCMR. Glomerulitis (A), double contours of the glomerular basement 
membrane (B) and peritubular capillaritis (C left panel) and complement 4D positivity in the peritubular 
capillaritis (C, right panel) are features of ABMR. Interstitial inflammation (D), tubulitis (D) and arteritis 
(E) can be seen in biopsies with aTCMR.
After primary antigen exposure, such as after an infection, vaccination, pregnancy, blood 
transfusion or organ transplantation, memory T- and B cells are formed. These cells provide 
long-lasting immunity to previously encountered antigens and upon re-exposure will rapidly 
respond to this same antigen. Memory T- and B cells have a reduced activation threshold 
17
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and are less dependent on costimulation21,22. In case of an infection, memory T- and B-cells 
are extremely helpful in effectively fighting an infection. However, in transplantation 
memory T- and B cells pose a threat to the allograft23. 
Prevention of kidney transplant rejection
To prevent kidney transplant rejection, kidney transplant recipients receive life-
long immunosuppressive therapy. This treatment can be divided into induction and 
maintenance immunosuppressive therapy. Induction therapy is administered around the 
time of transplant surgery. Because patients are at a high risk of acute rejection in the first 
months after transplantation (when direct and semidirect allorecognition are in effect) 
they require extra immunosuppression. Induction therapy generally consists of high-dose 
glucocorticoids in combination with biologicals (an interleukin [IL]-2 receptor antagonist 
[basiliximab], rabbit anti-thymocyte globulin [rATG] or alemtuzumab)24. Maintenance 
immunosuppressants are started at the time of transplantation and must be continued life-
long. The typical maintenance immunosuppressive regimen includes glucocorticoids plus 
a calcineurin inhibitor (CNI; i.e. tacrolimus and ciclosporin), an antiproliferative agents 
(mycophenolic acid [MPA] or azathioprine), or a mammalian target of rapamycin (mTOR) 
inhibitor10,24. 
After the clinical introduction of CNIs in the 1980s (ciclosporin) and mid-1990’s 
(tacrolimus), short-term kidney transplant outcomes improved dramatically, mainly as a 
result of a marked reduction in the incidence of acute rejection (Figure 1)6. In contrast, the 
long-term kidney transplant survival has only improved to a limited degree25. One of the 
factors that negatively influences the long-term allograft- and patient outcome is the toxicity 
of CNIs, which includes nephrotoxicity and metabolic side effects (post-transplant diabetes 
mellitus, hypertension, dyslipidemia). Furthermore, many kidney transplant recipients 
experience other side effects, like neurotoxicity (i.e. tremors and peripheral polyneuropathy), 
(opportunistic) infections, and malignancies13,26,27. Therefore, numerous strategies to 
eliminate or reduce the exposure to CNIs have been investigated over the last 25 years. 
These include more precise dosing of CNI by means of therapeutic drug monitoring and 
CNI-sparing strategies (minimization, withdrawal, conversion or avoidance). Alternative 
immunosuppressive drugs have been tested in CNI conversion or avoidance regimens, 
for instance mTOR inhibitors (everolimus and sirolimus), costimulation blockade drugs 
(i.e. belatacept), protein kinase C inhibitor (sotrastaurin), and Janus kinase (JAK)1/JAK3 
inhibitor (tofacitinib). Because these drugs either had a lower efficacy (increased incidence of 
acute rejection as compared with CNI-based therapy) and/or serious sides effects (infections, 
1
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malignancy and toxicity), the standard of care immunosuppressive regimen still includes 
CNIs in 93% of kidney transplant recipients8,10,28-33.
Belatacept, a fusion protein composed of a crystallizable fragment of immunoglobulin 
G1 and the extracellular domain of Cytotoxic T Lymphocyte Antigen (CTLA)-4, is an 
immunosuppressive drug that selectively targets the CD28-CD80/CD86 costimulatory 
pathway34. It is the only costimulation blockade drug that is currently approved for the 
prevention of kidney transplant rejection35. Further information regarding the use of 
belatacept in kidney transplantation is provided in Chapter 2 of this introduction. 
Diagnosis of kidney transplant rejection
Early detection of rejection is important to prevent allograft damage. Most patients 
with rejection of their transplant are asymptomatic and therefore clinical monitoring of 
allograft function is necessary. Clinical monitoring is currently based on the measurement 
of creatinine and urea in the blood (serum) and quantification of urinary protein 
excretion. However, these biomarkers are suboptimal as they are not specific for transplant 
rejection. Serum creatinine concentration may increase as a results of a number of clinical 
conditions, including urinary tract infections, hydronephrosis, drug toxicity or recurrence 
of primary kidney disease. Therefore, in case of an unexplained rise in the serum creatinine 
concentration, a rejection must be excluded. The gold standard to diagnose rejection is 
the histopathologic evaluation of a core needle biopsy from the allograft (Figure 4). The 
Banff classification is an international, standardized, histopathology-based classification 
that provides guidance for the diagnosis of transplant rejection19. Two main categories of 
rejection are described in the most recent Banff guideline: 1) Antibody-mediated changes 
(active ABMR [aABMR], chronic active ABMR [c-aABMR]); and 2) Borderline changes 
suspicious for acute TCMR (b-aTCMR), TCMR (acute [aTCMR] and chronic-active 
TCMR [c-aTMCR])19. 
A considerable number of transplant centers worldwide perform kidney transplant biopsies 
at predetermined time points after kidney transplantation. These so-called surveillance 
or protocol biopsies help to monitor the health of the allograft and identify subclinical 
rejection. The latter is the unexpected finding of a rejection in a clinically stable patient.
According to the Banff classification, the diagnosis of aABMR encompasses the histologic 
evidence of acute tissue injury (microvascular inflammation, intimal or transmural arteritis, 
acute thrombotic microangiopathy and/or acute tubular injury) and recent antibody 
19
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interaction with vascular endothelium (as evidenced by linear complement 4d [C4d] 
staining in peritubular capillaries, microvascular inflammation and/or increased intragraft 
expression of genes associated with ABMR; Figure 4). In addition, donor-specific anti-HLA 
(DSA) and non-HLA antibodies should be analyzed in the recipient’s blood19. Evidence of 
chronic tissue injury (transplant glomerulopathy, multilayering of the peritubular capillary 
basement membrane or arterial intimal fibrosis) in combination with the afore-mentioned 
criteria for aABMR is diagnostic for c-aABMR19. 
Three grades of aTCMR are defined according to the Banff classification and this depends 
on the presence and severity of interstitial inflammation, tubulitis and/or arteritis19. 
Borderline changes suspicious for aTCMR are denoted by mild interstitial inflammation 
and tubulitis in transplant biopsies (Figure 4)19. c-aTCMR is diagnosed when inflammation 
is present in areas with interstitial fibrosis and tubular atrophy (i-IF/TA) in combination 
with moderate or severe tubulitis19. 
Although histologic examination of kidney tissue is the gold standard for the diagnosis of 
kidney transplant rejection, a kidney biopsy has its limitations. It is an invasive procedure 
with a risk for significant complications, such as bleeding. Furthermore, a biopsy is not 
always possible in patients with uncontrolled hypertension or a bleeding diathesis36. 
Therefore, there is an unmet need for an alternative, non- or minimally-invasive biomarker 
with a high sensitivity and specificity to detect kidney transplant rejection. Biomarkers may 
provide early detection of rejection, (i.e. detection at an early stage), preferentially before 
irreversible damage develops. It is vital that the assay is fast (short turnaround time) and 
inexpensive. Examples of material that can be used for the detection of minimally-invasive 
biomarkers are blood and urine. Various biomarkers are currently under investigation, and 
these include the analysis of messenger ribosomal nucleic acid (mRNA; transcriptomics), 
proteins (proteomics), and small deoxyribonucleic acid (DNA) fragments outside the donor 
cells (donor-derived cell free DNA)37,38. 
Two other limitations of a kidney biopsy are sampling error and limited reproducibility 
due to interobserver variation between (nephro)pathologists39,40. It is suggested in the Banff 
2017 report that the application of gene expression analysis of a kidney transplant biopsy 
combined with the histopathologic evaluation by a pathologist, may improve diagnostic 
classification and prognosis19. The report offers a list of genes, many associated with ABMR 
and TCMR19. Several platforms can be used to analyze the intragraft gene expression, 
1
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such as real-time polymerase chain reaction, microarray and direct digital quantification 
analysis41-44.
Treatment of acute kidney transplant rejection
Treatment of kidney transplant rejection is essential to prevent transplant failure45. The type 
(TCMR versus ABMR and acute versus chronic) and severity (tubulointerstitial rejection 
[aTMCR grade I] versus vascular rejection [aTMCR grade II and III]) of rejection determine 
the type of therapy19,46. 
The optimal treatment regimen for aABMR remains to be determined24. The empirical 
treatment of aABMR includes the augmentation of baseline immunosuppression in 
combination with removal and the suppression of the production of DSA with high-
dose intravenous glucocorticoids, intravenous immunoglobulins, plasma-exchange, and/
or lymphocyte-depleting antibodies24,47,48. No approved therapies are registered for the 
treatment of c-aABMR. Various combinations of immunomodulatory therapies are 
described in the literature, including high-dose intravenous glucocorticoids, intravenous 
immunoglobulins, plasma-exchange, rituximab (an anti-CD20 antibody), lymphocyte-
depleting drugs, bortezomib (a proteasome inhibitor) and tocilizumab (an IL-6 receptor 
antibody)49-53. However, none of these treatments have demonstrated unequivocal benefit 
and some of these are not effective at all.
TCMR requires a different therapeutic intervention than ABMR. The first-line therapy 
for aTCMR includes high-dose intravenous glucocorticoids and intensification of the 
maintenance immunosuppressive therapy24. In case of a severe (aTCMR grade IIA or higher), 
recurrent or glucocorticoid-resistant aTCMR, the Kidney Disease: Improving Global 
Outcomes (KDIGO) guideline advises the use of rATG, a lymphocyte-depleting drug24. 
rATG is a purified polyclonal immunoglobulin preparation of sera from rabbits immunized 
with fresh human thymocytes54. Therapy with rATG leads to immunomodulation by 
elimination of various cell types, including T- and B cells, NK cells, macrophages, dendritic 
cells and other non-lymphoid cells (i.e. erythrocytes and platelets) that lasts for several 
months. Furthermore, rATG interferes with the function of regulatory T cells and NK 
cells and downregulates key cell-surface molecules that mediate leukocyte-endothelium 
interactions55. 
Alemtuzumab is another lymphocyte-depleting drug. However, it is rarely used as treatment 
for severe, recurrent or glucocorticoid-resistant aTCMR. It is a humanized monoclonal 
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antibody directed against the CD52 antigen that is present on T- and B cells, NK cells, 
dendritic cells, monocytes and granulocytes56. These cells are lysed after therapy with 
alemtuzumab and depletion is long-lasting (ranging between 3 months [monocytes] and 
three years [T cells]). Further information on the use of alemtuzumab in kidney transplant 
recipients is provided in Chapter 3 of this introduction. 
Patients with a b-aTCMR show very heterogeneous outcomes, ranging from spontaneous 
resolution to the development of aTCMR in up to a third of cases57. No clinical guideline 
exists for the management of b-aTCMR. Most physicians will treat patients with a 
b-aTCMR when they have an impaired renal function which is not explained otherwise. 
The type of therapy is uncertain but generally follows that of aTCMR57. Patients with a 
subclinical b-aTCMR in a protocol biopsy (b-aTCMR in clinically stable patients) should 
be monitored closely, including histological surveillance, and their immunosuppressive 
drugs should not be minimized57. 
The category c-aTCMR was for the first time incorporated into the 2015 Banff guideline58. 
The presence of i-IF/TA lesions in a kidney allograft is thought to be related to chronic 
underimmunosuppression, is frequently preceded by aTCMR, and is associated with adverse 
transplant outcomes59-62. However, the optimal management of c-aTCMR is currently 
unknown61,62. 
Outcomes after kidney transplant rejection
Despite improvement in clinical care, kidney transplant rejection still occurs in a 
considerable number of kidney transplant recipients. Kidney transplant rejection is 
associated with long-lasting consequences. First, transplant rejection is associated with a 
decline in renal function, proteinuria and premature transplant failure, especially in patients 
with a kidney function that does not return to baseline after anti-rejection treatment and in 
patients with a vascular- or antibody-mediated rejection9. Second, patients who experience 
an acute rejection within the first six months after transplantation have a higher risk of a 
recurrent rejection beyond six months (Hazard Ratio [HR], 1.85; 95%-confidence interval 
[CI], 1.39 to 2.46)9. Furthermore, aTCMR appears to be a risk factor for the formation 
of de novo DSA and subsequent development of ABMR63,64. Increased sensitization can 
also lead to a reduced likelihood to receive a subsequent solid organ transplant. Third, 
the potent immunosuppressive effect of anti-rejection therapy is necessary to control the 
rejection but also leads to an increased risk of adverse events, such as sepsis, secondary 
auto-immunity, and malignancy9,65. Fourth, the combination of an inferior transplant 
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function, higher risk of transplant loss and the adverse events associated with anti-rejection 
therapy, leads to an increased risk of death9. Fifth, kidney transplant rejection causes higher 
costs due to increased need for laboratory testing, treatment, hospital admissions, and re-
transplantation66. Lastly, rejection impacts the psychological well-being of patients67. 
To conclude, kidney transplant rejection is a serious complication after kidney 
transplantation and is associated with a high burden of morbidity, mortality and higher 
health care-related costs. Improvement in terms of prevention, early recognition and 
treatment are key to improve kidney transplant- and patient survival. 
23
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ABSTRACT
Costimulation between T cells and antigen-presenting cells is essential for the 
regulation of an effective alloimmune response and is not targeted with the conventional 
immunosuppressive therapy after kidney transplantation. Costimulation blockade therapy 
with biologicals allows precise targeting of the immune response but without non-immune 
adverse events. Multiple costimulation blockade approaches have been developed that 
inhibit the alloimmune response in kidney transplant recipients with varying degrees of 
success. Belatacept, an immunosuppressive drug that selectively targets the CD28-CD80/
CD86 pathway, is the only costimulation blockade therapy that is currently approved 
for kidney transplant recipients. In the last decade, belatacept therapy has been shown a 
promising therapy in subgroups of kidney transplant recipients; however, the widespread use 
of belatacept has been tempered by an increased risk of acute kidney transplant rejection. 
The purpose of this review is to provide an overview of the costimulation blockade therapies 
that are currently in use or being developed for kidney transplant indications. 
Key points:
• Multiple costimulation blockade drugs have been developed and tested in kidney 
transplant recipients. Belatacept, a biological that inhibits the interaction between the 
antigen CD28 and CD80/86, is the only costimulation blockade drug that is currently 
approved for the prevention of kidney transplant rejection. 
• Belatacept is well-tolerated and is associated with a better allograft function compared 
with calcineurin inhibitors. A reason for concern is the higher risk of acute kidney 
transplant rejection as compared with the current standard immunosuppressive therapy. 
• Optimization of the selection of patients with a low risk for belatacept-resistant 
rejection in combination with new treatment strategies are necessary to expand the 
use of belatacept in the future.
•  The safety and efficacy of several other biologicals that target costimulation pathways 
(i.e. CD28 and CD40) are currently investigated for kidney transplantation.
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INTRODUCTION
Kidney transplant recipients (KTR) require lifelong immunosuppressive therapy to prevent 
acute kidney transplant rejection (AR). Currently, the standard immunosuppressive regimen 
consists of induction therapy (either a T cell-depleting agent or basiliximab, an antibody 
directed against the interleukin [IL]-2 receptor), followed by maintenance therapy consisting 
of a calcineurin inhibitor (CNI; either tacrolimus or ciclosporin), mycophenolic acid (MPA) 
with or without glucocorticoids1-4. Although transplantation is a success story of modern 
medicine, the long-term allograft- and patient survival are influenced by the toxicity of 
CNIs, which include infections, malignancies, metabolic side effects, nephrotoxicity and 
neurotoxicity5-7. Another limitation of current immunosuppression is that it is a ‘one size 
fits all’ therapy and is not tailored to the individual needs of a KTR. Therefore, novel and 
personalized therapeutic strategies have to be developed.
Several approaches have been investigated to limit the side effects of CNI, including 
monitoring of CNI concentrations to guide dosing, and CNI-sparing regimens. Examples 
of the latter are CNI minimization, CNI withdrawal, CNI conversion to alternative 
immunosuppressive agents, and lastly, CNI avoidance from the time of the transplantation 
with substitution of an alternative immunosuppressive drug8. However, many such trials 
failed because they resulted in unacceptably high incidences of AR and toxicity, or an 
increased incidence of infections associated with the alternative immunosuppressants9-15. 
Costimulation is essential for the regulation of an effective alloimmune response. The 
costimulatory pathway is not targeted with the conventional immunosuppressive therapy. 
Biologicals that intervene with the costimulatory pathway may allow more precise targeting 
of the immune response without causing non-immune adverse events. Belatacept, a 
fusion protein composed of a crystallizable fragment (Fc) of immunoglobulin (Ig) G1 
and the extracellular domain of cytotoxic T lymphocyte protein 4 (CTLA4), is the only 
costimulation blockade therapy that is currently approved for the prevention of rejection 
after kidney transplantation16,17. Belatacept is well-tolerated and its use is associated with 
an improved allograft function compared with CNI in certain subgroups of KTRs18,19; 
however, belatacept may not be the game changer it was hoped to be due to a high risk 
of AR20. In this review, the current applications of biologicals that target costimulation 
pathways in kidney transplantation are discussed, including the current status and future 
strategies of belatacept therapy.
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COSTIMULATION 
The process of T-cell activation is a complex cascade consisting of three signals. First, 
alloantigens from the allograft are taken up by antigen-presenting cells (APCs; dendritic 
cells, macrophages and B cells) which then home to the draining lymph nodes. In the lymph 
nodes, the alloantigens are presented on the surface of APCs by human leucocyte antigen 
(HLA) molecules. In humans, the T-cell receptor (TCR) on naive T cells is activated after 
interaction with the alloantigen/HLA complex, which is also known as signal 1 (Figure 1). 
A costimulatory signal (signal 2) is necessary to achieve full activation of T cells. Several 
cell-surface proteins (costimulatory ligands) on APCs interact with their complementary 
receptors on naive T cells (Figure 1). Signal 2 represents a combination of positive and 
negative signals that regulate the outcome of the HLA/TCR. Without this signal, naive T 
cells will undergo apoptotic cell death21-23. 
Two costimulatory pathways are critical for T-cell activation: 1) the Ig superfamily (e.g. 
CD28 [T-cell specific surface glycoprotein CD28] family, the CD2/Signaling lymphocytic 
activation molecule (SLAM) family and the T-cell/transmembrane, Ig, and mucin (TIM) 
family; and 2) the TNF (tumor necrosis factor)-TNF receptor superfamily (Figure 1)21. 
Signal 3 is formed by cytokines and the (increased) expression of cytokine receptors such as 
the IL-2 receptor a-chain (CD25; Figure 1). Activation of CD25 will activate intracellular 
signaling pathways downstream of the TCR, including the mitogen-activated protein kinase 
(MAPK), calcineurin, and PI3K pathways, followed by the activation of transcription factors 
that regulate the production of several cytokines (i.e., IL-2 and interferon-γ)24. These and 
other cytokines promote T-cell proliferation of divers effector CD4+ T-cell subsets and 
cytotoxic CD8+ T cells25.
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Figure 1. Costimulation between T cells and antigen-presenting cells. Schematic overview of signal 
1, 2 and 3 of T-cell activation. During signal 2, costimulatory molecules on T cells and antigen-present-
ing cells interact to activate or inhibit T cells after alloantigen recognition. Two important groups of co-
stimulatory molecules are presented: the immunoglobulin superfamily and the TNF-TNFR superfamily. 
The costimulatory molecules discussed in this review are green and the costimulatory molecules that are 
not discussed in are in yellow. Several biologicals are developed that interfere with the costimulatory 
molecules on T cells and antigen-presenting cells. CTLA 4, cytotoxic T lymphocyte protein 4; HLA, 
human leucocyte antigen; ICOS, inducible T cell costimulator; PD, programmed death; SLAM, Signal-
ing lymphocytic activation molecule; TCR, T cell receptor, TIM, T cell/transmembrane, immunoglob-
ulin, and mucin; TNF, tumor necrosis factor.
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BELATACEPT THERAPY IN KIDNEY TRANSPLANTATION 
Development of belatacept
Belatacept targets the CD28:CD80/CD86 pathway. The costimulation molecule CD28 
is a surface receptor that is constitutively expressed on T cells (Figure 1). The inhibitory 
receptor CTLA4 is localized in intracellular vesicles in resting T cells and is expressed on 
the cell surface 48-72 hours after T-cell activation. CTLA4 binds to CD80 and CD86 with 
a higher affinity than CD2821. Therefore, the binding of CTLA4 to CD80/CD86 dampens 
the activation of T cells26. At birth, almost all human T cells express CD2827. Aging, 
continuous antigenic stimulation (which can be caused by e.g. end-stage renal disease, 
human immunodeficiency virus infection and auto-immune disease) and cytomegalovirus 
infection lead to loss of CD28 expression of T cells27-29. These CD28- effector memory T 
cells have reduced costimulatory requirements and an impaired proliferative capacity, but 
are highly proinflammatory27,30. These cells rapidly secrete effector cytokines (i.e. TNF-α 
and interferon-γ) upon restimulation. 
One of the first biologics that was designed to target the CD28-CD80/CD86 superfamily 
was abatacept (Figure 1), a fusion protein composed of a Fc of IgG1 and the extracellular 
domain of CTLA431. Because CTLA4 binds with a higher affinity to CD80/CD86 than 
CD28, it was hypothesized that T-cell activation could be inhibited with such a CTLA4 
construct. Abatacept is approved for the treatment of rheumatoid arthritis (Figure 2)32 and 
has been was tested in non-human primates transplanted with a kidney or pancreatic islets; 
however, alloreactivity appeared to be inhibited insufficiently33,34. Therefore, the development 
of abatacept therapy for transplantation was discontinued and a new CTLA4-Ig construct 
(belatacept) was developed with increased avidity for CD80 and CD86 by changing two 
amino acids (L104E and A29Y; Figure 1 and 2)16. Belatacept was found to have a fourfold 
higher binding affinity for CD86 and a twofold higher binding affinity for CD80 compared 
with abatacept16. Although the development of abatacept in transplantation was stopped, 
abatacept was recently used as rescue therapy in nine KTRs with an intolerance to CNI, 
because belatacept was temporarily unavailable due to manufacturing problems35,36. None 
of the allografts were lost after a median period of 115 months and one patient experienced 
AR35. 
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Figure 2. Timeline of the development of costimulation blockade. The costimulation blockade drugs 
that are currently used or tested in kidney transplant recipients are shown in black, whereas the costimula-
tion blockade drugs that are no longer being used anymore or not developed for kidney transplantation are 
shown in grey. EMA, European Medicines Agency; FDA, United States Food and Drug Administration; 
FR104, Pegylated Monoclonal Antibody Fragment Antagonist of CD28; TGN1412, CD28 humanized 
antibody. 
Belatacept was approved as treatment for the prevention of AR by the European Medicines 
Agency (EMA) and the United States Food and Drug Administration (FDA) in 2011 
based on the results of two large randomized, controlled multicenter phase III trials 
(Figure 2): The Belatacept Evaluation of Nephroprotection and Efficacy as First-line 
Immunosuppression (BENEFIT) study (with standard criteria donors) and the BENEFIT-
extended criteria donors (BENEFIT-EXT) study17,37,38. In these trials, 1,264 KTR were 
treated with either ciclosporin or belatacept as first-line treatment in combination with 
MPA and glucocorticoids. The main findings of BENEFIT and BENEFIT-EXT were that 
the 1-year-patient- and allograft survival of patients treated with belatacept were similar 
to patients treated with ciclosporin37,38. Although the incidence of acute T-cell-mediated 
rejection (aTCMR) was increased in belatacept-treated patients, the kidney function was 
better in these patients compared with ciclosporin-treated patients37,38. In addition, the use 
of belatacept was associated with increased risk for post-transplant lymphoproliferative 
disease mostly in Epstein-Barr virus seronegative KTR37-39.
The safety and efficacy of belatacept were also tested in a phase II randomized, controlled 
multicenter trial in liver transplant recipients40. This trial randomized 260 patients between 
therapy with belatacept (three different belatacept regimens) or tacrolimus (two different 
tacrolimus regimens). The primary composite end point consisted of incidence of acute 
liver transplant rejection, graft loss and death at six months after transplantation. The 
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occurrence of the composite end point was higher in the belatacept groups (42-48%) than 
in the tacrolimus groups (15-38%)40. The results of this study were reason to discontinue 
further development of belatacept for liver transplantation. However, the mean estimated 
glomerular filtration rate (eGFR) was 15-34 mL/min/1.73 m2 higher in the liver transplant 
recipients treated with belatacept40. Therefore, liver transplant recipients with an impaired 
renal function could benefit from belatacept therapy. Proper selection of patients and 
an adjusted treatment protocol can possibly improve the results of belatacept in liver 
transplantation in the future41.
Clinical outcomes of de novo use of belatacept in KTR
A systematic review with meta-analysis was performed of five studies that compared 
treatment with belatacept to CNIs (including the BENEFIT and BENEFIT-EXT studies) 
in 1,535 KTR42. Of the 521 patients treated with a CNI, 478 patients used ciclosporin, 
and 43 patients were treated with tacrolimus. After 3 years of treatment, no difference was 
seen between patients treated with either belatacept or CNI regarding the risk of death 
(relative risk 0.75, 95%-confidence interval [CI] 0.39-1.44, p = 0.39), allograft loss (relative 
risk 0.91, 95%-CI 0.61-1.38, p = 0.67), and incidence of aTCMR (RR 1.56, 95%-CI 0.85-
2.86, p = 0.15)42. However, the kidney allograft function was better in patients treated 
with belatacept (eGFR mean difference of 9.96 mL/min/1.73 m², 95%-CI 3.28-16.64, p 
= 0.0035). Furthermore, the use of belatacept was associated with a reduced incidence of 
post-transplant diabetes mellitus, a better blood pressure and a better lipid profile 1 year 
after therapy with belatacept42.
In 2016, the 7-years follow-up results of the BENEFIT and BENEFIT-EXT were published. 
In these studies, the risks of death and graft loss in KTR treated with belatacept were 
similar to those in KTR treated with ciclosporin18,19. Although, the risk of aTCMR was 
higher in belatacept-treated patients compared with the ciclosporin-treated patients, their 
kidney function after 7 years was better. An explanation for the better kidney function 
may be that belatacept is associated with less interstitial inflammation and tubular atrophy 
compared with CNIs. Vitalone et al., compared the 1-year protocol biopsies of KTR 
treated with belatacept or ciclosporin43, and found that he biopsies of patients treated with 
belatacept contained less interstitial inflammation, interstitial fibrosis and tubular atrophy 
and gene expression analysis revealed a lower expression of genes involved in fibrosis and 
tubulointerstitial damage compared with the biopsies of patients treated with ciclosporin43. 
In another study, 10-year protocol biopsies were analyzed of 23 clinically stable KTRs 
treated with belatacept and 10 KTR treated with CNI (seven taking ciclosporin and three 
37
CHAPTER 2 | COSTIMULATION BLOCKADE IN KIDNEY TRANSPLANT RECIPIENTS 
taking tacrolimus)44. The biopsies of belatacept-treated patients contained less interstitial 
inflammation and tubular atrophy, less interstitial inflammation and less hyalinosis44. 
The 7-year follow-up studies also showed that the formation of de novo donor-specific anti-
HLA antibodies (DSA) was reduced in the belatacept-treated patients compared to the 
patients treated with ciclosporin18,19. A possible explanation for this observation may be that 
costimulation blockade with belatacept leads to more effective prevention of DSA formation 
by B cells and that drug adherence is better in the patients treated with belatacept because 
of intravenous administration. The occurrence of post-transplant diabetes mellitus, blood 
pressure and lipid profile were not discussed in the long-term follow-up studies of belatacept. 
To conclude, these long-term outcomes demonstrate that belatacept therapy is a safe therapy 
for KTR and is associated with a better kidney function and a reduced incidence of de novo 
DSA. Whether long-term belatacept therapy leads to a better metabolic profile than CNI 
therapy is not known18,19,39. 
A limitation of the BENEFIT studies is that belatacept therapy was compared to ciclosporin 
therapy. Currently, the CNI of choice in most transplant centers is tacrolimus1,45. No 
large, head-to-head randomized-controlled trials have been performed that compared the 
outcomes of patients treated with either belatacept or tacrolimus. In our center, a trial 
was performed which included 40 KTR who were randomized between first-line therapy 
consisting of tacrolimus or belatacept, in combination with MPA and glucocorticoids46. 
The AR incidence in the first year after transplantation was higher in belatacept-treated 
patients (55% versus 10%, p = 0.006)46. Another randomized-controlled trial compared 
three treatment regimens in KTR: alemtuzumab induction with tacrolimus, alemtuzumab 
induction with belatacept, and basiliximab induction with belatacept and a three-month 
course of tacrolimus47. This study was halted prematurely after inclusion of 19 patients due 
to a high rate of serious adverse events in belatacept-treated patients, including thrombotic 
complications and aTCMR47. 
The comparison between belatacept and tacrolimus therapy has also been investigated in 
three indirect studies48-50. In a single-center retrospective analysis, the outcomes of KTR 
treated with belatacept (n = 97) were compared with a historical cohort of patients treated 
with tacrolimus (n = 205)48. An increased rate of aTCMR was noted in patients treated 
with belatacept compared with tacrolimus-treated patients (50.5% versus 20.5%)48. In a 
retrospective propensity score-matched cohort study, the outcomes of KTR treated with 
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either tacrolimus or belatacept were compared49. The risk of AR was higher in the first post-
transplant year in patients treated with belatacept (odds ratio 3.12, 95% CI 2.13-4.57, p < 
0.001) but no difference was seen in the risk of death (hazard ratio 0.84, 95%-CI 0.61-1.15, 
p = 0.28) or allograft loss (hazard ratio 0.83, 95%-CI 0.62-1.11, p = 0.20)49. Muduma et al. 
performed a systematic review and meta-analysis with an indirect treatment comparison 
analysis between tacrolimus (both immediate release and prolonged-release formulations) 
and belatacept50. The AR rate was reduced in patients treated with tacrolimus compared to 
belatacept (risk ratio 0.22 [95%-CI 0.13-0.39] to 0.44 [0.20, 0.99])50. The risks of allograft 
loss and death were similar between both treatments. 
One of the reasons for the high risk of aTCMR after belatacept may be that the 
immunosuppressive function of regulatory T cells (Tregs) is impaired51-55. Tregs are 
dependent on signaling via CTLA4 and binding of belatacept to CD80/86 interferes 
with CTLA4. Therefore, combination of belatacept with therapies that preserve Treg 
functionality, such as T-cell-depleting antibodies and mammalian target of rapamycin 
(mTOR) inhibitors could possibly lead to a reduced incidence of AR4,56,57. 
The combination of induction therapy with T-cell-depleting drugs and belatacept has been 
tested in several studies with various outcomes. In one study, alemtuzumab induction 
followed by tacrolimus or belatacept led to a similar incidence of AR58. In another study, 
patients treated with T-cell-depleting induction therapy (either rabbit anti-thymocyte 
globulin [rATG] of alemtuzumab) followed by belatacept were compared with patients 
treated with rATG induction followed by tacrolimus59. In all patients, glucocorticoids 
were withdrawn early. The AR incidence was higher in patients treated with belatacept, 
but the allograft- and patient survival were similar59. In a third study (described above), 
alemtuzumab induction with belatacept in KTR resulted in a high rate of serious adverse 
events and the study was halted prematurely47. T-cell-depleting induction therapy has 
also been tested in KTR treated with belatacept in combination with mTOR inhibitors 
(sirolimus or everolimus). The AR rate in patients treated with this combination of drugs 
is low, and a significant increase in Tregs is seen60-63. 
Possible explanations for a lower rate of acute rejection after T-cell-depleting induction 
therapy compared with basiliximab induction therapy are i) after T-cell-depletion therapy 
an increased repopulation of Tregs is seen, and ii) repopulated memory T cells in rATG-
treated KTR show impaired cytokine responsiveness compared with those of basiliximab-
treated KTR57,64.
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To conclude, although the studies that compare belatacept to tacrolimus therapy have their 
limitations (limited number of patients or indirect comparison), belatacept is associated 
with an increased risk of aTCMR.
Clinical outcomes after conversion to belatacept in KTR
Although the use of belatacept is associated with an increased risk of aTCMR, it has 
been shown to be a good alternative in KTRs with a contraindication to CNIs. Multiple 
studies have reported successful conversion to belatacept in KTR with CNI-induced 
nephrotoxicity, impaired allograft function, delayed graft function, CNI-mediated 
thrombotic microangiopathy, or atypical hemolytic uremic syndrome65-82. Furthermore, 
KTR with poorly controlled diabetes mellitus while receiving CNI therapy may benefit 
from belatacept83,84. In addition, since belatacept must be administered intravenously, it has 
the potential advantage of providing better compliance, for instance in adolescent KTRs85.
Several approaches for conversion to belatacept have been evaluated, such as early or late 
conversion77,86-89, belatacept combined with a short period of tacrolimus therapy48, and non-
invasive screening for AR after conversion to belatacept to detect AR at an early stage90. In a 
phase II prospective randomized trial, KTR with a stable kidney function were randomized 
6-36 months after transplantation to maintenance therapy with either belatacept (n = 84) 
or CNIs (n = 89)88. Three years after randomization, the kidney function was better in the 
belatacept group89. The rate of acute rejection was higher in the belatacept group (8.4%) 
compared with the CNI-treated patients (3.6%), but this difference was not statistically 
significant (p = 0.2)89. In retrospective studies, a beneficial effect on the kidney allograft 
function was seen in patients with early conversion to belatacept (within 3 months post-
transplantation) and in patients with low-grade proteinuria77,86,87. Combination of belatacept 
with 9 months of tacrolimus reduced the risk of aTCMR in a retrospective single center 
study (the 1-year aTCMR rate of belatacept therapy was 50%, of tacrolimus therapy 20.5%, 
and of belatacept plus nine months tacrolimus 16%), without an increased incidence of 
infections48. Malvezzi et al. also examined a strategy to safely convert KTR to belatacept90. 
After the start of belatacept, the dose of tacrolimus was gradually reduced and withdrawn 
after 2 months. Serial measurements (at time points 1-, 3-, 6-, and 12-month time points) 
of urine chemokine (C-X-C motif) ligand 9 (CXCL9) were used to screen for AR non-
invasively. In this study, 35 KTR with a contraindication for CNIs were converted to 
belatacept after median 3.3 years (interquartile range 1.3–7.2) after transplantation90. Only 
one patient had a biopsy-proven AR that responded well to glucocorticoid pulse therapy90. 
The urinary CXCL9 concentration was elevated during AR. In addition to CXCL9, other 
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potential minimally invasive biomarkers in urine and blood of KTR, such as cell-free DNA 
and extracellular vesicles, may assist clinicians to identify AR at an early stage91,92. 
Currently, two studies are actively recruiting KTR for conversion to belatacept: one study 
will investigate the effect of conversion to belatacept on proteinuria (ClinicalTrials.gov 
identifier NCT02327403) and the other study will examine the outcomes of conversion to 
belatacept three months after transplantation (ClinicalTrials.gov identifier NCT02213068). 
Belatacept therapy in sensitized kidney transplant recipients
Initially, most studies that investigated the effectiveness of belatacept included only 
immunological low-risk KTRs37,42,46. However, because belatacept therapy is associated 
with a reduced incidence of de novo DSA production, a growing number of studies on 
the application of belatacept (de novo and conversion) in sensitized KTR are available18,19. 
In the BELACOR study, 49 KTRs with preformed DSAs (maximal mean fluorescence 
intensity between 500 and 3000) were treated with induction therapy of rATG followed 
by de novo belatacept maintenance therapy plus MPA and glucocorticoids93. The outcomes 
were compared with a retrospective control group of patients treated with CNIs. After 
1 year of follow-up, no patients in the belatacept group experienced antibody-mediated 
rejection, while aTCMR occurred significantly more often in the belatacept-treated patients. 
Complete disappearance of class II DSAs was significantly more often seen in belatacept-
treated patients93. 
In a retrospective study, the efficacy of belatacept in reducing anti-HLA antibodies in highly 
sensitized kidney transplant (current panel reactive antibodies ≥98-100%) was investigated94. 
Sixty highly sensitized KTRs were treated with belatacept de novo, glucocorticoids, MPA 
and low-dose tacrolimus (targeted to pre-dose concentrations 5‐8 ng/mL in the first six 
months, 3-5 ng/mL in month 6-9, followed by tapering and discontinuation at month 9-11 
post-transplantation). The control group existed of 44 highly sensitized KTRs treated with 
the current standard-of-care therapy (tacrolimus, MPA and glucocorticoids). In the KTRs 
treated with belatacept a decrease in the breadth and strength of HLA class I antibodies 
and current panel reactive antibodies was observed compared with the control group94. 
In another retrospective single-center study, 29 DSA-positive KTRs with a contraindication 
for CNI therapy were converted to belatacept after median 444 days95. The control 
group consisted of 44 non-immunized belatacept-treated KTRs. After the follow-up of 
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median 308 days one belatacept-treated patient experienced AR and two rejections were 
diagnosed in the CNI-treated patients. The eGFR improved from 32 to 41 mL/min/1.73 
m2 after conversion to belatacept95. In a smaller retrospective study, similar results were 
reported in six immunized KTR (panel reactive antigen >80% or positive flow cytometry 
crossmatch) who were converted from tacrolimus to belatacept (median four months after 
transplantation)96. 
Biomarkers predicting belatacept-resistant rejection
Because of the increased risk of aTCMR, belatacept may not be the game changer it was 
hoped to be20. Possibly, the drug should be reserved for KTRs with a low risk of belatacept-
resistant AR. Quantification of an individual KTR’s risk of AR prior to transplantation 
is essential to identify those who might benefit from belatacept-based immunosuppressive 
therapy. Clinical tests to reliably predict the risk of belatacept-resistant AR are not yet 
available. The risk of AR is currently estimated with pretransplant assessment of donor-
specific anti-HLA antibodies, and HLA mismatch; however, alloreactive memory T-cell 
responses are not measured with these assays. The presence of alloreactive T cells pre-
transplantation can lead to rapid recognition of alloantigens after transplantation and early 
AR97,98. These alloreactive T cells can be measured with pre-transplantation functional 
assays (e.g. measurement donor-reactive immune cells with ELISpot)97,99. 
Several studies have been performed to elucidate the pathogenesis of AR after belatacept 
therapy. An immunomic analysis of biopsies with AR of KTR treated with tacrolimus or 
belatacept showed no difference in the intragraft gene expression and immunohistochemistry 
of markers that are involved in AR100. This implies a final common pathway of AR which 
is independent of the immunosuppressive regimen.
Apart from the effect of belatacept on Tregs51-55, other T cells have been associated with 
belatacept-resistant AR, such as highly cytotoxic CD28- memory T cells, CD4+ CD28+ 
effector memory T cells, CD4+CD57+Programmed Death-1- T cells, and Th17 memory 
cells46,98,101-105. However, conflicting data have been reported about the possibility to predict 
belatacept-resistant AR by measuring some of these T cell subsets46,98,101-105 and currently 
none is a clinically reliable for AR risk.
Another reason that may contribute to the increased incidence of AR is that belatacept 
therapy does not inhibit the T cell activation pathway downstream of the TCR, in contrast 
to tacrolimus therapy106. In a study with 20 belatacept treated KTR, no inhibition of the 
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phosphorylation of three important signaling molecules (p38MAPK, extracellular signal-
regulated kinases 1 and 2 [ERK1/2] and AKT8 virus oncogene cellular homolog [Akt]) 
was noted after treatment with belatacept106. Furthermore, the phosphorylation of ERK 
was increased in belatacept-treated patients on day 4 and day 90 in patients with an AR 
compared to patients without an AR106.
Prediction of AR was not possible with a targeted proteomic analysis of pre-rejection 
serum samples of KTR treated with belatacept107. In an assay with 92 inflammation-related 
proteins, no difference was seen in the proteomic profile between the pre-rejection samples 
and samples of patients without AR107. 
To conclude, there are several explanations for the increased risk of AR associated with 
belatacept therapy. At present no specific tests (besides pretransplant screening for degree 
of sensitization) are available that can predict the risk for belatacept-resistant AR. 
ALTERNATIVE APPROACHES OF COSTIMULATION BLOCKADE
CD28 antibodies
Selective targeting of the CD28 antigen on T cells might be a superior immunosuppressive 
therapy compared with belatacept, since this blockade leaves the inhibitory signal of 
CTLA-4 intact and may preserve Treg function (Figure 1)108,109; however, blockade of CD28 
has been challenging. Most anti-CD28 antibodies bind to an epitope lying in the basolateral 
C’’D domain of CD28. Crosslinking of this epitope with an anti-CD28 antibody results 
in receptor clusterization, which this leads to activation of the CD28 receptor instead 
of inhibition. In 2006, a CD28 humanized antibody TGN1412 was tested in a phase I 
study (Figure 2)110. This antibody was developed to cause activation and proliferation of 
Tregs independent of signals received from the TCR. In studies in cynomolgus macaques, 
TGN1412 revealed no toxic effects; however, in humans, infusion of TGN1412 led to 
life-threatening massive cytokine release in six healthy volunteers and all of them had to 
be transferred to the intensive care unit110. CD4+ effector memory T cells appeared to be 
responsible for the massive cytokine release111. The reason that preclinical testing failed to 
predict this dramatic side effect was that CD4+ effector memory T cells of cynomolgus 
macaques do not express CD28, therefore these cells cannot be stimulated with TGN1412111. 
Currently, two monovalent antibodies with only antagonistic action to CD28 are in 
clinical development: FR104 and lulizumab-pegol (Figure 2)112,113. In non-human primates 
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transplanted with a kidney allograft, FR104 in combination with rapamycin, a low dose of 
tacrolimus, or 1 month of low-dose tacrolimus, induced long-term allograft survival114,115. 
Lulizumab-pegol was tested in non-human primates and showed inhibition of T cell-
dependent antibody responses and cytokine production116. In humans, both drugs have 
been evaluated in phase I clinical studies and were safe and well tolerated (Figure 2)113. At 
present, a prospective multicenter study is started to investigate the efficacy of lulizumab 
in combination with rATG, glucocorticoids, belatacept, tocilizumab, and everolimus in 
KTRs (ClinicalTrials.gov identifier NCT04066114). 
CD2/SLAM family antibodies
An antibody that interferes with the CD2/SLAM family is alefacept (Figure 1). This is 
a fusion protein of lymphocyte function-associated antigen (LFA)-3 and the Fc part of 
IgG1117. LFA-3 is expressed on APCs and is the ligand of CD2 on T cells. CD2 is expressed 
on all T cells but memory T cells express the highest levels118. Alefacept binds to CD2 on 
T cells and blocks the interaction between CD2 and LFA-3. It was approved by the FDA 
in 2003 for the treatment of psoriasis and administration of alefacept leads to depletion of 
memory T cells (Figure 2)117. In a phase II, randomized, controlled, double-blind multicenter 
study, maintenance treatment with alefacept was compared with placebo in KTRs119. Both 
patient groups were also treated with tacrolimus, MPA and glucocorticoids. There was no 
significant difference in the rate of biopsy-proven AR (alefacept 11% versus placebo 7%, p 
= 0.3). Furthermore, malignancy occurred more often in the patients treated with alefacept 
(5.7%) compared with placebo (0.9%; p = 0.06)119. In 2011, the manufacturer decided to 
stop the development of alefacept120.
CD40-CD154 (CD40 ligand) antibodies
The CD40/CD154 pathway is a promising target for immunosuppressive therapy in 
KTRs. CD40 (TNF receptor superfamily 5, TNFRSF5) is constitutively expressed on the 
surface of APCs, including B cells, macrophages and dendritic cells, and T cells (mainly 
CD8+)121. CD154 is the ligand of CD40 and is expressed on activated T cells and subsets 
of natural killer cells, eosinophils and activated thrombocytes (Figure 1)121. Ligation of 
CD40 with CD154 leads to T-cell-dependent B-cell activation and proliferation, germinal 
center formation, Ig production and isotype class switching. Furthermore, stimulation of 
CD40 provides macrophage effector function and promotes CD28-mediated costimulation 
through upregulation of CD80/CD86 and HLA molecules on APCs122,123. 
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Multiple antibodies that target the CD40/CD154 pathway have been developed and tested 
in patients with autoimmune diseases, such as systemic lupus erythematosus, rheumatoid 
arthritis, psoriasis, inflammatory bowel disease and idiopathic thrombocytic purpura124. 
Several CD154 monoclonal antibodies (e.g. hu5C8, IDEC-131, ABI793 and H106) were tested 
in non-human primates and showed prolonged kidney allograft survival33,125-128. However, in 
humans, administration of anti-CD154 antibodies led to an unanticipated, higher incidence 
of thrombotic complications, possibly because of activation of the coagulation cascade through 
CD154 activation on thrombocytes129. Therefore, the clinical development of anti-CD154 
antibodies was terminated. Since CD40 is not expressed on thrombocytes, antagonistic anti-
CD40 antibodies might not evoke thrombotic events. At present, many antagonistic anti-
CD40 antibodies (e.g. ASKP1240, CFZ533, HCD122, Chi220, 3A8, 2C10R1, 2C10R4, BI-
655064, FFP104, ch5D12) are under investigation124,130. Two of these anti-CD40 antibodies 
are tested in KTRs, namely CFZ533 (iscalimab) and ASKP1240 (bleselumab).
Bleselumab is a fully humanized non-depleting anti-CD40 IgG4 antibody. In non-human 
primates, bleselumab prolonged kidney allograft survival131. In a phase Ib study in KTRs, 
bleselumab was well tolerated and no thrombotic events occurred132. A more extensive 
(phase II) trial examined the efficacy and safety of bleselumab in KTR (ClinicalTrials.gov 
identifier NCT01780844; Figure 2). Preliminary data presented at a conference showed that 
the incidence of AR three years of therapy was 13% in KTRs treated with standard therapy 
(tacrolimus), 11% in patients treated with bleselumab with low-dose tacrolimus (p = 1.00 
versus standard therapy), and 41% in patients treated with bleselumab (p = 0.02 versus standard 
therapy)133. Furthermore, an increased incidence of CMV and BKV infections was seen in 
patients treated with bleselumab132,133. 
Iscalimab is a non-B-cell-depleting anti-CD40 antibody and iscalimab induced prolonged 
survival and function of kidney allografts in cynomolgus monkeys 134. Furthermore, iscalimab 
led to complete absence of splenic germinal center formation and formation of de novo DSA134. 
Iscalimab is currently tested in 325 KTRs in a phase II trial (ClinicalTrials.gov identifier 
NCT02217410) comparing standard-of-care therapy (tacrolimus, MPA and glucocorticoids) 
with subcutaneous iscalimab every 2 weeks in combination with MPA and glucocorticoids 
(Figure 2). Data from a proof-of-concept trial performed in 2016-2017 demonstrated a 
comparable efficacy on the composite endpoint of AR, graft loss, or death (21.2% versus 
22.2%), better kidney function (55.8 versus 45.5 mL/min/1.73 m2) and a reduced incidence 
of post-transplant diabetes mellitus (14.7 versus 38.9%) in patients treated with iscalimab 
compared with tacrolimus after 6 months of treatment135.
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FUTURE DIRECTIONS 
Modulation of the costimulation pathway with biologicals remains a promising strategy 
for the prevention of AR because it is more specific than traditional pharmacologic 
immunosuppression and appears to have the advantage of having only limited non-immune 
toxicity. To date, belatacept is the only costimulation blockade therapy approved for the 
prevention of rejection. Although belatacept has been shown to be a promising therapy in 
subgroups of patients, its widespread use has been limited because of 1) the increased risk 
of aTCMR compared with tacrolimus; 2) concerns regarding its safety (increased risk of 
post-transplant lymphoproliferative disorder); and 3) logistic aspects including the need for 
regular infusions and the temporarily unavailability due to production shortages. 
The use of belatacept could be expanded in the future when it is possible to reliably identify 
patients who are at a low risk for belatacept-resistant AR (Figure 3). Belatacept-based therapy 
may be given to these low-risk patients, while the standard of care (tacrolimus-based therapy) 
should be offered to KTRs with a high risk for belatacept-resistant AR (Figure 3). Belatacept 
may also be an attractive alternative for patients with contraindications for CNIs (Figure 3). 
Another strategy to expand the use of belatacept is to combine belatacept with tacrolimus or 
other immunosuppressive therapies (Figure 3). The risk of belatacept-resistant AR is reduced 
when it is used in combination with a short period or low-dose of tacrolimus48,90. Belatacept 
therapy influences the immunosuppressive function of Tregs51-55; therefore, combination 
of belatacept with therapies that preserve Treg functionality, such as mammalian target 
of rapamycin (mTOR) inhibitors, T -cell-depletion therapy, anti-CD40 antibodies, and 
adoptive therapy with Tregs could possibly lead to a more precise control of alloimmunity 
(Figure 3)56. The combination of CTLA4-Ig and blockade of CD40-CD154 has not yet 
been tested in humans; however, in several animal transplant models, this combination 
produced long-term allograft survival136-140. 
CD28- memory T cells are insensitive to belatacept therapy; therefore, belatacept should 
be avoided in KTRs with a high number of these cells, or should be combined with drugs 
that effectively control CD28- memory T cell immunity (Figure 3). Mesenchymal stem cell 
therapy has immunomodulatory properties and, in vitro, these cells are shown to inhibit 
CD28- memory T cells141,142. The combination of alemtuzumab induction followed by 
infusion with mesenchymal stem cells, belatacept and sirolimus is currently being tested 
(ClinicalTrials.gov identifier NCT03504241). 
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More intensive monitoring of KTRs after conversion to belatacept might lead to a better 
prevention or earlier recognition of AR. Belatacept dosing is administered at fixed intervals 
and is based on the body weight of the patient. According to the manufacturer of belatacept, 
it is not advisable to perform therapeutic drug monitoring of belatacept143. However, in the 
BENEFIT studies a more intensive regimen was associated with an increased incidence of 
malignancies and infections, without an increase in efficacy37,38. An automated assay to 
determine belatacept serum concentrations was recently developed144. The authors found 
reduced peak concentrations of belatacept in patients with a lower bodyweight144; however, 
whether this reduced exposure to belatacept leads to an increased risk of AR is unknown, 
but certainly a reason for further investigation (Figure 3). 
Belatacept is currently dosed every 4 weeks in the maintenance phase. In a 10-year follow-
up study, the belatacept 4-weekly regimen was compared to administration of belatacept 
every 8 weeks145. After 10 years, kidney function and the risk of allograft loss or death 
was similar between the two groups; however, the risk of AR was higher in patients who 
received belatacept every 8 weeks2. With further investigation, such as the above-mentioned 
measurement of belatacept serum concentrations, the 8-weekly dosing regimen could offer 
logistical advantages in subgroups of KTRs in the future.
Early recognition and treatment of AR leads to less allograft damage; therefore, minimal-
invasive screening for (preclinical) AR in KTRs could lead to a better allograft survival 
(Figure 3). Potential biomarkers for minimal-invasive screening of AR in blood or urine 
are now entering the clinic91,107,146. Applying these minimal-invasive screening tools to 
belatacept-treated patients could be a way to expand the use of belatacept.
To conclude, targeting the costimulation pathway is a complex but exciting task. Belatacept 
is a promising immunosuppressive therapy for KTRs, but a more tailored approach in the 
selection of patients, treatment protocol and posttransplant monitoring is necessary to 
expand the use of belatacept. 
2
48
PART I
REFERENCES
1. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of 
kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299-311.
2. Brunet M, van Gelder T, Asberg A, et al. Therapeutic Drug Monitoring of Tacrolimus-Personalized 
Therapy: Second Consensus Report. Ther Drug Monit. 2019;41(3):261-307.
3. van Gelder T, Hesselink DA. Mycophenolate revisited. Transpl Int. 2015;28(5):508-515.
4. van der Zwan M, Baan CC, van Gelder T, Hesselink DA. Review of the Clinical Pharmacokinetics 
and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. Clin 
Pharmacokinet. 2018;57(2):191-207.
5. Claes K, Meier-Kriesche HU, Schold JD, et al. Effect of different immunosuppressive regimens 
on the evolution of distinct metabolic parameters: evidence from the Symphony study. Nephrol 
Dial Transplant. 2012;27(2):850-857.
6. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. 
N Engl J Med. 2003;349(24):2326-2333.
7. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal 
transplantation. N Engl J Med. 2007;357(25):2562-2575.
8. Neuberger JM, Bechstein WO, Kuypers DR, et al. Practical Recommendations for Long-term 
Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report 
and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation 
(COMMIT) Group. Transplantation. 2017;101(4S Suppl 2):S1-S56.
9. Tedesco-Silva H, Kho MM, Hartmann A, et al. Sotrastaurin in calcineurin inhibitor-free regimen 
using everolimus in de novo kidney transplant recipients. Am J Transplant. 2013;13(7):1757-1768.
10. Baan CC, Kannegieter NM, Felipe CR, Tedesco Silva H, Jr. Targeting JAK/STAT Signaling to 
Prevent Rejection After Kidney Transplantation: A Reappraisal. Transplantation. 2016;100(9):1833-
1839.
11. Vincenti F, Silva HT, Busque S, et al. Evaluation of the effect of tofacitinib exposure on outcomes 
in kidney transplant patients. Am J Transplant. 2015;15(6):1644-1653.
12. Bouamar R, Shuker N, Osinga JAJ, et al. Conversion from tacrolimus to everolimus with complete 
and early glucocorticoid withdrawal after kidney transplantation: a randomised trial. Neth J Med. 
2018;76(1):14-26.
13. Shipkova M, Hesselink DA, Holt DW, et al. Therapeutic Drug Monitoring of Everolimus: A 
Consensus Report. Ther Drug Monit. 2016;38(2):143-169.
14. Pascual J, Berger SP, Witzke O, et al. Everolimus with Reduced Calcineurin Inhibitor Exposure 
in Renal Transplantation. J Am Soc Nephrol. 2018;29(7):1979-1991.
15. Karpe KM, Talaulikar GS, Walters GD. Calcineurin inhibitor withdrawal or tapering for kidney 
transplant recipients. Cochrane Database Syst Rev. 2017;7:CD006750.
16. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a 
high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 
2005;5(3):443-453.
17. Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J. Summary of the US FDA approval of 
belatacept. Am J Transplant. 2012;12(3):554-562.
49
CHAPTER 2 | COSTIMULATION BLOCKADE IN KIDNEY TRANSPLANT RECIPIENTS 
18. Durrbach A, Pestana JM, Florman S, et al. Long-Term Outcomes in Belatacept- Versus 
Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From 
BENEFIT-EXT, a Phase III Randomized Study. Am J Transplant. 2016;16(11):3192-3201.
19. Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and Long-Term Outcomes in Kidney 
Transplantation. N Engl J Med. 2016;374(4):333-343.
20. Van Gelder T, Hesselink DA. Belatacept: A Game Changer? Transplantation. 2016;100(7):1390-
1392.
21. Sharpe AH. Mechanisms of costimulation. Immunol Rev. 2009;229(1):5-11.
22. June CH, Ledbetter JA, Gillespie MM, Lindsten T, Thompson CB. T-cell proliferation involving 
the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol 
Cell Biol. 1987;7(12):4472-4481.
23. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: 
a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. 
Annu Rev Immunol. 1989;7:445-480.
24. Nakayama T, Yamashita M. The TCR-mediated signaling pathways that control the direction of 
helper T cell differentiation. Semin Immunol. 2010;22(5):303-309.
25. O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ 
T cells. Science. 2010;327(5969):1098-1102.
26. Linsley PS, Greene JL, Tan P, et al. Coexpression and functional cooperation of CTLA-4 and 
CD28 on activated T lymphocytes. J Exp Med. 1992;176(6):1595-1604.
27. Weng NP, Akbar AN, Goronzy J. CD28(-) T cells: their role in the age-associated decline of 
immune function. Trends Immunol. 2009;30(7):306-312.
28. Betjes MG, Huisman M, Weimar W, Litjens NH. Expansion of cytolytic CD4+CD28- T cells in 
end-stage renal disease. Kidney Int. 2008;74(6):760-767.
29. Pawelec G, Derhovanessian E. Role of CMV in immune senescence. Virus Res. 2011;157(2):175-179.
30. Sprent J, Surh CD. T cell memory. Annu Rev Immunol. 2002;20:551-579.
31. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen 
B7. J Exp Med. 1991;174(3):561-569.
32. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition 
of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349(20):1907-1915.
33. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal 
allograft rejection in primates. Proc Natl Acad Sci U S A. 1997;94(16):8789-8794.
34. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-
human primate model of allogeneic pancreatic islet transplantation. J Immunol. 1997;159(11):5187-
5191.
35. Badell IR, Karadkhele GM, Vasanth P, et al. Abatacept as rescue immunosuppression after 
calcineurin inhibitor treatment failure in renal transplantation. Am J Transplant. 2019;19(8):2342-
2349.
36. Gabardi S, van Gelder T. Causes and Consequences of the Worldwide Belatacept Shortage. 
Transplantation. 2017;101(7):1520-1521.
2
50
PART I
37. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based 
immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). 
Am J Transplant. 2010;10(3):535-546.
38. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine 
in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 
2010;10(3):547-557.
39. van den Hoogen MW, Pipeleers L. Three-year outcomes of belatacept studies; reason to be 
optimistic? Am J Transplant. 2012;12(8):2259; discussion 2260.
40. Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosuppression in de novo liver 
transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 
2014;14(8):1817-1827.
41. Knechtle SJ, Adams AB. Belatacept: is there BENEFIT for liver transplantation too? Am J 
Transplant. 2014;14(8):1717-1718.
42. Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant 
recipients. Cochrane Database Syst Rev. 2014(11):CD010699.
43. Vitalone MJ, Ganguly B, Hsieh S, et al. Transcriptional profiling of belatacept and calcineurin 
inhibitor therapy in renal allograft recipients. Am J Transplant. 2014;14(8):1912-1921.
44. Furuzawa-Carballeda J, Uribe-Uribe NO, Arreola-Guerra JM, et al. Tissue talks: immunophenotype 
of cells infiltrating the graft explains histological findings and the benefits of belatacept at 10 years. 
Clin Exp Immunol. 2019.
45. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as 
primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression 
of randomised trial data. BMJ. 2005;331(7520):810.
46. de Graav GN, Baan CC, Clahsen-van Groningen MC, et al. A Randomized Controlled 
Clinical Trial Comparing Belatacept With Tacrolimus After De Novo Kidney Transplantation. 
Transplantation. 2017;101(10):2571-2581.
47. Newell KA, Mehta AK, Larsen CP, et al. Lessons Learned: Early Termination of a Randomized 
Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept. Am J Transplant. 
2017;17(10):2712-2719.
48. Adams AB, Goldstein J, Garrett C, et al. Belatacept Combined With Transient Calcineurin 
Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft 
Function. Am J Transplant. 2017;17(11):2922-2936.
49. Cohen JB, Eddinger KC, Forde KA, Abt PL, Sawinski D. Belatacept Compared With Tacrolimus 
for Kidney Transplantation: A Propensity Score Matched Cohort Study. Transplantation. 
2017;101(10):2582-2589.
50. Muduma G, Hart WM, Patel S, Odeyemi AO. Indirect treatment comparison of belatacept versus 
tacrolimus from a systematic review of immunosuppressive therapies for kidney transplant patients. 
Curr Med Res Opin. 2016;32(6):1065-1072.
51. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential 
role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J 
Exp Med. 2000;192(2):295-302.
51
CHAPTER 2 | COSTIMULATION BLOCKADE IN KIDNEY TRANSPLANT RECIPIENTS 
52. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)
CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. 
J Exp Med. 2000;192(2):303-310.
53. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. 
Science. 2008;322(5899):271-275.
54. Alvarez Salazar EK, Cortes-Hernandez A, Aleman-Muench GR, et al. Methylation of FOXP3 
TSDR Underlies the Impaired Suppressive Function of Tregs from Long-term Belatacept-Treated 
Kidney Transplant Patients. Front Immunol. 2017;8:219.
55. Riella LV, Liu T, Yang J, et al. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant 
model. Am J Transplant. 2012;12(4):846-855.
56. Zwang NA, Leventhal JR. Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells. 
J Am Soc Nephrol. 2017;28(7):1960-1972.
57. Bouvy AP, Klepper M, Kho MM, et al. The impact of induction therapy on the homeostasis 
and function of regulatory T cells in kidney transplant patients. Nephrol Dial Transplant. 
2014;29(8):1587-1597.
58. Sparkes T, Ravichandran B, Opara O, et al. Alemtuzumab induction and belatacept maintenance 
in marginal pathology renal allografts. Clin Transplant. 2019;33(6):e13531.
59. Woodle E, Kaufman D, Shields A, et al. The BEST Trial: A Prospective Randomized Multicenter 
Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression [abstract]. https://
atcmeetingabstracts.com/abstract/the-best-trial-a-prospective-randomized-multicenter-trial-of-
belatacept-based-cni-and-corticosteroid-free-immunosuppression/. Accessed August 15, 2019.
60. Kirk AD, Guasch A, Xu H, et al. Renal transplantation using belatacept without maintenance 
steroids or calcineurin inhibitors. Am J Transplant. 2014;14(5):1142-1151.
61. Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-
avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011;11(1):66-76.
62. Bestard O, Cassis L, Cruzado JM, et al. Costimulatory blockade with mTor inhibition abrogates 
effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transpl Int. 
2011;24(5):451-460.
63. Wojciechowski D, Chandran S, Yang JYC, Sarwal MM, Vincenti F. Retrospective evaluation of 
the efficacy and safety of belatacept with thymoglobulin induction and maintenance everolimus: 
A single-center clinical experience. Clin Transplant. 2017;31(9).
64. Bouvy AP, Klepper M, Kho MM, et al. T cells Exhibit Reduced Signal Transducer and Activator 
of Transcription 5 Phosphorylation and Upregulated Coinhibitory Molecule Expression After 
Kidney Transplantation. Transplantation. 2015;99(9):1995-2003.
65. Ebcioglu Z, Liu C, Shapiro R, et al. Belatacept Conversion in an HIV-Positive Kidney Transplant 
Recipient With Prolonged Delayed Graft Function. Am J Transplant. 2016;16(11):3278-3281.
66. Kumar D, Yakubu I, Cooke RH, Halloran PF, Gupta G. Belatacept rescue for delayed kidney 
allograft function in a patient with previous combined heart-liver transplant. Am J Transplant. 
2018;18(10):2613-2614.
67. Wojciechowski D, Chandran S, Vincenti F. Early post-transplant conversion from tacrolimus 
to belatacept for prolonged delayed graft function improves renal function in kidney transplant 
recipients. Clin Transplant. 2017;31(5).
2
52
PART I
68. Ashman N, Chapagain A, Dobbie H, et al. Belatacept as maintenance immunosuppression 
for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant. 
2009;9(2):424-427.
69. Cicora F, Paz M, Mos F, Roberti J. Use of belatacept as alternative immunosuppression in three 
renal transplant patients with de novo drug-induced thrombotic microangiopathy. Case Rep Med. 
2013;2013:260254.
70. Koppula S, Yost SE, Sussman A, Bracamonte ER, Kaplan B. Successful conversion to belatacept 
after thrombotic microangiopathy in kidney transplant patients. Clin Transplant. 2013;27(4):591-
597.
71. Merola J, Yoo PS, Schaub J, et al. Belatacept and Eculizumab for Treatment of Calcineurin 
Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report. 
Transplant Proc. 2016;48(9):3106-3108.
72. Dedhia P, Govil A, Mogilishetty G, et al. Eculizumab and Belatacept for De Novo Atypical 
Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant 
Recipient: A Case Report. Transplant Proc. 2017;49(1):188-192.
73. Midtvedt K, Bitter J, Dorje C, Bjorneklett R, Holdaas H. Belatacept as immunosuppression in 
patient with recurrence of hemolytic uremic syndrome after renal transplantation. Transplantation. 
2009;87(12):1901-1903.
74. Tatapudi VS, Lonze BE, Wu M, Montgomery RA. Early Conversion from Tacrolimus to Belatacept 
in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-
Transplant Hemolytic Uremic Syndrome. Case Rep Nephrol Dial. 2018;8(1):10-19.
75. Gupta S, Rosales I, Wojciechowski D. Pilot Analysis of Late Conversion to Belatacept in 
Kidney Transplant Recipients for Biopsy-Proven Chronic Tacrolimus Toxicity. J Transplant. 
2018;2018:1968029.
76. Snyder HS, Duhart BT, Jr., Krauss AG, Rao V. Belatacept conversion in African American 
kidney transplant recipients with severe renal dysfunction. SAGE Open Med Case Rep. 
2016;4:2050313X16674865.
77. Le Meur Y, Aulagnon F, Bertrand D, et al. Effect of an Early Switch to Belatacept Among 
Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors. 
Am J Transplant. 2016;16(7):2181-2186.
78. Bertrand D, Cheddani L, Etienne I, et al. Belatacept Rescue Therapy in Kidney Transplant 
Recipients With Vascular Lesions: A Case Control Study. Am J Transplant. 2017;17(11):2937-2944.
79. Belliere J, Guilbeau-Frugier C, Del Bello A, et al. Beneficial effect of conversion to belatacept 
in kidney-transplant patients with a low glomerular-filtration rate. Case Rep Transplant. 
2014;2014:190516.
80. Abdelwahab Elhamahmi D, Heilman RL, Smith B, et al. Early Conversion to Belatacept in Kidney 
Transplant Recipients With Low Glomerular Filtration Rate. Transplantation. 2018;102(3):478-
483.
81. Nair V, Liriano-Ward L, Kent R, et al. Early conversion to belatacept after renal transplantation. 
Clin Transplant. 2017;31(5).
82. Brakemeier S, Kannenkeril D, Durr M, et al. Experience with belatacept rescue therapy in kidney 
transplant recipients. Transpl Int. 2016;29(11):1184-1195.
53
CHAPTER 2 | COSTIMULATION BLOCKADE IN KIDNEY TRANSPLANT RECIPIENTS 
83. de Graav GN, van der Zwan M, Baan CC, Janssen J, Hesselink DA. Improved Glucose Tolerance in 
a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To 
Belatacept: A Case Report and Review of Potential Mechanisms. Transplant Direct. 2018;4(3):e350.
84. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated 
with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney 
transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011;91(9):976-
983.
85. Lerch C, Kanzelmeyer NK, Ahlenstiel-Grunow T, et al. Belatacept after kidney transplantation 
in adolescents: a retrospective study. Transpl Int. 2017;30(5):494-501.
86. Durr M, Lachmann N, Zukunft B, et al. Late Conversion to Belatacept After Kidney 
Transplantation: Outcome and Prognostic Factors. Transplant Proc. 2017;49(8):1747-1756 e1741.
87. Darres A, Ulloa C, Brakemeier S, et al. Conversion to Belatacept in Maintenance Kidney Transplant 
Patients: A Retrospective Multicenter European Study. Transplantation. 2018;102(9):1545-1552.
88. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to 
a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am 
Soc Nephrol. 2011;6(2):430-439.
89. Grinyo JM, Del Carmen Rial M, Alberu J, et al. Safety and Efficacy Outcomes 3 Years After 
Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results 
From a Phase 2 Randomized Trial. Am J Kidney Dis. 2017;69(5):587-594.
90. Malvezzi P, Fischman C, Rigault G, et al. Switching renal transplant recipients to belatacept 
therapy: results of a real-life gradual conversion protocol. Transpl Immunol. 2019.
91. Verhoeven J, Boer K, Van Schaik RHN, et al. Liquid Biopsies to Monitor Solid Organ Transplant 
Function: A Review of New Biomarkers. Ther Drug Monit. 2018;40(5):515-525.
92. Hurkmans DP, Verhoeven J, de Leur K, et al. Donor-derived cell-free DNA detects kidney 
transplant rejection during nivolumab treatment. J Immunother Cancer. 2019;7(1):182.
93. Leibler C, Matignon M, Moktefi A, et al. Belatacept in renal transplant recipient with mild 
immunologic risk factor: A pilot prospective study (BELACOR). Am J Transplant. 2019;19(3):894-
906.
94. Parsons RF, Zahid A, Bumb S, et al. The impact of belatacept on third party HLA alloantibodies 
in highly sensitized kidney transplant recipients. Am J Transplant. 2019.
95. Ulloa CE, Anglicheau D, Snanoudj R, et al. Conversion From Calcineurin Inhibitors to Belatacept 
in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies. 
Transplantation. 2019;103(10):2150-2156.
96. Gupta G, Regmi A, Kumar D, et al. Safe Conversion From Tacrolimus to Belatacept in High 
Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. Am J Transplant. 
2015;15(10):2726-2731.
97. Crespo E, Bestard O. Biomarkers to assess donor-reactive T-cell responses in kidney transplant 
patients. Clin Biochem. 2016;49(4-5):329-337.
98. de Graav GN, Hesselink DA, Dieterich M, et al. An Acute Cellular Rejection With Detrimental 
Outcome Occurring Under Belatacept-Based Immunosuppressive Therapy: An Immunological 
Analysis. Transplantation. 2016;100(5):1111-1119.
2
54
PART I
99. van Besouw NM, Yan L, de Kuiper R, et al. The Number of Donor-Specific IL-21 Producing Cells 
Before and After Transplantation Predicts Kidney Graft Rejection. Front Immunol. 2019;10:748.
100. van der Zwan M, Baan CC, Colvin RB, et al. Immunomics of Renal Allograft Acute T Cell-
Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients. Transplant Direct. 
2019;5(1):e418.
101. Cortes-Cerisuelo M, Laurie SJ, Mathews DV, et al. Increased Pretransplant Frequency of CD28+ 
CD4+ TEM Predicts Belatacept-Resistant Rejection in Human Renal Transplant Recipients. Am 
J Transplant. 2017;17(9):2350-2362.
102. Espinosa J, Herr F, Tharp G, et al. CD57(+) CD4 T Cells Underlie Belatacept-Resistant Allograft 
Rejection. Am J Transplant. 2016;16(4):1102-1112.
103. Krummey SM, Cheeseman JA, Conger JA, et al. High CTLA-4 expression on Th17 cells results 
in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. Am J Transplant. 
2014;14(3):607-614.
104. de Graav GN, Hesselink DA, Dieterich M, et al. Down-Regulation of Surface CD28 under 
Belatacept Treatment: An Escape Mechanism for Antigen-Reactive T-Cells. PLoS One. 
2016;11(2):e0148604.
105. Kraaijeveld R, de Graav GN, Dieterich M, et al. Co-inhibitory profile and cytotoxicity of CD57(+) 
PD-1(-) T cells in end-stage renal disease patients. Clin Exp Immunol. 2018;191(3):363-372.
106. Kannegieter NM, Hesselink DA, Dieterich M, et al. Differential T Cell Signaling Pathway 
Activation by Tacrolimus and Belatacept after Kidney Transplantation: Post Hoc Analysis of a 
Randomised-Controlled Trial. Sci Rep. 2017;7(1):15135.
107. van der Zwan M, Hesselink DA, Clahsen-van Groningen MC, Baan CC. Targeted Proteomic 
Analysis Detects Acute T Cell-Mediated Kidney Allograft Rejection in Belatacept-Treated Patients. 
Ther Drug Monit. 2019;41(2):243-248.
108. Poirier N, Blancho G, Vanhove B. A more selective costimulatory blockade of the CD28-B7 
pathway. Transpl Int. 2011;24(1):2-11.
109. Liu D, Krummey SM, Badell IR, et al. 2B4 (CD244) induced by selective CD28 blockade 
functionally regulates allograft-specific CD8+ T cell responses. J Exp Med. 2014;211(2):297-311.
110. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 
monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018-1028.
111. Eastwood D, Findlay L, Poole S, et al. Monoclonal antibody TGN1412 trial failure explained 
by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 
2010;161(3):512-526.
112. Shi R, Honczarenko M, Zhang S, et al. Pharmacokinetic, Pharmacodynamic, and Safety Profile 
of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects. J Clin Pharmacol. 
2017;57(2):161-172.
113. Poirier N, Blancho G, Hiance M, et al. First-in-Human Study in Healthy Subjects with FR104, a 
Pegylated Monoclonal Antibody Fragment Antagonist of CD28. J Immunol. 2016;197(12):4593-
4602.
114. Poirier N, Dilek N, Mary C, et al. FR104, an antagonist anti-CD28 monovalent fab’ antibody, 
prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate 
renal allograft. Am J Transplant. 2015;15(1):88-100.
55
CHAPTER 2 | COSTIMULATION BLOCKADE IN KIDNEY TRANSPLANT RECIPIENTS 
115. Ville S, Poirier N, Branchereau J, et al. Anti-CD28 Antibody and Belatacept Exert Differential 
Effects on Mechanisms of Renal Allograft Rejection. J Am Soc Nephrol. 2016;27(12):3577-3588.
116. Suchard SJ, Davis PM, Kansal S, et al. A monovalent anti-human CD28 domain antibody 
antagonist: preclinical efficacy and safety. J Immunol. 2013;191(9):4599-4610.
117. Krueger GG. Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for 
psoriasis. Expert Opin Biol Ther. 2002;2(4):431-441.
118. Sanders ME, Makgoba MW, Sharrow SO, et al. Human memory T lymphocytes express 
increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other 
molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J Immunol. 
1988;140(5):1401-1407.
119. Rostaing L, Charpentier B, Glyda M, et al. Alefacept combined with tacrolimus, mycophenolate 
mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. Am J 
Transplant. 2013;13(7):1724-1733.
120. https://www.nanostring.com/products/gene-expression-panels/gene-expression-panels-overview/
human-organ-transplant-panel, assessed on 2 October 2019.
121. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 
1998;16:111-135.
122. Bingaman AW, Pearson TC, Larsen CP. The role of CD40L in T cell-dependent nitric oxide 
production by murine macrophages. Transpl Immunol. 2000;8(3):195-202.
123. Larsen CP, Pearson TC. The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr 
Opin Immunol. 1997;9(5):641-647.
124. Karnell JL, Rieder SA, Ettinger R, Kolbeck R. Targeting the CD40-CD40L pathway in 
autoimmune diseases: Humoral immunity and beyond. Adv Drug Deliv Rev. 2018.
125. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against 
CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med. 1999;5(6):686-
693.
126. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in 
rhesus macaques. Transplantation. 2002;74(7):933-940.
127. Schuler W, Bigaud M, Brinkmann V, et al. Efficacy and safety of ABI793, a novel human 
anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. 
Transplantation. 2004;77(5):717-726.
128. Kanmaz T, Fechner JJ, Jr., Torrealba J, et al. Monotherapy with the novel human anti-CD154 
monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation. 
2004;77(6):914-920.
129. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) 
improves serologic activity and decreases hematuria in patients with proliferative lupus 
glomerulonephritis. Arthritis Rheum. 2003;48(3):719-727.
130. Zhang T, Pierson RN, 3rd, Azimzadeh AM. Update on CD40 and CD154 blockade in transplant 
models. Immunotherapy. 2015;7(8):899-911.
131. Song L, Ma A, Dun H, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate 
mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014;98(3):267-276.
2
56
PART I
132. Vincenti F, Klintmalm G, Yang H, et al. A randomized, phase 1b study of the pharmacokinetics, 
pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal 
antibody, in kidney transplantation. Am J Transplant. 2019.
133. Harland R, Klintmalm G, Jensik S, Yang H, Bromberg J, Holman J, Kumar MAnil, Santos V, 
Larson T, Wang X. Efficacy and Safety of Bleselumab in Kidney Transplant Recipients: A Phase 
2, Randomized, Open-Label Study [abstract]. https://atcmeetingabstracts.com/abstract/efficacy-
and-safety-of-bleselumab-in-kidney-transplant-recipients-a-phase-2-randomized-open-label-study/. 
Accessed July 4, 2019.
134. Cordoba F, Wieczorek G, Audet M, et al. A novel, blocking, Fc-silent anti-CD40 monoclonal 
antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion. 
Am J Transplant. 2015;15(11):2825-2836.
135. Nashan B, Tedesco H, van den Hoogen MW, et al. CD40 Inhibition with CFZ533 - A New, 
Fully Human, Non-Depleting, Fc Silent mAB - Improves Renal Allograft Function While 
Demonstrating Comparable Efficacy vs. Tacrolimus in De-Novo CNI-Free Kidney Transplant 
Recipients. Transplantation. 2018;102:S366.
136. Page A, Srinivasan S, Singh K, et al. CD40 blockade combines with CTLA4Ig and sirolimus to 
produce mixed chimerism in an MHC-defined rhesus macaque transplant model. Am J Transplant. 
2012;12(1):115-125.
137. Gilson CR, Milas Z, Gangappa S, et al. Anti-CD40 monoclonal antibody synergizes with 
CTLA4-Ig in promoting long-term graft survival in murine models of transplantation. J Immunol. 
2009;183(3):1625-1635.
138. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts 
after blocking CD40 and CD28 pathways. Nature. 1996;381(6581):434-438.
139. Zhu P, Chen YF, Chen XP, et al. Mechanisms of survival prolongation of murine cardiac allografts 
using the treatment of CTLA4-Ig and MR1. Transplant Proc. 2008;40(5):1618-1624.
140. Pinelli DF, Wagener ME, Liu D, et al. An anti-CD154 domain antibody prolongs graft survival 
and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig. Am J Transplant. 
2013;13(11):3021-3030.
141. Engela AU, Baan CC, Litjens NH, et al. Mesenchymal stem cells control alloreactive CD8(+) 
CD28(-) T cells. Clin Exp Immunol. 2013;174(3):449-458.
142. Hoogduijn MJ, Betjes MG, Baan CC. Mesenchymal stromal cells for organ transplantation: 
different sources and unique characteristics? Curr Opin Organ Transplant. 2014;19(1):41-46.
143. Belatacept Product Monograph: https://www.ema.europa.eu/en/documents/product-information/
nulojix-epar-product-information_en.pdf, assessed on 8 August, 2019.
144. Klaasen RA, Egeland EJ, Chan J, et al. A Fully Automated Method for the Determination of Serum 
Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients. 
Ther Drug Monit. 2019;41(1):11-18.
145. Vincenti F, Blancho G, Durrbach A, et al. Ten-year outcomes in a randomized phase II study 
of kidney transplant recipients administered belatacept 4-weekly or 8-weekly. Am J Transplant. 
2017;17(12):3219-3227.
146. Eikmans M, Gielis EM, Ledeganck KJ, et al. Non-invasive Biomarkers of Acute Rejection in 
Kidney Transplantation: Novel Targets and Strategies. Front Med (Lausanne). 2018;5:358.
57
CHAPTER 2 | COSTIMULATION BLOCKADE IN KIDNEY TRANSPLANT RECIPIENTS 
2

Marieke van der Zwan
Carla C. Baan
Teun van Gelder
Dennis A. Hesselink
Clinical Pharmacokinetics 2018;57(2):191-207
3CHAPTER
Review of the clinical 
pharmacokinetics and 
pharmacodynamics 
of alemtuzumab and 
its use in kidney 
transplantation
60
PART I
ABSTRACT
Background
Alemtuzumab is a humanized monoclonal antibody against CD52 and causes depletion of T 
and B lymphocytes, monocytes, and NK cells. Alemtuzumab is registered for the treatment 
of multiple sclerosis (MS) and is used off-label in chronic lymphocytic leukemia (CLL). 
Alemtuzumab is used off-label in kidney transplantation as induction and anti-rejection 
therapy. The objective of this article is to review the pharmacokinetics, pharmacodynamics, 
and use of alemtuzumab in kidney transplantation.
Methods
We conducted a systematic literature search using Ovid MEDLINE, EMBASE, and the 
Cochrane Central Register of controlled trials.
Results
No pharmacokinetic or dose-finding studies of alemtuzumab exist for kidney 
transplantation. Although such studies were conducted in patients with CLL and MS, 
these findings could not be directly extrapolated to transplant recipients because CLL 
patients have a much higher load of CD52-positive cells and therefore target-mediated 
clearance will differ between these two indications. Alemtuzumab used as induction 
therapy in kidney transplantation results in a lower incidence of acute rejection compared 
to basiliximab therapy and comparable results as compared with rabbit anti-thymocyte 
globulin. Alemtuzumab used as anti-rejection therapy results in a comparable graft survival 
rate compared with rabbit anti-thymocyte globulin, although infusion-related side effects 
appear to be less. 
Conclusion
There is a need for pharmacokinetic and dose-finding studies of alemtuzumab in kidney 
transplant recipients to establish the optimal balance between efficacy and toxicity. 
Furthermore, randomized controlled trials with sufficient follow-up are necessary to provide 
further evidence for the treatment of severe kidney transplant rejection.
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Key points:
• Alemtuzumab, a monoclonal antibody against CD52, is registered for multiple sclerosis, 
but is used off-label in patients with chronic lymphocytic leukemia and as induction- 
and anti-rejection therapy after kidney transplantation.
• Alemtuzumab causes a rapid and profound depletion of T and B lymphocytes, as well 
as various cells of the innate immune system. Reconstitution of cells form the innate 
immune system is faster (within 6 months) than that of T and B lymphocytes, which 
may take more than 1 year.
• No pharmacokinetic studies of alemtuzumab exist for kidney transplant recipients. The 
results of the pharmacokinetic studies performed in patients with chronic lymphocytic 
leukemia could not be extrapolated directly to the kidney transplant population because 
patients with chronic lymphocytic leukemia have a much higher load of CD52-positive 
(tumor) cells.
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INTRODUCTION 
Alemtuzumab (Campath-1H) is a humanized, rat monoclonal IgG1 antibody with a 
molecular weight of approximately 150 kDa, directed against CD52. The depletion of donor 
T lymphocytes from stem cell transplants to eliminate graft-vs.-host disease was developed 
in the laboratory of Herman Waldmann and Geoff Hale at the university of Cambridge, 
UK1. The first anti-CD52 antibody developed was of the IgM class (Campath-1M), which 
was very effective in eliminating T lymphocytes in vitro. In vivo, there was depletion of blood 
lymphocytes in stem cell transplant recipients, but there was no depletion of lymphocytes in 
the bone marrow and no effect on solid lymphoma masses or splenomegaly1,2. This fueled 
further research and led to the development of a new IgG1 antibody (Campath-1G) which 
was found to result in long-lasting depletion of lymphocytes from both blood and bone 
marrow. A few years later, this antibody was humanized (Campath-1H) to reduce the anti-
globulin responses (Fig. 1)2-4. 
Figure 1. Timeline of alemtuzumab. In the 1980s, alemtuzumab was called Campath and was mainly 
used in hematology patients. Around 20 years later, alemtuzumab was approved for the treatment of 
chronic lymphocytic leukemia (CLL) and for the first time in kidney transplantation. A decade later, the 
registration of alemtuzumab for CLL was withdrawn and alemtuzumab was approved as Lemtrada® for the 
treatment of multiple sclerosis (MS). In 2014, a large randomized controlled trial compared alemtuzumab 
induction therapy with basiliximab induction therapy. EMA European Medicines Agency, FDA US Food 
and Drug Administration.
In 2001, the US Food and Drug Administration and the European Medicines Agency 
approved alemtuzumab for the treatment of chronic lymphocytic leukemia (CLL)5. Later, 
alemtuzumab was also approved by the Food and Drug Administration (2014) and European 
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Medicines Agency (2013) for the treatment of remitting-relapsing multiple sclerosis (RRMS) 
and is currently marketed for this indication under the name Lemtrada® (Sanofi-Genzyme, 
Cambridge, Massachusetts, United States)6. Following the market approval of Lemtrada®, 
the approval for the treatment of CLL was withdrawn (Fig. 1). However, alemtuzumab 
remains available for patients with CLL via the world-wide Campath Distribution Program7. 
In addition, alemtuzumab has also been used off-label for a variety of other diseases and 
conditions, including the prevention and treatment of acute rejection after solid organ 
transplantation (SOT).
In recent years, there has been a renewed interest in the use of alemtuzumab in SOT. In 
this review, we discuss the pharmacokinetics and pharmacodynamics of alemtuzumab, 
its use as induction and anti-rejection therapy in kidney transplantation, and strategies to 
improve the outcomes of alemtuzumab therapy.
METHODS
A systematic literature search was performed (8 February 8, 2017) of Ovid MEDLINE, 
EMBASE and the Cochrane Central Register of controlled trials. The search terms included 
‘alemtuzumab’, ‘campath’, ‘pharmacokinetics’, ‘pharmacodynamics’, ‘induction therapy’, 
‘rejection therapy’, and ‘adverse effects’ (see Electronic Supplementary Material). The 
search revealed 1668 articles. After exclusion of irrelevant articles (after reading the title 
and abstract), 730 articles remained, of which the relevant were included in this review. 
Examination of the reference list of the included studies identified further studies. There 
were no restrictions with regard to publication date. Only papers published in English 
were included. 
PHARMACODYNAMICS OF ALEMTUZUMAB
CD52 is a 21-28 kDa cell surface glycoprotein that is attached to the cell membrane by a 
glycosylphosphatidyl-inositol anchor of 12 amino acids. CD52 is one of the most abundant 
membrane glycoproteins on T and B lymphocytes and is also expressed on natural killer 
(NK) cells, monocytes, macrophages, dendritic cells, eosinophilic granulocytes and to 
a lesser extent on neutrophilic granulocytes1,8. CD52 is not expressed on erythrocytes, 
platelets and hematopoietic progenitor cells9. The exact function of CD52 is unknown 
but it is suggested that the molecule may be involved in T lymphocyte co-stimulation, 
the induction of regulatory T lymphocytes and T lymphocyte migration and adhesion10,11. 
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Administration of alemtuzumab causes a profound depletion of T and B lymphocytes, 
NK cells, dendritic cells, granulocytes and monocytes by three mechanisms: complement-
dependent cytotoxicity (through C1q activation and subsequent generation of the membrane 
attack complex), antibody-dependent cellular cytotoxicity (after the activation of NK cells 
and macrophages through their IgG fragment C receptor), and induction of apoptosis 
(Fig. 2)12,13. Depletion of peripheral lymphocytes occurs within 1 h after alemtuzumab 
administration. Lymphocyte depletion from secondary lymphoid tissues occurs over 3-5 
days14. Alemtuzumab administration significantly depletes peripheral monocytes and NK 
cells15. 
Figure 2. Mechanism of action of alemtuzumab. Alemtuzumab binds to CD52 on target cells (T and 
B lymphocytes, natural killer (NK) cells, monocytes, granulocytes and dendritic cells) and via three 
pathways depletion of the target cells occur. The antibody-dependent cellular cytotoxicity involves the 
IgG fragment C receptor (FcγR) on NK cells, macrophages and granulocytes. The FcγR recognizes the Fc 
region of alemtuzumab and binds to it. The NK cell, macrophage, or granulocyte releases perforins and 
granzyme B which causes lysis and apoptosis of the target cell. In complement-dependent cytotoxicity, the 
C1 complex (consisting of C1q, C1r and C1s), binds to alemtuzumab and this initiates the complement 
activation cascade and subsequently the formation of the membrane attack complex (MAC). Finally, 
binding of alemtuzumab to CD52 induces apoptosis directly. IFN interferon.
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Alemtuzumab has a long-lasting depletional effect. In kidney transplant recipients receiving 
alemtuzumab as induction therapy (40-mg total dose), B lymphocytes recovered after 12 
months. In contrast, T lymphocyte numbers recovered to approximately 50% of baseline 
36 months after alemtuzumab administration. CD8+ T lymphocytes repopulated more 
rapidly than CD4+ T lymphocytes16. Cells of the innate immune system reconstitute faster 
than cells of the adaptive immune system. After 1 month, more than half of the peripheral 
lymphocytes consists of NK cells and the number of NK cells returns to 60-80% of baseline 
by 6 months17. Monocytes are only mildly depleted and recover after 3 months16. Dendritic 
cells recover to baseline levels 6 months after alemtuzumab treatment18. 
Immunological reconstitution of T lymphocytes, either partial or complete, appears to 
occur predominantly trough homeostatic proliferation of residual CD4+CD25+Forkhead 
box P3+ (FoxP3+) regulatory lymphocytes, as well as memory T lymphocytes and not by 
thymopoiesis19. Normally, levels of FoxP3+ regulatory T lymphocytes in kidney transplant 
recipients make up 3-4% of the total CD4+ population. After alemtuzumab treatment, a 
relative increase of FoxP3+ regulatory T lymphocytes is seen (up to 12%) which persists for 2 
years20. During immunological reconstitution skewing of the immune system to a more anti-
inflammatory pattern is observed: an increase in the percentage of the anti-inflammatory 
cytokines interleukin (IL)-10 and transforming growth factor-β1 (produced by CD4+ and 
CD8+ cells), an increased percentage of IL-4-producing T-helper 2 cells, and decreased levels 
of the pro-inflammatory cytokines IL-17 and interferon (IFN)-γ21. 
Anderson et al. described the reconstitution of T lymphocytes 12 years after treatment with 
alemtuzumab because of rheumatoid arthritis22. Twenty patients treated with alemtuzumab 
were compared to 13 age-matched rheumatoid arthritis patients. Total CD4+ lymphocyte 
counts were lower in the alemtuzumab group compared with the controls (median 0.55 
x109/l vs. 0.85 x 109/l; p = 0.0014). The naïve and central memory CD4+ lymphocytes were 
significantly reduced in the alemtuzumab-treated patients (0.09 x109/l vs. 0.21 x109/l (p = 
0.0007) and 0.1x109/l vs. 0.36 x109/l (p <0.0001), respectively). However, effector memory 
CD4+ lymphocyte counts were not different. Total CD8+ lymphocytes were similar in both 
groups, but the naïve and central memory CD8+ lymphocytes were significantly lower in 
the alemtuzumab treated patients (0.05x109/l vs. 0.07x109/l (p = 0.0061) and 0.02x109/l vs. 
0.04x109/l (p = 0.0342)22. 
B lymphocyte reconstitution in patients treated with alemtuzumab coincides with a high 
level of the cytokine B lymphocyte activating factor (BAFF, also known as TALL-1, BLyS, 
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THANK and zTNF4), that persists for over 12 months23,24. From the second month after 
alemtuzumab administration, B lymphocytes start to repopulate. First the transitional B 
lymphocytes dominate, followed by Bm2’ (mature naïve) B lymphocytes25. Differentiation 
to memory B lymphocytes is slow and reaches 25% of baseline after 12 months23,24. After 
alemtuzumab induction therapy there is an increased risk of formation of de novo donor-
specific anti–HLA antibodies (DSA) compared with basiliximab or anti-thymocyte globulin 
(ATG), which can lead to chronic humoral immune responses against graft alloantigens 
and subsequent graft failure25,26. The authors hypothesized that the spared alemtuzumab-
resistant memory cells in presence of alloantigens can rapidly convert to plasmablasts and 
secrete donor-specific antibodies25.
PHARMACOKINETICS OF ALEMTUZUMAB 
Administration
Alemtuzumab is available as a solution for intravenous or subcutaneous administration. A 
vial contains 30 mg in 1 mL, or in case of Lemtrada® 12 mg in 10 mL. The recommended 
dose depends on the indication for alemtuzumab. In RRMS, the initial treatment is 12 mg/
day intravenously for 5 consecutive days (cumulative dose of 60 mg) followed at 12 months 
by a second treatment course with 12 mg/day for 3 consecutive days (cumulative dose of 
36 mg)27. For the indication CLL, it is advised to start with a maximum dose of 3 mg, 
intravenously, a second dose which is increased to 10 mg, which is followed by a third dose 
of 30 mg. Thereafter, the recommended alemtuzumab dose is 30 mg/day administered three 
times weekly for a maximum of 12 weeks (maximum cumulative dose 1080 mg)28. Dose 
recommendations have also been made for the reduced-intensity hematopoietic stem cell 
transplantation setting for non-malignant hematologic disease29. A typical dosing scheme 
of alemtuzumab in SOT is 1 or 2 gifts of 30 mg intravenously or subcutaneously30-32. This 
dose is empirical and has been deducted from the maximum dose used in hematology. No 
formal dose-finding studies have been performed in SOT recipients. It is recommended 
that patients are pre-medicated with glucocorticoids, acetaminophen and anti-histamines 
immediately prior to the administration of alemtuzumab to diminish infusion-related 
reactions33,34.
Absorption
No pharmacokinetic studies of alemtuzumab have been performed in SOT recipients, 
whereas in patients with CLL and MS only a few such studies have been conducted. By 
definition, the bioavailability of alemtuzumab is 100% after intravenous administration. In 
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one study, the maximum concentration (Cmax) of intravenously administered alemtuzumab 
was evaluated in 216 patients with RRMS34. Administration of 12 mg per day for 5 
consecutive days resulted in a mean Cmax of 3014 ng/mL directly after the last administration 
on day 5. In patients with CLL, Cmax of 2800-26,400 ng/ml (mean 10,700 ng/mL) were 
measured after intravenous administration of 30 mg three times a week for 8 weeks35. 
Alemtuzumab can also be administered subcutaneously. Subcutaneous administration is 
more convenient and causes less infusion-related reactions as compared to intravenous 
administration36,37. The bioavailability of subcutaneously administered alemtuzumab was 
studied in cynomolgus monkeys. Doses of 1, 2 and 3 mg/kg were slowly absorbed from 
the site of injection and the time to reach Cmax was around 48 h. The bioavailability after 
subcutaneous administration was approximately 47%28. In humans, Hale et al.35 compared 
blood concentrations from patients with CLL who were treated either intravenously or 
subcutaneously (30 mg three times weekly). The highest measured pre-dose concentrations 
were similar between the two routes of administration (mean 5400 ng/mL). To reach a 
pre-dose concentration of 1000 ng/mL (an arbitrary threshold known to be potentially 
lympholytic), a higher cumulative dose was required when the drug was given subcutaneously 
as compared with intravenous administration (1106 mg and 146 mg, respectively). 
Induction therapy with alemtuzumab in simultaneous pancreas-kidney transplant (SPKT) 
recipients showed no clinical difference between subcutaneous or intravenous therapy. 
Total lymphocyte and CD3+ lymphocyte depletion were not significantly different and the 
incidence of acute rejection episodes, as well as patient survival, were comparable in the 
two groups31.
Distribution 
Because of its size, alemtuzumab is not likely to cross cell membranes and is therefore 
expected to distribute between the plasma and interstitial space. In patients with MS the 
volume of distribution was reported to be 14.1 L34. To measure the volume of distribution in 
CLL patients, Mould et al.38 pooled the data of 67 patients from four studies. This resulted 
in a steady-state volume of distribution of 11.3 L. 
In addition to being expressed on the cell surface, CD52 also exists in soluble form. Soluble 
CD52 can bind alemtuzumab, form immune complexes, and thereby reduce the amount 
of free and bioactive drug. Soluble CD52 levels are likely to be lower in patients with MS 
and recipients undergoing SOT compared with CLL patients39. Higher plasma levels of 
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soluble CD52 may require higher doses of alemtuzumab for sufficient efficacy40. There are 
no data on binding of alemtuzumab to other plasma proteins. 
Metabolism and elimination 
The half-life of alemtuzumab depends on the concentration of its target. In the case of a high 
concentration of CD52, such as in patients with CLL with a large tumor burden, the half-
life of alemtuzumab is short, because binding of alemtuzumab to CD52 leads to cytotoxicity 
of malignant cells and rapid receptor-mediated clearance from the blood. When CD52 levels 
decrease (following successful treatment), the half-life of alemtuzumab increases. Therefore, 
patients with CLL will require a higher cumulative dose than patients treated for another 
indication. The half-life of alemtuzumab in patients with CLL is 6.1 days and in stem cell 
transplant recipients 8-21 days35,41,42. The half-life of alemtuzumab in patients with RRMS 
(12 mg on 5 consecutive days) was approximately 4-5 days and low or undetectable serum 
concentrations were measured within 30 days after completion of the course34. 
The mechanism of clearance of alemtuzumab from the circulation and interstitial space 
is not well understood. In a study of patients with CLL, alemtuzumab showed time- and 
concentration-dependent pharmacokinetics with (non-linear) clearance with large inter-
patient variability38. This is probably explained by a difference in tumor burden. It is not 
known whether individual variations in factors such as hepatic function or macrophage 
activity affect the elimination rate of alemtuzumab43. No studies of the pharmacokinetics 
of alemtuzumab have been performed in patients with renal insufficiency or hepatic 
impairment.
It is also unknown if alemtuzumab binds to the neonatal Fc-receptor like some other 
monoclonal antibodies. The Fc-receptor is expressed on endothelial cells and influences 
the half-life of IgG1 by internalization of immunoglobulins and protection from lysosomal 
degradation44. 
The expected metabolic pathway of alemtuzumab is degradation to small peptides 
and individual amino acids by widely distributed proteolytic enzymes. Classical 
biotransformation studies have not been conducted but are unlikely to be relevant for 
alemtuzumab clearance34. 
There is no known antidote available in case of an accidental overdose and treatment 
consist of supportive measures34. The effect of hemodialysis on the plasma concentration 
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of alemtuzumab is unknown. However, it is unlikely that alemtuzumab is removed with 
hemodialysis because of its size (150 kDa). Likewise, no studies investigated if alemtuzumab 
is removed by plasmapheresis. For the monoclonal antibody rituximab, it is known that 
plasmapheresis removes an important proportion of the drug if performed within the first 
72 h after administration45. Like rituximab, alemtuzumab has a small volume of distribution 
and it is therefore likely that plasmapheresis can reduce the plasma concentration of 
alemtuzumab. However, the depletional effect on peripheral lymphocytes is already seen 
in the first hour after alemtuzumab administration.
Immunogenicity
Alemtuzumab is a recombinant humanized protein with a variable framework with constant 
regions from a human IgG1 immunoglobulin and six complementarity-determining regions 
from a rat IgG2a antibody. The humanization of alemtuzumab has reduced the risk of 
antiglobulin responses46. Anti-drug antibodies are still observed after administration of 
alemtuzumab35,46. 
In patients with CLL, no patient developed anti-alemtuzumab antibodies in the group 
treated with intravenous alemtuzumab (n = 30), whereas two patients in the group given 
subcutaneous alemtuzumab developed such antibodies (n = 32). The antibodies likely 
inactivated alemtuzumab, because these two patients did not show a significant reduction 
in lymphocyte count following alemtuzumab administration35. 
The phase III studies CARE MSI (Comparison of alemtuzumab and Rebif ® efficacy) and 
CARE MSII (trials performed in patients with MS) showed a much higher percentage of 
anti-alemtuzumab antibodies. These antibodies were detectable in 29% of patients just 
before the second course of alemtuzumab (12 months after the last alemtuzumab gift) and 
in 81-86% of patients 1 month after the second course. Although the presence of anti-
alemtuzumab antibodies was associated with a lower alemtuzumab concentration after 
the second course, the clinical outcome, lymphocyte depletion and repopulation were not 
influenced47,48. Rebello et al. described 12 patients treated with alemtuzumab because of 
kidney transplant rejection. No anti-alemtuzumab antibodies were detected46. 
Many factors possibly influence the immunogenicity of alemtuzumab including the dose 
and length of treatment, the route of administration, prior exposure to chemotherapy, and 
the concomitant use of other immunosuppressive drugs46,49. Additionally, the incidence of 
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anti-alemtuzumab antibodies is dependent on the sensitivity and specificity of the assay 
that is used.
THERAPEUTIC DRUG MONITORING
Pharmacokinetic monitoring is performed by three assays to measure alemtuzumab 
concentrations: an enzyme-linked immunosorbent assay, an indirect immunofluorescence 
method with flow cytometry detection, and liquid chromatography mass spectrometry50-52.
For enzyme-linked immunosorbent assay, serum samples are added to microtiter plates 
that contain rabbit anti-rat IgG antibodies that recognize the remaining rat sequence in 
the alemtuzumab molecule50. After incubation the plates are washed and incubated with 
peroxidase-conjugated, affinity purified rabbit anti-human Fc. After washing, the substrate 
(3,3’-5,5’-tetramethylbenzidine; DAKO, Carpinteria, CA, USA) is added. The reaction 
is stopped with hydrochloride and the signal is measured with a spectrophotometer. No 
significant difference was seen between serum or plasma. The lower limit of detection of 
the assay is 0.05 µg/mL50.
Alemtuzumab can also be measured by means of flow cytometry. For this technique a 
HUT-78 cell line is used. This CD8+ T- cell line is derived from a patient with Sézary 
syndrome and expresses high levels of CD5253. The cell line is incubated with the serum of 
the patient treated with alemtuzumab. After washing, fluorescein isothiocyanate-labelled 
polyclonal anti-human Ig Fc antibodies are added and fluorescence is measured by flow 
cytometry. The lower limit of detection is 0.15 µg/L and the lower limit of quantification 
is 0.25 µg/L51. Recently, Marsh et al. used flow cytometry with normal donor peripheral 
blood mononuclear cells instead of the HUT-78 cell line to measure alemtuzumab 
concentrations54. The lower limit of detection was 0.02 µg/mL which is lower than that of 
the HUT-78 cell line-based assay54.
Mass spectrometry has been described as a method to measure alemtuzumab52. It is currently 
not frequently used for the measurement of alemtuzumab. However, liquid chromatography-
tandem mass spectrometry might become an important method to measure the blood 
concentrations of monoclonal antibodies in the future55. Pharmacodynamic monitoring is 
mainly done by flow cytometry to quantify the numbers of circulating T and B lymphocytes 
and NK cells. 
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From the above, it is clear that measuring the serum or plasma concentration of alemtuzumab 
is possible. However, these assays are not widely available, technically demanding and 
difficult to standardize. In SOT, no formal dose finding studies exist and at present there 
are no tests that support specific alemtuzumab target concentrations, with an optimal 
balance between efficacy and toxicity. Such studies have been performed in patients 
undergoing hematopoietic stem cell transplantation, and based upon pharmacokinetic-
pharmacodynamic model target concentrations for this specific population have been 
proposed (personal communication, R. Admiraal, Leiden University Medical Center, The 
Netherlands). 
CLINICAL USE OF ALEMTUZUMAB IN KIDNEY TRANSPLANTATION 
Alemtuzumab was never registered for SOT indications. The drug has been used off-label 
for both the prevention and treatment of acute allograft rejection in kidney, pancreas, 
intestinal and lung transplantation. 
Alemtuzumab as induction therapy 
Kidney transplantation
In many transplant centers, induction therapy is used to reduce early rejection rates. Two 
types of induction therapy are recognized: T lymphocyte-depleting antibody therapy 
and antibody therapy directed against the IL-2 receptor. Basiliximab is a non-depleting 
monoclonal antibody directed against the IL-2 receptor, whereas ATG and alemtuzumab 
are depleting antibodies. Alemtuzumab was first used as induction therapy in 1998 in a 
case series of 13 kidney transplant recipients. The patients received induction therapy with 
alemtuzumab (two doses of alemtuzumab 20 mg intravenously on day 0 and 1) followed 
by low-dose ciclosporin as maintenance therapy. In the 6- to 11-month follow-up, only one 
patient experienced acute rejection56. 
Following this initial experience, the efficacy of alemtuzumab to prevent acute rejection 
following kidney transplantation was compared to IL-2 receptor antibodies in randomized-
controlled trials (RCTs). A systematic review of five of these RCTs described a reduced risk 
of acute rejection using alemtuzumab as compared with an IL-2 receptor antagonist at 12 
months after kidney transplantation (659 patients; relative risk = 0.54; 95% confidence 
interval (CI) 0.37-0.79; p <0.01)57. No significant difference was seen in graft loss, delayed 
graft function, or patient survival. 
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Recently, the results of the first phase of the ‘Campath, calcineurin inhibitor reduction and 
chronic allograft nephropathy’ (3C) study were published. The hypothesis of this RCT was 
that a more potent induction therapy at the time of transplantation allows for minimization 
of tacrolimus exposure without an increased risk of acute rejection. An immunosuppressive 
regimen with reduced exposure to the nephrotoxic tacrolimus could potentially lead to 
better renal function and longer graft survival. In the 3C study, induction therapy with 
alemtuzumab (30 mg on days 0 and 1, subcutaneously or intravenously) was compared with 
basiliximab (20 mg intravenously on days 0 and 4). A total of 852 patients were included (n 
= 426 in the alemtuzumab and n = 426 in the control arm). Patients in the alemtuzumab 
arm were co-treated with low-dose tacrolimus (aiming for pre-dose concentrations of 5-7 
ng/mL) and mycophenolate sodium (360 mg twice daily) without glucocorticoids. In the 
control arm, basiliximab-treated patients were co-treated with a standard-dose tacrolimus 
(target pre-dose concentrations 5-12 ng/mL), mycophenolate sodium (540-720 mg twice 
daily) and glucocorticoids (15 to 20 mg prednisone, withdrawn in accordance with local 
practice). 
The primary endpoint of the 3C study was the incidence of biopsy-proven acute rejection 
(BPAR) at month 6 after transplantation. Induction therapy with alemtuzumab in 
combination with low-dose tacrolimus and mycophenolate sodium without glucocorticoids 
significantly reduced the incidence of BPAR: 26 (6.1%) vs. 65 (15.3%; (p <0.0001, hazard 
ratio 0.37 (95% CI 0.23-0.58)), for the alemtuzumab and control arms, respectively. No 
significant difference was seen in the occurrence of biopsy-proven antibody-mediated 
rejection (ABMR): 8 (1.9%) vs. 5 (1.2%) (p = 0.41, hazard ratio 1.59 (95% CI 0.52-4.86). 
There was no difference 6 months after randomization between the two groups in terms of 
graft function (mean eGFR 50.1 mL/min per 1.73 m2 in the alemtuzumab-treated patients 
vs. 49.8 mL/min per 1.73 m2 in the basiliximab group), the incidence of graft failure, 
mortality, or serious infection58. Limitations of the 3C study were the short follow-up 
duration of 6 months and no blinding of the induction therapies. In addition, the difference 
in tacrolimus exposure was limited: The average pre-dose concentration of tacrolimus in 
the alemtuzumab treated patients was 6.9 ng/mL and in patient treated with basiliximab 
8.3 ng/mL59.
Hanaway et al. compared alemtuzumab induction therapy (a single shot of 30 mg, 
intravenously) with basiliximab induction therapy (in patients with low risk of acute 
rejection) or with rabbit ATG (rATG) induction therapy in high risk patients. A high risk 
of acute rejection was defined as panel-reactive antibody (historical or current) above 20%, 
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repeat transplantation or black ethnicity. There were 139 high risk patients; 70 received 
alemtuzumab and 69 received rATG. In the low risk group, 335 patients were included; 164 
received alemtuzumab and 171 patients received basiliximab. Basiliximab was given on day 
0 and day 3,4, or 5 (20 mg per gift). The total dose of rATG was 6 mg/kg (divided over four 
gifts). All patients received tacrolimus (target pre-dose concentration of 7-14 ng/mL in the 
first 3 months after transplantation, and 4-12 ng/mL after month 3), mycophenolate mofetil 
(1000 mg twice daily), and glucocorticoids (withdrawn on post-operative day 5). The rate of 
BPAR at 12 months in the alemtuzumab group was lower than in the basiliximab-treated 
patients (3% vs. 20%, p <0.0001). No significant difference in BPAR after month 12 was 
observed between alemtuzumab and rATG in the high risk group (10% vs. 13%, p = 0.53)60.
A systematic review with meta-analysis compared induction therapy with alemtuzumab to 
rATG. A total of 446 patients was included and a comparable incidence of BPAR (relative 
risk = 0.79; 95% CI 0.52-1.21; p = 0.28) was seen. There was also no significant difference 
in graft loss and overall survival57. A recent Cochrane systematic review also showed 
comparable rates of BPAR between the alemtuzumab and rATG in a total of six studies (446 
patients; RR 0.68 (95% CI 0.44-1.05; p = 0.66). However, rates of BPAR after alemtuzumab 
induction were lower in four studies with early glucocorticoid withdrawal (360 patients; 
RR 0.57; 95% CI 0.35-0.93; p = 0.025). Rabbit ATG plus glucocorticoid continuation vs. 
alemtuzumab plus early glucocorticoid withdrawal showed no difference between the two 
groups (2 studies; 86 patients, RR 1.27, 95% CI 0.5-3.19; p = 0.57)61. 
Although no higher rejection rate was seen after alemtuzumab induction therapy in the 
studies described above, higher rates of acute ABMR have been described in a few studies62-64. 
LaMattina et al.64 compared in a retrospective study induction therapy with either 
alemtuzumab (n = 632), basiliximab (n = 690) or rATG (n = 125). Alemtuzumab was given 
one or two times (30 mg), basiliximab was administered on postoperative day 0 and 4 (20 
mg) and the total dose of rATG was 6-8 mg/kg. Maintenance immunosuppression consisted 
of tacrolimus or ciclosporin in combination with mycophenolate mofetil and glucocorticoids 
(tapered to 5-10 mg/day after the first post-operative month). No significant difference was 
seen in overall frequency of BPAR; however, ABMR was significantly increased in the group 
of patients treated with alemtuzumab induction therapy compared to the group treated 
with rATG or basiliximab induction therapy. The 1-, 3- and 5- year cumulative incidence 
of alemtuzumab treated patients was 18.8, 23.8 and 26.5% respectively, vs. 11.3, 15.2 and 
17.6% for the group receiving rATG or basiliximab (p<0.0001). The higher incidence of 
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ABMR could have been caused by a higher incidence of DSA after alemtuzumab treatment; 
however, this study did not test for the presence of DSA. 
Simultaneous pancreas-kidney transplantation
Adding a pancreas allograft to a kidney transplant seems to increase the risk of acute 
rejection. Over 90% of SPKT receive antibody induction, with nearly 80% receiving a T 
lymphocyte depleting antibody65. 
In a single-center RCT, 28 SPKT recipients treated with alemtuzumab induction were 
compared to 18 SPKT patients treated with rATG. Alemtuzumab induction consisted of 
a single dose of 30 mg intravenously or rATG (cumulative dose 5-6 mg/kg). All patients 
received maintenance immunosuppression consisting of tacrolimus, mycophenolate 
mofetil, and glucocorticoids (with complete withdrawal on post-operative day 5). Patients 
identified as being high immunological risk remained on maintenance glucocorticoids. In 
this underpowered study, no significant difference was seen in the frequency of rejection 
after 1 year (18 and 39%, respectively for alemtuzumab and rATG; p = 0.17)) and 5 year 
(21 and 44%; p = 0.12). Total patient survival after 5 years was not significantly different 
(82 vs. 89% for alemtuzumab and rATG, respectively). Also, after 5 years, no significant 
difference was seen in kidney graft survival (78.6 vs. 66.7%) and pancreas graft survival 
(64.3 vs. 55.5%)66. 
Alemtuzumab induction therapy was compared with basiliximab in a retrospective cohort 
study of 136 SPKT recipients. All patients received maintenance immunosuppression with 
tacrolimus, mycophenolate mofetil and glucocorticoids. Basiliximab was given to 39 patients 
and alemtuzumab (30 mg, on days 0 and 1) was given to 97 patients. Acute cellular rejection 
of the kidney was significantly less frequent in the alemtuzumab-treated patients (3.1 vs. 
15.4%, p = 0.017). The occurrence of ABMR was not different between the two groups 
(18% vs.14.4%, p = 0.6, for alemtuzumab and basiliximab, respectively). After 3 years, no 
significant difference was seen in patient survival, allograft survival of the kidney (86.2% 
for alemtuzumab and 91.8% for basiliximab) or pancreas (88.6% for alemtuzumab and 
81.8% for basiliximab)67.
Taken together, alemtuzumab is frequently used as an induction agent in SOT. Compared 
with basiliximab induction therapy, alemtuzumab results in a lower incidence of acute 
rejection. However, when compared to rATG no difference in the risk of acute rejection 
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was observed. Graft survival and patient survival are mostly comparable between induction 
therapy with alemtuzumab and basiliximab or rATG. 
Alemtuzumab as anti-rejection therapy 
In most centers, the first line treatment of BPAR of a kidney transplant is pulse therapy with 
glucocorticoids. In case of glucocorticoid-resistant rejection or in case of severe (histological 
grade) rejection, depleting antibody therapy is indicated68. The standard depleting antibody 
is rATG69. However, treatment with ATG has limitations. First, ATG must be administered 
via a high-flow intravenous access (often a central venous catheter) or an arteriovenous 
fistula to avoid thrombophlebitis. Second, administration of ATG can cause cytokine release 
syndrome immediately after infusion. Cytokine release syndrome is characterized by fever, 
hypotension, pulmonary edema, nausea, tachycardia, rash or chills. Furthermore, anti-
rabbit antibodies can form after rATG administration. In case of subsequent exposure to 
rATG, this can lead to diminished activity and adverse reactions like serum sickness70. An 
alternative treatment would be necessary in these patients. 
Alemtuzumab has incidentally been used as treatment of BPAR after kidney 
transplantation30,32,46,71-73. No RCTs investigating this application have been performed. 
Clatworthy et al 73 described the long-term outcome of first line treatment of BPAR with 
alemtuzumab. Of the 15 patients described in this retrospective case series, 12 patients were 
diagnosed with an acute cellular rejection, one with an ABMR and two with a mixed-type 
rejection. Alemtuzumab was administered intravenously and the first six patients were 
treated with 10 mg per day for 7 days (cumulative dose of 70 mg). The remaining nine 
patients received alemtuzumab in a dose of 6 mg/day for 4-10 days. The control group 
consisted of 25 patients with an acute rejection treated in the same period with intravenous 
methylprednisolone (1000 mg/day for 3 consecutive days). Of the 25 biopsies, 22 showed 
acute cellular rejection and three mixed-type rejections. Maintenance immunosuppressive 
therapy consisted of ciclosporin, azathioprine, and glucocorticoids. Baseline characteristics 
were comparable in both groups. All rejection episodes were treated successfully, as shown by 
a fall in serum creatinine within 3-10 days of treatment. Long-term transplant survival and 
allograft function were similar in both groups. There was no excess rate of cytomegalovirus 
infection, malignancy, autoimmunity, or post-transplant lymphoproliferative disorder in 
the alemtuzumab-treated patients. Serious infections during the first year were noted in 
47% of patients treated with alemtuzumab and three patients died in the first year because 
of infection73. In conclusion, this study demonstrates that treatment of acute rejection 
with alemtuzumab results in comparable long-term outcomes as with methylprednisolone 
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pulse treatment; however, with an excess of infection-related death in the first year after 
treatment73.
Alemtuzumab has also been used as second line treatment in glucocorticoid-resistant 
or severe acute rejection. Basu et al. described 40 patients with glucocorticoid-resistant 
rejection (29 patients) or severe rejections (Banff 1B or worse, 11 patients). No control group 
was included. The patients were treated with alemtuzumab intravenously (30 mg, one to 
four doses). All patients had previously received induction therapy consisting of rATG or 
alemtuzumab followed by tacrolimus monotherapy as maintenance immunosuppression. 
Graft survival after a mean duration of 453 ± 163 days was 62.5%. In 14 patients, 
infectious complications occurred. Two patients died: one patient developed post-transplant 
lymphoproliferative disorder and the other patient died because of an intraabdominal 
abscess72. The authors concluded that the outcome after treatment with alemtuzumab is 
comparable to the outcome of other antibody preparations (indirect comparisons with 
RCT). However, infectious complications were frequent72. 
Another retrospective study compared alemtuzumab to rATG for the treatment of 
glucocorticoid-resistant rejection. Eleven patients were treated with 15-30 mg alemtuzumab 
(subcutaneously) for 1-2 consecutive days. The reason for treating these patients with 
alemtuzumab were as follows: fluid overload, positive test for anti-rabbit IgG antibodies, 
treatment with ATG after previous transplantation and cardiac ischemia. Three patients had 
no contra-indication for ATG. The control group consisted of 20 patients who were treated 
with rATG (2.5-4.0 mg/kg for 10-14 days). These historical controls consisted of patients 
with a glucocorticoid-resistant rejection and were matched for date after transplantation. 
The endpoint of this small study was a composite endpoint named ‘treatment failure’ after 
three months which was defined as either graft loss, the need for additional anti-rejection 
therapy or the lack of improvement of renal allograft function (drop of less than 25% of 
serum creatinine at 3 months after treatment with alemtuzumab or rATG). The incidence 
of treatment failure was comparable in both groups (alemtuzumab 27% vs. rATG 40%, 
p = 0.89)30.
Taken together, anti-rejection therapy with alemtuzumab results in a comparable graft 
survival compared with rATG. However, head-to-head RCTs with an rATG control and 
with longer follow-up are necessary to support this conclusion. 
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Alemtuzumab in pediatric kidney transplantation
Reducing the toxicity of immunosuppressive drugs is of paramount importance in pediatric 
kidney transplant recipients. In particular, the minimization of glucocorticoids, which can 
cause, among others growth retardation, post-transplant diabetes mellitus and weight gain, 
is an important goal in this population. Induction therapy with alemtuzumab has been 
used incidentally to avoid glucocorticoids and reduce calcineurin inhibitor exposure but no 
prospective, randomized controlled clinical trials comparing different induction therapies 
have been performed in children74-83. Several reasons may exist why limited studies have 
been performed with alemtuzumab in children. First, most children are unsensitized at the 
time of transplantation because most patients did not have prior kidney transplantations 
or pregnancies. Second, physicians may be concerned for the development of primo-
cytomegalovirus and Epstein–Barr virus (EBV) infections and EBV-related post-transplant 
lymphoproliferative disease (PTLD) after alemtuzumab administration.
The first experience with alemtuzumab as induction therapy in pediatric kidney transplant 
recipients was described in 200575. Four patients ranging from 20 months to 16 years of age 
received alemtuzumab intraoperatively (one dose of 30 mg in three patients and two doses 
of 30 mg in one patient). Three patients also received a calcineurin inhibitor, mycophenolate 
mofetil with or without corticosteroids as maintenance immunosuppressive therapy. In 
the fourth patient, calcineurin inhibitor therapy was withheld because of concerns for 
recurrence of Factor H, deficiency-associated hemolytic uremic syndrome. In the short 
follow-up period of 5-12 months, three children experienced acute rejection (of which two 
were C4d-positive suggesting an antibody-mediated rejection) without graft loss. No serious 
infections or PTLD occurred75. White blood cell counts were measured by flow cytometry 
in one patient and demonstrated that CD3+, CD4+, CD8+ and CD20+ lymphocyte counts 
had recovered to 50% of baseline one year after administration. Monocytes recovered to 
baseline level by month 375.
After this initial and disappointing experience, better results were obtained in a larger 
case series of 42 pediatric kidney transplant patients (mean age 9.0 years) treated with 
alemtuzumab induction therapy (in a dose of 0.4 - 0.5 mg/kg intravenously) followed by 
tacrolimus monotherapy76. The mean follow-up was 24.1 months. The aim of tacrolimus 
dosing was a pre-dose concentration of 8-12 ng/mL in the first 6 months. In case of no 
rejection and in the absence of the development de novo DSA and graft dysfunction, the 
tacrolimus dose was lowered to every other day. This strategy was successful in 12 patients. 
Only two patients experienced an episode of an acute cellular rejection and no cases of acute 
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antibody-mediated rejection were observed. The 4-year graft survival rate was 85.4%. No 
cases of cytomegalovirus infection were seen and two patients were diagnosed with BK 
viremia. No PTLD or serious infections occurred. Two children died: one of unknown 
cause and one because of a disconnected tracheostomy at home76. 
A larger case series of 101 pediatric kidney transplant patients (mean age 10.7 years) 
described a different outcome regarding the incidence of rejection and infection77. The 
patients were treated with two 30-mg doses of alemtuzumab: the first dose 12-29 days 
before transplantation and the second dose on the day of transplantation. The mean follow-
up was 3.8 years. Maintenance therapy consisted of a calcineurin inhibitor (tacrolimus 
or ciclosporin) in combination with mycophenolate mofetil. Glucocorticoids were 
discontinued around day 5 if the graft function was acceptable and target calcineurin 
blood concentrations were reached. The incidence of acute rejection (including subclinical 
rejections) was 37%. In four patients rejection led to graft loss. Overall graft survival was 
89.1% after three years. Cytomegalovirus and BK viremia occurred mostly during the first 
three months (30% and 25%, respectively). Twenty percent of patients experienced EBV 
viremia by year 2. No patients developed PTLD. Eight patients died (range 26-1457 days) 
of which five because of an infection77.
In a phase II multicenter prospective analysis 35 pediatric kidney transplant patients were 
treated with one gift of alemtuzumab (0.3 mg/kg, maximum 20 mg) as induction therapy84. 
The primary aim of this study was to characterize the reconstitution of lymphocyte subsets 
in pediatric renal transplant recipients after alemtuzumab induction therapy followed by 
calcineurin inhibitor withdrawal. The patients were unsensitized and were first-time recipients 
with living donors. Maintenance immunosuppressive therapy consisted of tacrolimus and 
mycophenolate mofetil. Tacrolimus was switched to sirolimus after 2-3 months. In the 
follow-up period of 2 years six patients developed acute rejection. Two patients experienced 
graft loss: one to focal and segmental glomerulosclerosis and one to non-adherence of 
medication. Fourteen children experienced infectious episodes. The reconstitution of the 
lymphocytes in these patients mimicked the pattern seen in adults. CD8+ T lymphocytes 
recovered faster than CD4+ lymphocytes: after 24 months, CD8+ T lymphocytes recovered 
to 60% of baseline and CD4+ lymphocytes to 25% of baseline (p = 0.014). No significant 
difference was seen in the recovery of CD4+ naïve and memory lymphocyte subsets and 
CD8+ naïve and memory lymphocytes. In the CD4+ memory lymphocyte population, the 
effector memory lymphocytes recovered faster than the central memory lymphocytes (44% 
vs. 24% after 24 months, respectively (p = 0.027)). No significant difference was seen in 
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the recovery of CD8+ central memory and effector memory lymphocytes. At baseline, 4% 
of CD4+ lymphocytes were CD4+CD25+FoxP3+ regulatory T lymphocytes. Three months 
after alemtuzumab, there was relatively less depletion of regulatory CD4+ lymphocytes 
(around 10% of the CD4+ cells had a regulatory T lymphocyte phenotype) and this effect 
persisted until month 12 months alemtuzumab treatment84.
Alemtuzumab has also been successfully used as part of the induction therapy in highly 
sensitized pediatric kidney transplant patients in two small case series85,86. To our 
knowledge, only one paper has described the use of alemtuzumab as anti-rejection therapy 
in pediatric kidney transplant recipients87. Three patients were treated with alemtuzumab 
(0.3 mg/kg, intravenously) because of five episodes of a late (i.e. more than 3 months after 
transplantation) glucocorticoid-resistant acute rejection. All patients were treated with ATG 
on two previous occasions. The first 14-year old patient suffered from recurrent rejection 
because of non-adherence. The first two episodes (acute cellular rejection (ACR) Banff 
type 1B) responded well to alemtuzumab. The third episode (ACR Banff type 1A) did not 
respond and the patient experienced graft loss soon thereafter. The second patient (14 years 
old) received one gift of alemtuzumab because of a ACR Banff type 1B. The serum creatinine 
concentration dropped from 292 µmol/L to 150 µmol/L 1 week after the administration 
of alemtuzumab. Two months after the alemtuzumab treatment, the patient experienced a 
borderline rejection with good response to high-dose glucocorticoids. The serum creatinine 
concentration stabilized around 175 µmol/L. The absolute lymphocyte count recovered to 
baseline level after 23 months. After 10 months there was an asymptomatic rise in serum 
EBV load with spontaneous resolution. The third patient (5 years old) experienced an 
ACR Banff type 1B-2A. He was treated unsuccessfully with methylprednisolone, ATG, 
rituximab, intravenous immunoglobulins, and finally alemtuzumab after which he lost 
his graft. In the year after the anti-rejection treatment this patient suffered from multiple 
serious infections probably related to the severe leukopenia, which required treatment 
with granulocyte colony-stimulating factor87. In conclusion, alemtuzumab reversed three 
of five rejection episodes in pediatric patients with a late glucocorticoid- and ATG-resistant 
rejection. However it did not prevent graft loss in two of the three patients. 
In summary, alemtuzumab is sometimes used as induction therapy and rarely as anti-
rejection therapy in pediatric renal transplant recipients. The results are variable and 
different dosing schemes (some are weight adjusted and some not) of alemtuzumab are 
used. Prospective, randomized controlled trials comparing different induction therapies 
3
80
PART I
(like basiliximab, ATG and alemtuzumab) are needed to establish the efficacy and long-
term safety of alemtuzumab in pediatric renal transplant recipients.
COMPLICATIONS OF ALEMTUZUMAB ADMINISTRATION
Infusion associated reactions 
Acute infusion-related reactions occur in 70-80% of patients during treatment with 
alemtuzumab when given intravenously. These reactions are caused by cytokine release from 
lysed immune cells. These reactions are mostly mild to moderate and include headache, rash, 
nausea, hypotension, rigors and pyrexia. Following subcutaneous administration, infusion-
related reactions occur less frequently, although local injection site reactions do occur34,37 . 
Infections
Alemtuzumab results in a prolonged depletion of T- and B lymphocytes (usually for over 12 
months). This profound immunosuppression predisposes patients to infections. However, 
no depletion of the neutrophilic granulocytes typically occurs and reconstitution of the 
cells of the innate immune system is faster: monocytes typically recover after 3 months 
(although repopulation may occur in as little as 1 month) and NK cells return to 60-80% 
of baseline after 6 months).
Prophylaxis with an oral anti-herpes agent and prophylaxis against Pneumocystis jirovecii 
should be started directly after administration of alemtuzumab and be continued for a 
minimum of 2 months after the last alemtuzumab gift or until the CD4+ T lymphocyte 
count is ≥ 200 cells /μL33,34. In our center, we do not routinely screen kidney transplant 
recipients for adenovirus or EBV, whereas we do for BK virus. 
Published data on the occurrence of opportunistic infections after alemtuzumab treatment 
are limited. BK virus infection is more common after alemtuzumab induction in kidney 
transplantation compared to ATG induction32. Cytomegalovirus and opportunistic and 
non-opportunistic infections were not more common when comparing alemtuzumab with 
ATG induction therapy32. In contrast to induction therapy with alemtuzumab, anti-rejection 
therapy with alemtuzumab is associated with a higher risk of opportunistic infections (4.5% 
vs 21% p<0.001). The higher incidence of opportunistic infections may be directly related 
to the alemtuzumab treatment, but could also be owing to the fact that after rejection the 
maintenance immunosuppressive therapy is also intensified88.
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Malignancy
Long term data linking alemtuzumab treatment with malignancy are scarce and the risk of 
developing of malignancy is poorly defined. In a single-center retrospective analysis among 
1350 kidney transplant recipients no increased cancer incidence 4 years after induction 
therapy with alemtuzumab (2.8%) compared with ATG (5.4%) or no induction therapy 
(3.3%), was seen (across all groups; p = 0.234). This study did not include non-melanoma 
skin cancer89.
In contrast, another study which used US transplantation and cancer registries data to 
explore the relationship between induction therapy and cancer after transplantation came 
to a different conclusion90. A total of 111,857 kidney transplant recipients were available for 
inclusion with a median follow-up of 3.5 years. Of the total group, 3394 patients received 
alemtuzumab induction therapy. Alemtuzumab induction, compared to no induction 
therapy, was associated with an increased risk of non-Hodgkin lymphoma (n = 15, adjusted 
incidence rate ratio (aIRR), 1.79; 95% CI, 1.02–3.14; p = 0.04) and all virus-related tumors 
like non-Hodgkin lymphoma, Hodgkin lymphoma, human papilloma virus-related cancers, 
Kaposi sarcoma, and liver cancer (n = 19, aIRR 1.84; 95% CI, 1.11– 3.03; p = 0.02). 
Alemtuzumab induction was also associated with increased colorectal cancer (n = 7, aIRR 
2.46; 95% CI, 1.03–5.91; p = 0.04) and thyroid cancer (n = 10, aIRR 3.37; 95%-CI, 
1.55–7.33; p = 0.002). Alemtuzumab induction was not associated with an increased risk 
of lung or kidney cancer, or melanoma90. No direct comparison between alemtuzumab and 
polyclonal depleting induction therapy was made.
Three RCTs compared alemtuzumab with interferon-β-1a in RRMS. In both the phase II 
(CAMMS223) and III trials (CARE-MSI and CARE-MS-II), malignancy was not more 
frequent after alemtuzumab compared with IFN-β-1a47,48,91. In the CAMMS223 trial, 
malignancy was observed in 2.8% of patients treated with alemtuzumab (one patient with 
cervical cancer and one patient with breast cancer) and 0.9% of patients taking IFN-β-1a 
(colon cancer) after a follow up of 3 years. In the extension part of this trial, one patient in 
the alemtuzumab group died of sepsis following chemotherapy for Burkitt’s lymphoma91. 
In CARE-MSI, two patients (0.5%) in the alemtuzumab group developed thyroid papillary 
carcinoma. It is not clear whether these cases were induced by alemtuzumab or were an 
incidental finding on ultrasound investigation of patients with thyroid dysfunction after 
screening. No patients in the IFN-β-1a group developed a malignancy47. In CARE-MSII, 
malignancy rates for alemtuzumab- vs. IFN-β-1a treated patients were 0.6% vs. 1.5%, 
respectively, after 24 months of follow-up. These malignancies included one case of papillary 
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thyroid cancer, basal cell carcinoma (two patients), cervical cancer (one patient) and colon 
cancer (one patient) in the alemtuzumab-treated group. In the IFN-β-1a group, two 
malignancies were observed (one patient with a basal cell carcinoma and one case of acute 
myeloid leukemia)48. No further malignancies were observed in the long-term open-label 
follow-up (median 7 years, range 33-144 months)92. 
Occurrence of EBV-positive large-cell lymphoma has been described after administration 
alemtuzumab in patients with CLL. In a study to investigate the efficacy and safety of 
alemtuzumab in patients with CLL with residual disease, 3 of 41 patients developed EBV-
positive large-cell lymphoma. Two of three patients had spontaneous resolution without 
therapy and one patient was treated with immunoglobulins and anti-viral medication93. 
A case report described the development of an EBV-positive lymphoma in an 80-year old 
patient with CLL treated with chemotherapy and alemtuzumab94.
In conclusion, alemtuzumab results in an increased risk of malignancy as compared with no 
induction therapy in kidney transplantation. In contrast, no increased risk of malignancy 
was seen associated with the use of alemtuzumab in patients with MS when compared to 
IFN-β-1a. 
Autoimmunity
Secondary autoimmune events have been reported after alemtuzumab treatment. 
Interleukin-21 seems to play a role in the development of this autoimmunity. Interleukin-21 
is involved in the proliferation of cytotoxic T lymphocytes, the inhibition of regulatory T 
lymphocytes, and the differentiation of B lymphocytes into antibody-producing plasma 
cells95. Pre-treatment concentrations of IL-21 in patients with MS were two-fold higher 
in patients developing autoimmunity after alemtuzumab treatment compared to patients 
without autoimmunity96. 
Most commonly, the thyroid gland is affected. Autoimmune thyroid disorders, especially 
hypothyroidism and hyperthyroidism (Graves’ disease) tend to occur between 6 and 
61 months, peaking in the third year post-treatment in patients with MS. In kidney 
transplantation, Graves’ disease has also been observed after alemtuzumab administration97. 
The total incidence of thyroid events, described in CAMMS223, CARE-MSI and CARE-
MSII, ranged between 16 and 30%47,48. In the patients treated with IFN-β-1a the incidence 
of thyroid events was 3-6%. It is advised that thyroid function tests should be obtained 
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prior to initiation of treatment and tested on a regular basis until 48 months after the last 
infusion34.
Immune thrombocytopenia (idiopathic thrombocytopenic purpura) as a side effect of 
alemtuzumab treatment was first described in the CAMMS223 study. A patient presented 
with intracranial hemorrhage and died. The incidence of idiopathic thrombocytopenic 
purpura was 1-2% in the CAMMS223 and CARE-MS studies47,48,91. Furthermore, four 
cases of glomerulopathy (0.3%) were described after alemtuzumab treatment in the 
CAMMS223, CARE-MSI and CARE-MSII trials. Two patients developed anti-glomerular 
basement membrane disease and two patients membranous glomerulopathy. The onset 
of kidney disease ranged from 4 to 39 months after alemtuzumab administration47,48,91. 
One case of Guillain-Barre syndrome was reported in a patient who was treated with 
alemtuzumab because of a T lymphocyte prolymphocytic leukemia98.
Fertility and pregnancy
Alemtuzumab has been assigned to pregnancy category C by the Food and Drug 
Administration, meaning that animal production studies have shown an adverse effect 
on pregnancy outcomes but that no adequate studies have been performed in humans34. 
Immunoglobulin G molecules, such as alemtuzumab, are known to cross the placental 
barrier and may potentially affect the fetus. 
Six months after delivery, levels of infliximab and adalimumab can be detected in the 
baby99. The administration of live vaccines (such as Bacillus Calmette-Guerin, rotavirus, 
varicella zoster, mumps, measles and rubella) in the first six months after delivery to babies 
of mothers treated with infliximab can be life threatening100. It is not known whether 
alemtuzumab can cause fetal harm when administered to pregnant women or whether it can 
affect reproductive capacity. In the Cambridge long-term follow-up study of MS patients a 
total of 15 babies were born to 12 women treated with alemtuzumab after a median interval 
from most recent treatment of 26 months (range 13–86 months). All deliveries and births 
were uncomplicated92.
CD52 is expressed in the male reproductive system, including the epididymis, vas deferens, 
seminal vesicles and mature spermatocytes101. Although CD52 antibodies agglutinate and 
inactivate sperm in vitro, reproductive problems have not been reported following therapy 
with alemtuzumab, although available data are limited. A long term follow up study 
reported six males fathering seven live births, a median of 14 months (range 8–44 months) 
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from most recent treatment to conception92. Another (sub)study (n = 13) showed that at 
baseline, and 1, 3, and 6 months post alemtuzumab treatment, there was no evidence of 
aspermia, azoospermia, motility disorders, or depressed sperm counts102.
It is unknown if alemtuzumab is excreted in human breast milk, but it has been detected 
in the milk of lactating mice. Therefore, breastfeeding should be discouraged to women 
for at least 4 months following treatment34.
SUMMARY AND FUTURE DIRECTIONS 
Alemtuzumab is frequently used off-label in kidney transplantation as induction therapy 
and less frequently as anti-rejection therapy. No pharmacokinetic studies have been 
performed in SOT recipients, probably because alemtuzumab never has been registered 
for this indication. Most pharmacokinetic and pharmacodynamics studies have been 
performed in patients with CLL and MS. However, the pharmacokinetics of alemtuzumab 
in the latter two patient populations may be very much different from SOT recipients. The 
alemtuzumab dose used in induction and anti-rejection therapy (30 mg one to two times) 
is not based on formal dose finding studies in SOT recipients, but is based on experience 
in CLL and MS. The duration of depletion of immune cells of the innate and the adaptive 
immune system is much longer after alemtuzumab treatment compared to rATG103. It 
may therefore be possible that lower doses of alemtuzumab will result in the same effect 
on graft survival, though with less toxicity. Subcutaneous administration showed the same 
outcomes compared to intravenous administration, but with less adverse events, although 
anti-alemtuzumab antibody formation may be more frequent. 
Induction therapy with alemtuzumab in kidney transplantation shows comparable results 
in terms of graft and patient survival as compared with basiliximab and rATG. However, 
induction therapy with alemtuzumab is more effective in preventing acute rejection as 
compared to induction therapy with basiliximab. Results are comparable with induction 
therapy with rATG. The use of alemtuzumab induction therapy may facilitate minimization 
of the exposure to nephrotoxic immunosuppressive drugs, which may possibly lead to better 
long-term graft survival. Alemtuzumab used as anti-rejection therapy has shown some 
promising results. Replacement of rATG by alemtuzumab for this indication could lead to 
less infusion-related adverse events, shorter hospital stay and reduction in costs. However, 
long-term adverse events like infection, autoimmunity, malignancies and a higher frequency 
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of ABMR might be more frequent among alemtuzumab-treated patients compared with 
rATG. 
Although alemtuzumab is used off-label in kidney transplantation it can be an additional 
treatment option to the drugs now used as induction or anti-rejection therapy. We should 
start the discussion with the pharmaceutical company to expand the indication for 
alemtuzumab to SOT, and thus more clinical studies can be performed. There is an unmet 
need to optimize alemtuzumab dosing in SOT patients, and we believe dose-finding studies 
are needed. Furthermore, RCTs are required to compare the effectiveness and long-term 
results of alemtuzumab with rATG for the treatment of acute rejection. 
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ELECTRONIC SUPPLEMENTARY MATERIAL: 
APPENDIX S1 SYSTEMATIC LITERATURE SEARCH
A systematic literature search was performed with the following search terms. 
Embase.com 
(‘alemtuzumab’/mj OR (alemtuzumab OR campath):ab,ti) AND (‘pharmacodynamics’/
exp OR ‘pharmacokinetics’/exp OR ‘drug monitoring’/de OR ‘toxicity’/exp OR 
‘immunogenicity’/de OR ‘immunosuppressive treatment’/de OR ‘immunomodulation’/
de OR ‘transplantation conditioning’/de OR ‘adverse drug reaction’/exp OR 
(pharmacodynamic* OR pharmacokinetic* OR ‘drug monitoring’ OR absor* OR distribut* 
OR metabol* OR excret* OR eliminat* OR induction OR ((reject* OR rescue*) NEAR/6 
(therap* OR immunotherap* OR prevent* OR revers*)) OR toxic* OR immunogenicit* 
OR precondition* OR pretreat* OR pre-condition* OR pre-treat* OR efficac* OR 
(concentration* NEAR/6 effect*) OR (clinical* NEAR/3 use) OR immunosuppress* OR 
(immun* NEXT/1 (suppress* OR modulation)) OR immunomodulat* OR ((transplant* 
OR pretransplant*) NEAR/3 condition*) OR adverse OR side-effect*):ab,ti) AND (‘kidney 
transplantation’/exp OR ‘kidney graft rejection’/exp OR ‘kidney allograft rejection’/exp OR 
‘organ transplantation’/de OR ‘multiple sclerosis’/exp OR (((kidney* OR renal OR organ*) 
NEAR/6 (transplant* OR allotransplant* OR graft* OR allograft* OR recipient* OR 
reject* OR donor* OR donat*)) OR ‘multiple sclerosis’):ab,ti) NOT ([animals]/lim NOT 
[humans]/lim) AND [english]/lim
Medline Ovid  
(“alemtuzumab”.mp. OR (alemtuzumab OR campath).ab,ti,kf.) AND (exp 
“pharmacokinetics”/ OR pharmacokinetics.xs. OR exp “Drug Monitoring”/ OR toxicity.
xs. OR “Immunosuppression”/ OR “immunomodulation”/ OR “Transplantation 
Conditioning”/ OR exp “Drug-Related Side Effects and Adverse Reactions”/ OR 
(pharmacodynamic* OR pharmacokinetic* OR “drug monitoring” OR absor* OR 
distribut* OR metabol* OR excret* OR eliminat* OR induction OR ((reject* OR 
rescue*) ADJ6 (therap* OR immunotherap* OR prevent* OR revers*)) OR toxic* OR 
immunogenicit* OR precondition* OR pretreat* OR pre-condition* OR pre-treat* OR 
efficac* OR (concentration* ADJ6 effect*) OR (clinical* ADJ3 “use”) OR immunosuppress* 
OR (immun* ADJ (suppress* OR modulation)) OR immunomodulat* OR ((transplant* 
OR pretransplant*) ADJ3 condition*) OR adverse OR side-effect*).ab,ti,kf.) AND (“kidney 
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transplantation”/ OR kidney/tr OR “Organ Transplantation”/ OR exp “multiple sclerosis”/ 
OR (((kidney* OR renal OR organ*) ADJ6 (transplant* OR allotransplant* OR graft* 
OR allograft* OR recipient* OR reject* OR donor* OR donat*)) OR “multiple sclerosis”).
ab,ti,kf.) NOT (exp animals/ NOT humans/) AND english.la.
Cochrane CENTRAL 
((alemtuzumab OR campath):ab,ti) AND ((pharmacodynamic* OR pharmacokinetic* OR 
‘drug monitoring’ OR absor* OR distribut* OR metabol* OR excret* OR eliminat* OR 
induction OR ((reject* OR rescue*) NEAR/6 (therap* OR immunotherap* OR prevent* 
OR revers*)) OR toxic* OR immunogenicit* OR precondition* OR pretreat* OR pre-
condition* OR pre-treat* OR efficac* OR (concentration* NEAR/6 effect*) OR (clinical* 
NEAR/3 use) OR immunosuppress* OR (immun* NEXT/1 (suppress* OR modulation)) 
OR immunomodulat* OR ((transplant* OR pretransplant*) NEAR/3 condition*) OR 
adverse OR side-effect*):ab,ti) AND ((((kidney* OR renal OR organ*) NEAR/6 (transplant* 
OR allotransplant* OR graft* OR allograft* OR recipient* OR reject* OR donor* OR 
donat*)) OR ‘multiple sclerosis’):ab,ti) 
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CHAPTER 4 | AIMS OF THE THESIS
Kidney transplant rejection remains a serious complication with long-lasting consequences, 
including progressive deterioration of renal function, premature transplant failure and 
death. The objectives of this thesis are to investigate strategies to optimize the prevention, 
diagnosis and treatment of kidney transplant rejection. In more detail, the following will 
be investigated:
• To examine the diagnostic performance of gene expression analysis in discriminating 
aTCMR from no rejection in kidney transplant biopsies (Chapter 5).
• To investigate if the pathogenesis of acute transplant rejection is different in transplant 
biopsies of patients treated with either belatacept or tacrolimus maintenance therapy 
using gene expression analysis and immunohistochemistry (Chapter 5).
• To assess if a proteomic extension assay on sera of kidney transplant recipients is a tool 
to diagnose aTCMR in a minimally-invasive manner (Chapter 6).
• To study the effect of belatacept maintenance therapy on glucose tolerance in a kidney 
transplant recipient with type 2 diabetes mellitus (Chapter 7).
• To analyze the efficacy and long-term outcome of rATG treatment for acute kidney 
transplant rejection in patients treated with the current standard immunosuppressive 
regimen consisting of tacrolimus and MPA (Chapter 8).
• To investigate patient-, and allograft outcome, in addition to adverse events in kidney 
transplant recipients treated with alemtuzumab for acute kidney transplant rejection 
and to compare these to the outcome of patients treated with rATG for the same 
indication (Chapter 9).
• To determine the frequency and outcomes of inflammatory polyneuropathy in kidney 
transplant recipients treated with either alemtuzumab or rATG (Chapter 10).
• To examine the occurrence, treatment and outcome of acquired hemophilia A after 
treatment with alemtuzumab (Chapter 11).
In Chapters 12 and 13, the main findings are summarized and placed in a broader context.
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ABSTRACT
Background 
Belatacept-based therapy in kidney transplant recipient has been shown to increase long-
term renal allograft and patient survival compared with calcineurin inhibitor-based 
therapy, however with an increased risk of acute T cell-mediated rejection (aTCMR). An 
improved understanding of costimulation blockade-resistant rejections could lead to a more 
personalized approach to belatacept therapy. Here, immunomic profiles of aTCMR biopsies 
of patients treated with either tacrolimus or belatacept were compared. 
Methods
Formalin-fixed paraffin-embedded renal transplant biopsies were used for 
immunohistochemistry and gene expression analysis using the innovative NanoString 
technique. To validate NanoString, transcriptomic profiles of patients with and without 
biopsy-proven aTCMR were compared. Biopsies from 31 patients were studied: 14 
tacrolimus-treated patients with aTCMR, 11 belatacept-treated patients with aTCMR, 
and 6 controls without rejection. 
Results
A distinct pattern was seen in biopsies with aTCMR compared to negative controls: 78 genes 
had a higher expression in the aTCMR group (false discovery rate P value < 0.05 to 1.42e-
05). The most significant were T cell-associated genes (CD3, CD8, and CD4; p < 1.98e-04), 
γ-interferon-inducible genes (CCL5, CXCL9, CXCL11, CXCL10, TBX21; p < 1.33e-04) 
plus effector genes (GNLY, GZMB, ITGAX; p < 2.82e-03). Immuno-phenotypical analysis 
of the classic immune markers of the innate and adaptive immune system was comparable 
between patients treated with either tacrolimus or belatacept. In addition, the transcriptome 
of both groups was not significantly different.
Conclusions
In this small pilot study, no difference was found in immunomics of aTCMR biopsies of 
tacrolimus- and belatacept-treated patients. This suggests that clinically diagnosed aTCMR 
reflects a final common pathway of allorecognition which is unaffected by the type of 
immunosuppressive therapy.
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INTRODUCTION
Gene expression analysis of the kidney transplant biopsy has been shown to improve 
classification and risk stratification of patients when used in combination with current 
diagnostic standards1. The “molecular microscope” has been postulated to give a better 
insight into the classification of renal transplant pathology1-4. With the use of both gene 
and protein expression analysis, also known as immunomics, more insight can be gained 
in the pathophysiology of inflammatory reactions in the renal allograft. 
The Banff guideline is a pathology-based classification system to diagnose acute renal 
transplant rejection5. However, this classification is vulnerable to misinterpretation and 
the Banff 2017 guideline states that the combination of conventional histomorphologic 
examination of a kidney transplant biopsy with molecular diagnostics leads to superior 
diagnostic classification and has the potential to guide therapy and improve allograft 
outcomes5,6. The novel technique NanoString® allows for multiplex messenger RNA (mRNA) 
analysis of minute quantities of mRNA from formalin-fixed, paraffin-embedded (FFPE) 
biopsies without the need of pre-amplification2. With this technique, residual material from 
conventional histopathological diagnosis can be analyzed7,8. NanoString® makes it possible 
to render data on the intragraft gene expression of up to 770 targets of interest within two 
days and with a comparable sensitivity to quantitative real time-polymerase chain reaction, 
and a better sensitivity than microarray8,9. 
Long-term outcomes of kidney transplantation are negatively inf luenced by the 
nephrotoxicity and metabolic side effects of calcineurin inhibitor (CNI)-based therapy10,11. 
A CNI-free immunosuppressive regimen with the costimulation blocking drug belatacept 
has been shown to increase long-term renal allograft and patient survival12-14. However, 
belatacept-based immunosuppressive therapy is associated with an increased risk of 
acute T cell-mediated rejection (aTCMR)15-18. Identification of factors that underlie such 
costimulation blockade-resistant rejection could lead to a more personalized approach to 
belatacept-based treatment through the identification of patients at “low risk” for acute 
rejection15,19-21. 
To expand the understanding of the pathogenesis of costimulation blockade-resistant 
rejections, we have compared the immunomic profiles of aTCMR biopsies of patients treated 
with maintenance therapy consisting of either tacrolimus or belatacept. Gene expression 
analysis of 209 genes with the innovative NanoString® technique in combination with 
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immunohistochemistry (IHC) was used. To validate NanoString® for our research question, 
transcriptomic profiles of patients with and without biopsy-proven aTCMR were compared.
MATERIALS AND METHODS
Study population and materials
Renal allograft biopsies were obtained from kidney transplant recipients who previously 
participated in one of two prospective randomized controlled trials (RCT; a belatacept 
study and a tacrolimus-dosing study) performed at the Erasmus MC, the Netherlands (see 
below). The design and results of these trials were published previously20,22. Both studies 
were approved by the institutional review board of Erasmus MC (Medical Ethical Review 
Board numbers 2010-080 and 2012-421). Eleven belatacept-treated patients experienced 
an aTCMR20 and the renal allograft biopsies of these patients were analyzed here. These 
biopsies were compared with 14 biopsies of tacrolimus-treated patients with an aTCMR that 
were included in one of these two RCTs20,22. The biopsies were all for-cause biopsies that 
were matched for time after transplantation, Banff 2015 category and grade, and age of the 
recipient (Table 1). All biopsies were scored independently by two pathologists according to 
the Banff 2015 classification23. In case of differences in classification, consensus was met. 
Six renal transplant biopsies without histomorphologic changes (Banff category 1) were 
included as negative controls and these were either derived from one of the RCTs20 or from 
the archives of the department of pathology of the Erasmus MC (Table 1). The negative 
controls were matched for age of the recipient and time after transplantation.
The patients who participated in the belatacept study were randomized to a belatacept- 
or tacrolimus-based immunosuppressive regimen, as described previously20. The main 
objective of the tacrolimus-dosing study was to examine whether a CYP3A5 genotype-
based tacrolimus starting dose leads to earlier achievement of the tacrolimus target predose 
concentration (C0)
22. The target C0 of tacrolimus and the dosing of mycophenolate mofetil 
and glucocorticoids were identical in both RCTs20,22. 
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Histo- and immunohistochemical (IHC) stainings and digital quantification
Two µm sections of FFPE renal allograft biopsies were stained with hematoxylin and 
eosin, Periodic acid-Schiff-diastase, and Jones’ silver stain according to standard diagnostic 
practice. Subsequently, IHC stainings were performed on 4 µm FFPE cut sections with 
an automated, validated and accredited staining system (Ventana Benchmark ULTRA, 
Ventana Medical Systems, Tucson, AZ, USA) using ultraview or optiview universal DAB 
detection Kit. Antibodies used (CD3, CD4, CD8, CD20, CD56, CD68, PD-1, and 
granzyme B) and dilutions are summarized in Table S1. FoxP3/CD4 staining was performed 
at MGH/Harvard, (Boston, MA, USA). All sections were scanned at 40x magnification 
using Nanozoomer XR digital slide scanner (Hamamatsu, Hamamatsu City, Japan). Digital 
image analysis was performed using Visiopharm integrator system (version 2017.2.4.3387) 
with AuthorTM module (Visiopharm®, Hoersholm, Denmark). For each section, manual 
selection of only cortical tissue was made, excluding the medulla, artefacts, and the lumen 
of blood vessels larger than glomeruli. Image analysis Application Protocol Packages were 
developed to measure the total tissue area (µm2) and the area percentage of positive staining. 
RNA extraction 
Three consecutive 20-μm sections cut from each FFPE block were immediately transferred 
to sterile microcentrifuge tubes and stored at room temperature. Microtome blades were then 
replaced, and equipment sterilization was performed with RNase AWAY (Life Technologies, 
Carlsbad, CA) between blocks. Xylene deparaffinization and RNA extraction of the curls 
were performed with use of the Recover All Total Nucleic Acid Isolation Kit for FFPE (Life 
Technologies). RNA concentration and purity were measured with the Nano-Drop 2000 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA).
NanoString® nCounter® assay, data normalization and analysis
A custom code set of 216 genes was created: 209 genes that are known to be involved in 
renal allograft rejection and renal injury, and 7 housekeeping genes. This was based on the 
panel described in the Banff 2017 report5. Probe description and sequences are provided in 
Table S2. Gene expression was measured on 120 to 200 ng of extracted RNA from FFPE 
biopsies with NanoString®. NanoString® was previously tested in renal allograft rejection in 
non-human primates24,25. Raw gene expression counts of all samples are provided in Table 
S3. Background correction, data quality control, normalization of the raw gene expression 
counts and data analysis was investigated with nSolverTM Analysis Software (Version 4.0.62). 
The geNorm algorithm was applied to analyze the stability of the reference genes26. Seven 
reference genes (DDX50, HDAC3, GUSB, POLR2A, OAZ1, UBB and SDHA) were used 
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for normalization. The parameters for quality control flagging as recommended by the 
manufacturer were used27.
Statistical analysis
SPSS version 21 (SPSS Inc., Chicago, IL, USA) was used for IHC analysis. Data are 
summarized as median and interquartile range. For comparisons between groups, the 
two-tailed Mann-Whitney U test was used. A two-sided p-value of less than 0.05 was 
considered significant. For comparison of the three groups, Kruskal-Wallis test was used. 
For gene expression analysis, normalized mRNA expression values were evaluated with the 
R-based advanced nSolverTM Advanced Analysis Software (Version 2.0.115). Differential 
gene expression data are presented as volcano plots and in a summary table showing the 
top differentially regulated genes. In addition, the data was subjected to unsupervised 
hierarchical clustering analysis (HCA). The false discovery rate (FDR; Benjamini-Hochberg) 
method was used to adjust the p-values for multiple t-testing.
RESULTS
Patients
The clinical-pathologic characteristics of the patients are presented in Table 1. Of the 
25 patients with rejection, 21 patients had an aTCMR (grade IB to III) and 4 patients 
had a mixed (aTCMR and active antibody mediated rejection [aABMR]) rejection. The 
timing of the biopsy and patient age at the time of rejection were not significantly different 
between the patients treated with belatacept, patients treated with tacrolimus and the 
negative controls (p = 0.42, and p = 0.14, respectively). The estimated glomerular filtration 
rate (eGFR) at the time of the acute rejection was similar in patients treated with either 
tacrolimus or belatacept (median 26; interquartile range [IQR] 15-35 mL/min per 1.73 m2; 
and 28; IQR 18-41 mL/min per 1.73 m2 (p = 0.57). The median age of the biopsy used for 
Nanostring® was 3.2 years (IQR 2.3-4.6).
Quality control of RNA and NanoString®
For the gene expression analysis, 7 samples of patients with tacrolimus maintenance therapy, 
10 samples of patients with belatacept maintenance therapy, and 6 negative controls 
(samples without rejection) were analyzed. The mean A260/A280 spectrophotometry ratio 
was 1.88 (standard deviation 0.17). Two samples (1 negative control and 1 sample of a 
belatacept-treated patient) did not pass the quality control of the nSolverTM Advanced 
Analysis Software because of low probe counts and were excluded from further analysis. 
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Of the 209 probes, 16 did not reach the detection threshold (less than double the counts of 
the median of the negative control) and were excluded from subsequent analysis (Table S2).
Validation of NanoString®
To validate NanoString®, it was tested whether NanoString® could distinguish between the 
transcriptome of samples with aTCMR and samples without aTCMR. Unsupervised HCA 
of the personalized gene panel showed that the samples with aTCMR clustered separately 
from the negative controls (Figure 1A). However, one sample with aTCMR (patient 18) 
clustered with the negative controls. The clinical data of this patient revealed that he had 
a slight deterioration of kidney function at the time of the biopsy (serum creatinine rose 
from 95 to 107 µmol/L). No rejection was diagnosed in the first examination of the biopsy. 
However, after revision in the setting of the RCT, the biopsy showed an isolated v-lesion 
and was therefore classified as an aTCMR grade IIA (Banff 2015 classification23). Following 
this for-cause biopsy, the kidney function of the patient improved to baseline without anti-
rejection therapy and without adjusting his maintenance immunosuppressive therapy. At 
present, 45 months after transplantation, the kidney function of this patient is excellent 
(serum creatinine concentration 92 µmol/L).
Differential gene expression analysis identified a distinct gene signature in biopsies with 
aTCMR compared to the negative controls (Figure 1B and Table S4). Comparison of 
aTCMR and negative controls identified 78 genes with higher expression levels in the 
aTCMR samples [FDR p-value (FDRPV) < 0.05 to 1.42e-05; Table S4], and one gene with 
significantly higher expression in samples without aTCMR (EEF1A1, FDRPV 0.047). The 
most differentially expressed genes (DEGs) were T cell-associated transcripts (CD3, CD8, 
and CD4; p< 1.98e-04), γ-interferon-inducible genes (CCL5, CXCL9, CXCL11, CXCL10, 
TBX21; p < 1.33e-04), effector genes (GNLY, GZMB, ITGAX; p < 2.82e-03), macrophage-
associated transcripts (SLAMF8, CD86, MS4A7, MRC1, ADAMDEC1; p < 0.04) and 
injury-repair response-associated transcripts (LCP2, CTSS, FCGR3A, MYBL1, LCN2 and 
HAVCR1; p < 4.63e-02). The top 15 DEGs were mainly aTCMR-associated transcripts, 
denoting an aTCMR profile (Table 2). A two-dimensional principal component analysis 
was performed with the top 15 DEGs and showed separate clustering of the samples with 
acute rejection compared to the negative controls without aTCMR (Figure 1C).
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Figure 1. A. Heatmap and unsupervised hierarchical cluster analysis of the 209 normalized genes of 
samples with aTCMR and samples without aTCMR (negative controls). Each row represents a probe. 
Each column represents a biopsy sample. The orange samples are the negative controls. The dark green 
samples are the samples with acute rejection. The color in each cell reflects the level of expression of the 
mRNA, relative to the geometric mean of all the samples (z-score). Increasing intensities of orange point 
out higher expression, while increasing intensities of blue indicate lower expression. The degree of related-
ness is represented by the dendrogram at the top of the panel. The probe threshold is depicted on the left 
of the heatmap. Blue cells represent probes that were below the detection threshold (less than double the 
counts of the median of the negative control). Grey cells represent probes that were above the detection 
threshold. B. Volcano plot of samples with aTCMR versus patients without aTCMR. The X-axis represents 
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fold change (log2). The Y-axis displays each gene’s p-value (-log10). The horizontal lines indicate various 
False Discovery Rate p-values. The 40 most statistically significant genes are labeled in the plot. Genes with 
a positive fold change are higher expressed in the samples with an acute rejection. Genes with a negative 
fold change are higher expressed in the samples without acute rejection. C. Principal component analysis 
(PCA) plot of the top 15 differentially expressed genes in samples with aTCMR and negative controls. PCA 
samples on the 1st (X-axis) and 2nd PC plane (Y-axis). The samples without acute rejection are displayed in 
pink. The samples with acute rejection are displayed in grey. D. Pathway scores of samples with aTCMR 
and samples without aTCMR. Unsupervised hierarchical cluster analysis and heatmap showing pathway 
scores. Pathway scores are fit using the first principal component of each gene set’s data. Scores are displayed 
on the same scale via a Z-transformation. Each row represents a sample with patient ID number. Each 
column represents a pathway. The orange samples are the negative controls. The dark green samples are the 
samples with rejection. Increasing intensities of orange point out higher pathway scores, while increasing 
intensities of blue indicate lower pathway scores. The degree of relatedness is represented by the dendro-
gram at the top of the panel. Each number of the column represents a different pathway: 1. Metabolism 
of proteins, 2. Gene expression, 3. Insulin receptor substrate signaling mediated signaling, 4. Signaling by 
Wnt, 5. Metabolism, 6. Signaling by fragment C gamma receptor 2 (FGCR2), 7. Co-stimulation by the 
CD28 family, 8. Immunoregulatory interactions between lymphoid and non-lymphoid cells, 9. Cytokine 
signaling in immune system, 10. Signaling by G-protein coupled receptor (GPCR), 11. Innate immune 
system, 12. MHC mediated Class I antigen processing and presentation, 13. Developmental biology, 14. 
Hemostasis, 15. Cellular response to stress, 16. Binding and uptake of ligands by scavenger receptors, 17. 
Extracellular matrix organization.
Table 2. Top 15 of differentially expressed genes in patients with an acute rejection compared with patients 
without an acute rejection.
mRNA FC (log2) SE (log2)
Lower confidence 
limit (log2)
Upper confidence 
limit (log2) FDRPVa Panelb
CCL5 3.32 0.354 2.63 4.02 1.42e-05 Rejection
AOAH 3.14 0.347 2.46 3.82 1.42e-05 TCMR
GBP5 4.87 0.592 3.71 6.03 3.59e-05 TCMR
CD4 2.33 0.287 1.77 2.9 3.59e-05 TCMR
CCR5 2.63 0.338 1.97 3.29 4.18e-05 Rejection
SP140 3.05 0.392 2.28 3.81 4.18e-05 TCMR
SH2D1A 2.5 0.322 1.86 3.13 4.18e-05 TCMR
LCP2 2.34 0.304 1.75 2.94 4.18e-05 TCMR
TIGIT 3.63 0.484 2.68 4.58 5.4e-05 TCMR / Exhaustion
CXCL11 6.17 0.835 4.53 7.81 6.01e-05 ABMR
TBX21 2.92 0.397 2.14 3.7 6.01e-05 ABMR / Exhaustion
CTSS 3.17 0.437 2.31 4.02 6.7e-05 AKI
ITGAX 3.41 0.478 2.47 4.35 7.35e-05 TOLs
FAM26F 3.53 0.498 2.55 4.51 7.35e-05 TCMR
PSTPIP1 2.41 0.341 1.75 3.08 7.35e-05 TCMR
Positive ratio means higher expression in samples with rejection. 
aFDR p-value was obtained from the adjusted p-value of FDR correction by Benjamini-Hochberg method
bPanel in Banff kidney report 20175.
ABMR, antibody mediated rejection; AKI, acute kidney injury; FC, fold change; FDRPV, false discovery rate p-value; SE, 
standard error; TCMR, T cell-mediated rejection; TOLs, tolerance associated transcripts.
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Next, pathway score profiles were compared between samples with aTCMR and negative 
controls. Seventeen pathways were analyzed (Figure 1D). Each pathway score was a 
combination of data from 6 to 23 genes (Table S5). Unsupervised HCA of the 17 pathways 
showed that the samples with aTCMR clustered separately from the samples without 
rejection (Figure 1D). Almost all pathway scores were higher in patients with aTCMR, for 
instance co-stimulation by the CD28 family, and cytokine signaling.
Immunomic comparison of aTCMR biopsies under belatacept- or tacrolimus 
therapy
Immunophenotypical analysis
 Twenty-five biopsies were included in the IHC analysis: 11 biopsies of patients treated with 
belatacept-based maintenance therapy and 14 patients with tacrolimus-based maintenance 
therapy. The infiltrates in the cortical area of tacrolimus-treated patients with aTCMR 
mainly consisted of T cells, monocytes and macrophages (Table 3). Representative IHC 
stainings of the infiltrate in an aTCMR biopsy of a patient with belatacept maintenance 
therapy are shown in Figure S1. The composition of cells in the cortical area was not 
significantly different for markers of the adaptive immune response (CD3, CD4, CD8, 
CD20, FoxP3, PD-1 and granzyme B) and for markers of the innate immune response 
(CD56 and CD68) in both belatacept- and tacrolimus-treated patients (Table 3). 
Furthermore, no significant difference was seen in the composition of cells in the cortical 
area between both groups of patients when only aTCMR grade IIA and IIB were analyzed, 
or when the mixed AR were compared (data not shown).
Gene expression analysis
In an unsupervised HCA, using the personalized panel, the gene expression profiles of 
belatacept-maintenance therapy did not cluster separately from the profiles of tacrolimus 
maintenance therapy (Figure 2A). Differential gene expression analysis demonstrated no 
significant difference between the aTCMR samples of patients who received maintenance 
therapy with either belatacept or tacrolimus (Figure 2B and Table S6). The top 15 DEGs 
(although not statistically different) are summarized in Table 4. In a two-dimensional 
principal component analysis, no separate clustering was seen between the samples of 
patients treated with belatacept or tacrolimus maintenance therapy (Figure 2C).
Unsupervised HCA of the pathway scores is depicted in Figure 2D. None of the 17 different 
pathways distinguished between aTCMR occurring under belatacept or tacrolimus 
maintenance therapy. Surprisingly, the genes that are involved in the CD28 costimulatory 
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pathway were similarly expressed in acute rejection samples of patients treated with either 
tacrolimus or belatacept (Table 5).
 
Table 3. Immunohistochemistry analysis of CD3, CD4, CD8, FoxP3, CD20, CD56, CD68, PD-1, and 
granzyme B.
Marker Treatment Mediana IQRa p-value
CD3 Tacrolimus 7.76 4.93-11.35 0.15
Belatacept 4.18 3.63-8.28
CD4 Tacrolimus 4.64 1.48-7.84 0.85
Belatacept 4.86 2.84-6.91
CD8 Tacrolimus 3.23 1.68-5.73 0.69
Belatacept 1.96 1.54-4.25
FoxP3 Tacrolimus 0.05 0.03-0.22 0.58
Belatacept 0.05 0.02-0.12
FoxP3/CD4 Tacrolimus 0.009 0.007-0.012 1.00
Belatacept 0.009 0.006-0.019
CD20 Tacrolimus 0.43 0.21-2.92 1.00
Belatacept 1.05 0.29-5.88
CD56 Tacrolimus 0.05 0.02-0.09 0.12
Belatacept 0.15 0.05-0.39
CD68 Tacrolimus 10.6 3.6-19.2 0.37
Belatacept 5.6 4.2-10.2
Granzyme B Tacrolimus 0.21 0.05-0.47 0.81
Belatacept 0.16 0.08-0.49
PD-1 Tacrolimus 0.35 0.22-0.70 0.12
Belatacept 0.05 0.02-0.88
aMedian (%) and interquartile range (%) of the ratio of positive stained cortex area divided by the total cortex area of CD3, CD4, 
CD8, CD20, CD56, CD68, granzyme B and PD-1. The ratio of FoxP3/CD3 is calculated by diving the percentage of FoxP3 
staining by the percentage of CD4 staining for each section. IQR, interquartile range; PD-1, programmed cell death protein 1.
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Figure 2. A. Heatmap and unsupervised hierarchical cluster analysis of the 209 normalized genes in 
samples of patients with aTCMR treated with belatacept or tacrolimus. Each row represents a probe. Each 
column represents a biopsy sample. The purple samples are the samples from belatacept-treated patients. 
The light green samples are the samples from tacrolimus-treated patients. The color in each cell reflects 
the level of expression of the mRNA, relative to the geometric mean of all the samples (z-score). Increasing 
intensities of orange point out higher expression, while increasing intensities of blue indicate lower expres-
sion. The degree of relatedness is represented by the dendrogram at the top of the panel. The probe thresh-
old is depicted on the left of the heatmap. Blue cells represent probes that were below the detection 
threshold (less than double the counts of the median of the negative control). Grey cells represent probes 
that were above the detection threshold. B. Volcano plot of samples of patients with aTCMR treated with 
belatacept versus patients treated with tacrolimus. The X-axis represents fold change (log2). The Y-axis 
displays each gene’s p-value (-log10). None of the genes was significant different between the two groups, 
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therefore no horizontal lines that indicate various False Discovery Rate p-values are visible. The 40 most 
statistically significant genes are labeled in the plot. Genes with a positive fold change are higher expressed 
in the samples of patients treated with tacrolimus. Genes with a negative fold change are higher expressed 
in the samples of patients treated with belatacept. C. Principal component analysis (PCA) plot of the top 
15 differentially expressed genes in samples of patients with aTCMR treated with belatacept or tacrolim-
us. PCA samples on the 1st (X-axis) and 2nd PC plane (Y-axis). The samples of patients treated with bela-
tacept are displayed in pink. The samples of patients treated with tacrolimus are displayed in grey. D. 
Pathway scores of samples of patients with aTCMR treated with belatacept or tacrolimus. Unsupervised 
hierarchical cluster analysis and heatmap showing pathway scores. Pathway scores are fit using the first 
principal component of each gene set’s data. Scores are displayed on the same scale via a Z-transformation. 
Each row represents a sample. Each column represents a pathway. The purple samples are the belata-
cept-treated patients. The light green samples are the samples of patients treated with tacrolimus. Increas-
ing intensities of orange point out higher pathway scores, while increasing intensities of blue indicate lower 
pathway scores. The degree of relatedness is represented by the dendrogram at the top of the panel. Each 
number of the column represents a different pathway: 1. Cellular response to stress, 2. Co-stimulation by 
the CD28 family, 3. Immunoregulatory interactions between lymphoid and non-lymphoid cells, 4. Me-
tabolism, 5. Developmental biology, 6. Hemostasis, 7. Binding and uptake of ligands by scavenger recep-
tors, 8. Extracellular matrix organization, 9. Metabolism of proteins, 10. Insulin receptor substrate sig-
naling mediated signaling, 11. Signaling by fragment C gamma receptor 2 (FGCR2), 12. Gene expression, 
13. Signaling by Wnt, 14. Cytokine signaling in immune system, 15. Innate immune system, 16. Class I 
MHC mediated antigen processing and presentation, 17. Signaling by G-protein coupled receptor (GPCR).
Table 4. Top 15 of differentially expressed genes in patients with acute rejection treated with belatacept 
compared with patients treated with tacrolimus.
mRNA
FC 
(log2)
SE 
(log2)
Lower 
confidence 
limit (log2)
Upper 
confidence 
limit (log2) p-value FDRPVa Panelb
EHD3 -1.14 0.28 -1.70 -0.59 0.0012 1.00 Glomerulus
SLC19A3 -0.98 0.29 -1.54 -0.41 0.0045 1.00 eGFR later
ASB15 -1.65 0.53 -2.68 -0.62 0.0073 1.00 GOCAR
VEGFA -1.44 0.46 -2.35 -0.54 0.0074 1.00 Macrophages
COL1A1 -2.67 0.90 -4.43 -0.91 0.0099 1.00 CADI progression /matrix
KLF4 0.83 0.29 0.27 1.39 0.0116 1.00 ABMR
SLC25A15 1.11 0.42 0.29 1.93 0.0189 1.00 eGFR later
IGHG3 1.66 0.66 0.36 2.95 0.0249 1.00 Plasma cells
CXCL11 1.88 0.76 0.39 3.37 0.0269 1.00 ABMR
TRAF4 0.21 0.09 0.04 0.38 0.0285 1.00 eGFR later
TNF 0.85 0.35 0.17 1.54 0.0288 1.00 ABMR
PLA1A 0.95 0.40 0.16 1.74 0.0328 1.00 ABMR
CD8B -0.83 0.36 -1.52 -0.13 0.0355 1.00 TCMR
PECAM1 0.40 0.17 0.06 0.74 0.0356 1.00 ABMR
TBX21 0.59 0.26 0.09 1.09 0.0369 1.00 ABMR / Exhaustion
aFDR p-value was obtained from the adjusted p value of FDR correction by Benjamini-Hochberg method
bPanel in Banff kidney report 20175.
ABMR, antibody mediated rejection; CADI, Chronic allograft damage index; FC, fold change; FDRPV, false discovery rate 
p-value; GOCAR, Genomics of Chronic Allograft Rejection; SE, standard error; TCMR, T cell-mediated rejection.
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Table 5. Gene expression ratios of genes involved in the CD28 pathway between patients with an 
acute rejection treated with belatacept and patients treated with tacrolimus.
mRNA FC (log2) SE (log2)
Lower confidence 
limit (log2)
Upper confidence 
limit (log2) p-value FDRPVa
BTLA -0.15 0.52 -1.16 0.87 0.77 1.00
CD274 0.47 0.41 -0.32 1.27 0.24 1.00
CD28 -0.42 0.46 -1.32 0.49 0.37 1.00
CD3D -0.41 0.38 -1.16 0.35 0.29 1.00
CD4 0.25 0.30 -0.33 0.83 0.40 1.00
CD86 0.05 0.49 -0.91 1.02 0.92 1.00
CTLA4 -0.59 0.73 -2.01 0.84 0.42 1.00
ICOS -0.17 0.45 -1.05 0.71 0.71 1.00
PDCD1 -0.42 0.53 -1.46 0.62 0.43 1.00
PDCD1LG2 0.03 0.41 -0.77 0.83 0.94 1.00
aFDR p-value was obtained from the adjusted p value of FDR correction by Benjamini-Hochberg method. 
FC, fold change; FDRPV, false discovery rate p-value; SE, standard error. 
 
Distinct pretransplant subsets of T cells have been described that may be 
responsible for triggering belatacept-resistant rejections, namely CD8+ CD28-T cells, 
CD4+CD57+programmed death 1 (PD-1)- T cells, and CD8+CD28+TEMRA
28-31. However, 
in our RCT, which included the belatacept-treated patients described here, these three 
subsets did not predict acute rejection pretransplantation, at least when measured in 
peripheral blood20. In addition, during acute rejection, the three subsets in the blood 
were not significantly different compared with belatacept-treated patients without acute 
rejection20. In the present study, the intra-graft mRNA concentrations of CD4, CD8, 
CD28, PD-1, and B3GAT1 (alias CD57) were determined and compared between 
belatacept- and tacrolimus treated patients with aTCMR Table S6). No difference in 
the expression of these markers was observed between the two groups.
DISCUSSION
The integration of immunomics with the conventional histomorphologic examination 
of renal biopsies will lead to improved classification and a deeper understanding of 
the pathogenesis of acute rejection5. This pilot study shows that with the innovative 
technique NanoString® it is feasible to derive gene expression data from FFPE 
kidney transplant biopsies and that it was possible to differentiate biopsies with 
and without aTCMR. These results were used to support our conclusion that the 
aTCMR immunomic profiles of patients treated with either tacrolimus or belatacept 
maintenance therapy were not significantly different.
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The Banff 2013 working group recommends the use of molecular diagnostics to define 
ABMR32. This includes increased expression analysis of transcripts involved in endothelial 
injury32. The Banff 2017 classification includes more diagnostic and prognostic molecular 
biomarkers for ABMR5. However, the Banff 2017 classification does not contain 
recommendations on the implementation of molecular diagnostics for the diagnosis of 
aTCMR. This may be useful in differential diagnostic dilemmas, such as borderline rejection 
or isolated v-lesions.
NanoString® is a high-throughput gene expression quantification system that delivers 
direct multiplexed measurements of gene expression through digital readouts of mRNA 
transcripts. Formalin-fixation can cause cross-linkage of nucleic acids to proteins, which 
can lead to inhibition of reverse transcriptase. The advantage of the NanoString® over other 
high-throughput techniques like real time polymerase chain reaction and microarray, is that 
it does not require a reverse transcriptase step9,33. NanoString® is suitable for clinical purposes 
because it is fast and has minimal hands-on time. Furthermore, the gene expression analysis 
can be performed in the same formalin fixed paraffin tissue that is used for conventional 
histopathologic examination. It has been accepted into international treatment guidelines 
as a prognostic assay for breast cancer34.
Here, the allograft transcriptome of aTCMR biopsies showed a significantly higher 
expression of 78 genes compared to the biopsies without aTCMR. The top pathogenesis-
based transcripts were mostly T cell-associated, γ-interferon inducible and effector cell, and 
injury-repair response-associated transcripts denoting an aTCMR profile35.
This is the first study that compared the immunomics of biopsies with aTCMR of patients 
treated with either tacrolimus or belatacept. A better understanding of the pathogenesis 
of costimulation blockade resistant rejections could lead to a more personalized approach 
of belatacept-based treatment in kidney transplant recipients. Besides, since molecular 
diagnostics of rejection biopsies are increasingly used in combination with conventional 
histomorphologic examination5, it is important to know whether the gene signature of 
rejection biopsies is dependent of the maintenance immunosuppressive therapy.
In this pilot study with a small sample size, the transcriptome of patients treated with either 
one of the two immunosuppressive regimens showed no distinct gene signature, including 
the genes involved in the CD28 costimulatory pathway. In addition, immunophenotypical 
analysis of the classic immune markers of the innate and adaptive immune system was not 
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significantly different between the two maintenance therapies. Furthermore, we could not 
confirm that the previously described T cell subsets (CD8+CD28- T cells, CD4+CD57+PD-1- 
T cells, and CD8+CD28+TEMRA
21,28,29) were associated with belatacept-resistant rejections, 
neither in the peripheral blood20 nor in the renal allograft (in this study).
One study analyzed biopsies with aTCMR of patients treated with belatacept or cyclosporine 
A (CsA) and compared the ratio of FoxP3+ cells among T cells with IHC36. This ratio was 
significantly elevated in acute rejection biopsies of belatacept-treated patients compared to 
CsA-treated patients (17.99% versus 6.45%, respectively, p = 0.044)36. Here, no difference 
was found in the ratio of FoxP3+ cells among CD4+ T cells between aTCMR biopsies of 
belatacept- and tacrolimus-treated patients. Besides, the intra-graft mRNA level of FoxP3+ 
was similar between the two groups.
No studies have compared the immunomics of biopsies without aTCMR of patients treated 
with belatacept or tacrolimus. However, several studies compared intra-graft gene expression 
and IHC of biopsies without rejection of patients treated with belatacept or cyclosporine. 
Two studies compared the intragraft gene expression of 12-month protocol biopsies without 
rejection of patients treated with belatacept or CsA37,38. Grimbert et al. found that the 
expression of FoxP3 was less in biopsies of patients treated with belatacept compared with 
CsA. No differences were found in granzyme B expression or the intra-graft expression of 
genes associated with Th1 (IFNγ, Tbet), Th2 (GATA3) and Th17 (RORγt, IL-17) cells37. 
Vitalone et al. compared the intra-graft gene expression of 4451 genes of preimplantation 
biopsies with 12-month protocol biopsies of patients treated with belatacept or CsA38. The 
biopsies of CsA-treated patients showed higher expression of genes associated with fibrosis, 
early tubulointerstitial damage and CsA-related toxicity. The biopsies of patients treated 
with belatacept showed enrichment of genes associated with NK cells and monocytes, 
progressive immune injury and wound healing38. Furuzawa et al. analyzed the 1-year 
protocol biopsies (without rejection) with IHC under belatacept- or CsA-maintenance 
treatment and observed that biopsies of belatacept-treated patients showed less senescence 
and a more immunomodulatory phenotype39.
The explanation for the absence of a difference in the immunomics of aTCMR biopsies 
of patients treated with tacrolimus or belatacept could be that the aTCMR as seen in 
biopsies is a shared final common pathway. This phenomenon was previously named the 
“immunologic constant of rejection”40,41. This hypothesis is based on the observation that 
different immune-mediated tissue destruction processes share the same final molecular 
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mechanism, like allograft rejection, cancer, autoimmunity and infections and includes 
activation of γ-interferon-regulated genes, recruitment of cytotoxic cells by chemokine 
ligands and activation of immune effector function genes40,41.
We recognize the limitations associated with this pilot study, most notably the small number 
of patients. This could have influenced the power of this study. However, to date, our 
RCT is the largest to have compared belatacept to tacrolimus maintenance treatment. 
Furthermore, we feel that studies on the immunomics of belatacept-resistant rejection with 
more statistical power are unlikely to become available anytime soon since the treatment of 
new patients with belatacept is currently very difficult because of a worldwide shortage of 
the drug42. Because of the limited sample size, no correlation between the IHC stainings, 
Banff grade and gene transcripts could be investigated. Furthermore, the scope of this 
study was to analyze the immunomics of tacrolimus- and belatacept-treated patients with 
acute rejections and not to study the gene expression profiles of different types of rejection. 
Therefore, we studied aTCMR only because ABMR did not occur in our belatacept RCT 
which compared belatacept and tacrolimus.
Additionally, we have used the NanoString® technique to measure the expression of a limited 
number of genes instead of using an untargeted approach, thereby excluding other possible 
differentiating biomarkers. The use of an untargeted genomic approach on the AR biopsies 
could possibly identify new genes and pathways that we did not analyze with the gene 
panel used in our study. However, we believe that most genes involved in aTCMR were 
included as they were derived from the panel presented in the Banff 2017 report5. Lastly, 
more biopsies of the tacrolimus-treated patients used for Nanostring® were taken earlier after 
transplantation than the biopsies of the belatacept-treated patients and the negative controls. 
This can be relevant because genes involved in the injury-repair response and inflammation 
could be affected by the transplant surgery. However, the timing of the acute rejection was 
not different between the three groups.
In summary, no differences were found in the immunomic profiles of aTCMR biopsies 
of patients treated with tacrolimus- or belatacept-based maintenance therapy, suggesting 
that clinically diagnosed rejection is a final common pathway of allo-recognition which is 
independent of the specific immunosuppressive regimen (tacrolimus or belatacept) under 
which it occurs. Follow-up studies with larger patient numbers are required to confirm our 
findings when belatacept is widely available again42.
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Figure S1. Representative immunohistochemical staining of an infiltrate in the kidney allograft biopsy 
of a belatacept-treated patient with an acute rejection. Stainings of CD3, CD4, CD8, CD20, CD56, 
CD68, PD1, granzyme B (GrzB) and FoxP3/CD4 were assessed on subsequent slides. Magnification of 
all slides is 10x.
Tables:
https://journals.lww.com/transplantationdirect/Fulltext/2019/01000/Immunomics_of_
Renal_Allograft_Acute_T.6.aspx#ej-article-sam-container
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ABSTRACT 
Background
There is an unmet need for reliable minimally invasive diagnostic biomarkers for 
immunological allograft monitoring and for the detection of acute kidney transplant 
rejection. Here, targeted proteomic analysis was applied to compare 92 proteins in sera 
of belatacept-treated patients who had biopsy-proven, acute T-cell-mediated rejection 
(aTCMR) with patients without aTCMR.
Methods
Proximity extension immunoassay was used to measure 92 inflammation-related protein 
concentrations in the pre-rejection and rejection sera of 11 patients with aTCMR and 9 
patients without aTCMR. This assay uses two matched oligonucleotide‐labeled antibody 
probes for each protein and polymerase chain reaction to measure normalized protein 
expression values.
Results
Five proteins (CD5, CD8A, NCR1, TNFRSF4 and TNFRSF9) were expressed significantly 
higher in samples with aTCMR compared with samples without aTCMR (adjusted 
p-value<0.014) and had a good predictive capacity for aTCMR (area under the curve in a 
receiver operator curve ranged from 0.83 to 0.91 [p<0.014]). These proteins are associated 
with CD8+ cytotoxic T cell and NK cell functions. Nonhierarchical clustering analysis 
showed distinct clustering of samples with aTCMR and samples without aTCMR. This 
clustering was not found in pre-rejection samples (one month after transplantation). In pre-
rejection samples, IFN-γ was expressed at a significantly lower level (normalized protein 
expression value median -0.15, interquartile range: -0.27 - 0.04) than in samples of patients 
without rejection (median 0.13, interquartile range: -0.07 - 0.15, adjusted p-value=0.00367). 
Conclusions
Targeted proteomic analysis with proximity extension immunoassay is a promising 
minimally invasive technique to diagnose aTCMR in kidney transplant recipients. 
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INTRODUCTION
Histopathological examination of a kidney allograft biopsy is the gold standard for 
diagnosing acute rejection (AR)1. However, sampling errors, limited reproducibility, and 
differential diagnostic dilemma’s remain a problem when examining a renal biopsy2. 
Furthermore, a percutaneous needle biopsy of the kidney is a costly and invasive procedure 
with considerable risk for complications, most notably bleeding3. A biopsy is not always 
possible in patients with bleeding diathesis, or uncontrolled hypertension. In addition, 
obtaining a biopsy from children is challenging. Therefore, there is an unmet need for 
reliable and minimally invasive biomarkers for the diagnosis of kidney transplant rejection4. 
Such a biomarker should have a short turnaround time, be cost-effective, and must have a 
high positive and negative predictive value.
Proteomic screening of blood or urine of kidney transplant recipients may be an alternative 
mean to diagnose AR without the need for a biopsy. Rejection may be identified before 
the onset of clinical symptoms or the occurrence of histomorphological damage5-8. AR is a 
heterogeneous time-dependent process that requires the activation of the immune system; 
it causes injury to the kidney and leads to scarring during the healing process. It is unlikely 
that a single biomarker can capture the multitude of these biological events. The use of a 
panel of proteins, also called targeted proteomics, may be more suitable9. For AR, a targeted 
proteomic analysis should include markers of the immune response, acute kidney injury, 
tissue regeneration and fibrosis. 
Since 2011, belatacept (a costimulatory blocking drug) is registered for the prevention of AR 
in kidney transplant patients as part of a calcineurin inhibitor (CNI)-free immunosuppressive 
regimen10. CNI-free immunosuppressive regimen with belatacept results in a comparable 
patient- and kidney allograft survival as achieved with CNI therapy, but with a superior 
metabolic profile11-16. However, belatacept-treated patients have more acute T cell-mediated 
rejections (aTCMR) compared with CNI-treated patients17,18. 
We performed a proteomic screening of 92 inflammation-related proteins in serum of 
belatacept-treated kidney transplant recipients with and without aTCMR with the multiplex 
Proximity Extension Immunoassay (PEA; Olink Bioscience, Uppsala, Sweden)19. This assay 
is widely used in several disciplines of medicine, including cardiovascular and inflammatory 
diseases. PEA has also been studied in the field of nephrology. In a cohort of 1047 senior 
adults, using a panel of 92 proteins with PEA, 20 proteins were independently associated 
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with the estimated glomerular filtration rate (eGFR) decline per year. These proteins are 
involved in phosphate homeostasis, inflammation, angiogenesis, apoptosis, extracellular 
matrix remodeling and endothelial dysfunction20.
The objectives of this pilot study were: 1) to compare the proteomic profiles with PEA 
between belatacept-treated patients with and without a biopsy-proven aTCMR, and 2) 
to screen pre-rejection serum samples of belatacept-treated patients for proteins that can 
potentially predict AR.
MATERIALS AND METHODS
Study population and materials
Serum samples were collected from kidney transplant recipients who participated in a 
prospective randomized controlled trial at Erasmus University Medical Center, Rotterdam, 
the Netherlands17. In this trial, kidney transplant recipients were randomized to receive 
belatacept- and tacrolimus-based immunosuppressive regimens. Patient characteristics, 
inclusion criteria and the immunosuppressive regimens have been described before17. In 
brief, all patients received induction therapy with basiliximab (Simulect®, Novartis Pharma, 
Basel, Switzerland), followed by maintenance therapy consisting of mycophenolate mofetil 
(MMF, Cellcept®, Roche Pharmaceuticals, Basel, Switzerland), glucocorticoids and either 
belatacept (Nulojix®, Bristol Myers-Squibb, New York City, NY) or tacrolimus (Prograft®, 
Astellas Pharma, Leiden, the Netherlands)17. 
As reported by de Graav et al., 11 of the 20 belatacept-treated patients experienced AR 
during the 1-year study period: 10 patients had aTCMR and 1 patient had a mixed rejection 
(aTCMR and acute/active antibody mediated rejection)17,21. All AR occurred within the first 
4 months after transplantation, three even occurred in the first week after transplantation 
(Figure 1A)17. The median time elapsed between transplantation and AR was 56 days (IQR 
5-94). 
The serum samples were centrifuged (3000 rpm, 10 minutes) within 4 hours after blood 
collection and the supernatant was stored at -80ºC. The samples of two time points (day 
30 after transplantation, and the day of kidney biopsy, Figure 1A) were used for this study. 
All biopsies with AR were scored independently by two pathologists according to the Banff 
2015 classification22. 
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Figure 1. A. Timeline of included serum samples. The green bars represent the patients with an acute 
rejection (n=11). The pink samples represent patients without acute rejection throughout the total follow-up 
period of 1 year (n=9). The blue samples represent the pre-rejection samples (day 30) of patients with 
aTCMR more than 30 days after transplantation (n=8). B. Volcano plot of 89 proteins of serum samples 
with and without aTCMR. The X-axis displays the difference in NPX of 89 proteins of the samples with 
aTCMR and samples without aTCMR. Proteins with a positive NPX value are higher in samples with 
aTCMR. The Y-axis represents each protein p-value (-log 10). The two horizontal lines depicts adjusted 
(dotted line) and unadjusted (solid line) p-values. C. Boxplot of the significantly different proteins of the 
comparison of samples with and without aTCMR. The pink samples are of 9 patients without aTCMR, 
and the green samples are of 10 patients with aTCMR. The Y-axis represents the NPX expression value 
and interquartile range. D. Table of the five significant proteins. The aliases, description, cell types and 
involved pathways are described. E. Area under the curve (AUC) of the significant proteins. A receiver 
operator characteristic curve analysis was performed of the 5 significant proteins and the AUC, NPX 
cutoff value with the sensitivity, specificity, positive predictive value and negative predictive value were 
calculated. F. Pearson’s correlation coefficient analysis. The correlation between the 5 significant proteins 
(CD5, CD8A, NCR1, TNFRSF4 and TNFRSF9) was tested with Pearson’s correlation coefficient analysis. 
95%-CI, 95%-confidence interval; NPV, negative predictive value; NPX, normalized protein expression; 
PPV, positive predictive value; SE, standard error.
Proximity Extension Immunoassay 
Ninety-two proteins were simultaneously measured in 1 µL serum by using the Immuno-
Oncology panel of Olink (Uppsala, Sweden). Each of the 92 proteins is recognized by 
two matched oligonucleotide‐labelled antibody probes. Upon simultaneous binding to the 
correct target protein, a real‐time polymerase chain reaction (PCR) amplicon is created by 
a proximity‐dependent DNA polymerization event. The resulting sequences were amplified 
and quantified by real time PCR (BiomarkTM HD system, Fluidigm, San Francisco, CA, 
USA). Quality control of the samples was performed using 2 incubation controls (2 different 
non-human antigens), and a detection control (a complete double stranded DNA amplicon 
which does not require any proximity binding or extension step). A negative control was 
included in triplicate on each plate to monitor background levels of each protein assay and 
were used to calculate the limit of detection. To minimize variation between samples, raw 
measurements were normalized. An extension control (an antibody linked to 2 matched 
unique olinonucleotides for immediate proximity independent of antigen binding) was 
used for normalization. For each sample and data point, the corresponding quantitation 
cycle (Cq)‐value for the extension control was subtracted. Three inter-plate controls (pool 
of 92 matching oligonucleotide pairs) are added to each 96 wells-plate to normalize the 
measurements between plates. In our study, only one plate was used. Finally, the data were 
transformed using a pre-determined correction factor (estimated during validation of the 
panel) of Olink. The generated Normalized Protein eXpression (NPX) value is on a log2 
scale where higher NPX values correspond to higher protein concentrations. Biomarkers 
with values below the limit of detection (less than 2.5 SDs above the negative controls) 
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were excluded from the analysis. The intra-assay and inter-assay coefficients of variation of 
PEA were 8% and 12% when tested in a validation study19.
Statistical analysis
All analyses were performed using R (R Foundation for Statistical Computing, Vienna, 
Austria, version 3.4.4), RStudio version 1.1.447 (RStudio Inc., Boston, MA, USA) and 
SPSS version 21 (SPSS Inc., Chicago, IL, USA). Continuous variables are expressed as 
median and interquartile range (first and third quartile, IQR). The unpaired t-test with false 
discovery rate (FDR) correction was used for the comparison between 2 groups. Results were 
considered statistically significant if p < 0.05. P-values were corrected for multiple testing 
using Benjamini-Hochberg’s approach. Receiver-operator characteristic curve analysis was 
performed on the significant proteins and the area under the curve (AUC) was calculated 
as a measure of discriminatory ability. Pearson’s correlation coefficient analysis was used to 
calculate correlations between the significantly different proteins.
RESULTS
The NPX values of the 92 proteins of the Immuno-Oncology panel were compared between 
the 11 samples with aTCMR (day of rejection, green samples in Figure 1A) and 9 samples 
without rejection (day 30 after transplantation, pink samples in Figure 1A). One sample 
(aTCMR on day 3) did not pass the quality control after PEA and was excluded from further 
analysis. Three proteins (IL-1α, TNF, and IL-35) did not pass the limit of detection and 
were excluded. 
Five proteins (T cell surface glycoprotein CD5 [CD5], T cell surface glycoprotein CD8 
[CD8a], Natural cytotoxicity triggering receptor 1 [NCR1], TNF receptor superfamily 
member 4 [TNFRSF4] and TNF receptor superfamily member 9 [TNFRSF9]) were 
expressed significantly higher in samples with aTCMR compared with samples without 
aTCMR (adjusted p-value<1.14E-02; Figure 1B and C). The pathways most enriched among 
these 5 proteins are related to T cell activation, T cell proliferation, and NK cell-mediated 
immune responses (Figure 1D). Receiver-operator characteristic curve analysis of these 
proteins revealed a good predictive capacity for aTCMR (Figure 1D). The AUC ranged from 
0.83 for CD5 to 0.91 for NCR1 (p<0.014; Figure 1E). The 5 proteins (CD5, CD8A, NCR1, 
TNFRSF4 and TNFRSF9) were all significantly correlated with each other (Figure 1F).
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 A non-hierarchical clustering analysis and heatmap showed clustering of samples with 
aTCMR and samples without aTCMR (Figure 2A). Two samples with aTCMR clustered 
with the samples without aTCMR. One sample was from a patient with an eGFR 
deterioration from 48 to 36 mL/min per 1.73 m2, 6 weeks after transplantation. The renal 
biopsy showed an isolated vascular lesion and was therefore classified as Banff category 
aTCMRIIA. This patient was treated with methylprednisolone. The other sample was 
obtained from a patient with an eGFR deterioration from 52 to 30 mL/min per 1.73 m2 4 
months after transplantation. The renal biopsy showed aTCMRIIB. This patient was treated 
with methylprednisolone and T cell-depleting therapy (alemtuzumab). One sample without 
aTCMR clustered with the aTCMR group. This patient was 1 month after transplantation 
and showed no clinical signs of AR. The kidney function (eGFR of 50 mL/min per 1.73m2) 
was stable at the time of serum collection and thereafter. 
Identification of patients with a higher probability for AR could potentially improve the 
long-term allograft outcome by changing the immunosuppressive regimen. Therefore, the 
pre-rejection serum (day 30 after transplantation, blue samples in Figure 1A) of 8 patients 
were compared with samples of 9 patients without aTCMR (pink samples in Figure 1A). 
Three proteins (IL-1α, IFN-β, and IL-35) were excluded due to low detection. No clustering 
was seen of pre-rejection samples (blue samples in Figure 1A) and no rejection samples (pink 
samples in Figure 1A) in a hierarchical cluster analysis (Figure 2B). One protein, IFN-γ, 
was expressed significantly higher in samples of patients without rejection (NPX value 
median 0.13, IQR -0.07 - 0.15) compared with pre-rejection samples (median -0.15, IQR 
-0.27 - 0.04, adjusted p-value=0.00367). The NPX values of the 5 proteins (CD5, CD8A, 
NCR1, TNFRSF4 and TNFRSF9) that were significantly higher in rejection samples when 
compared with those without rejection, were not higher in pre-rejection samples. 
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Figure 2. A. Unsupervised hierarchical cluster analysis and heatmap of the 89 proteins of samples with 
and without aTCMR. Each row represents a serum sample. The green samples are the samples with aTCMR 
and the pink samples are without aTCMR. Each column represents a NPX value of one of the 89 proteins. 
The columns are ordered by p-value, with the most significant proteins on the left and the least significant 
proteins on the right. The color in each cell reflects the level of relative expression of the protein (red is 
high and blue is low). *Sample with isolated vascular lesion. B. Unsupervised hierarchical cluster analysis 
and heatmap of the 89 proteins of pre-rejection samples (day 30) and samples without aTCMR (day 30). 
Each row represents a serum sample. The blue samples are the pre-rejection samples of patients with 
aTCMR in the follow up period. The pink samples are of patients without aTCMR during the follow-up 
period. Each column represents a NPX value of one of the 89 proteins. The columns are ordered by p-val-
ue, with the most significant proteins on the left and the least significant proteins on the right. *Sample 
with isolated vascular lesion.
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DISCUSSION
In the present study, targeted proteomic analysis with PEA was performed for the first 
time in kidney transplant recipients. Sera of belatacept-treated patients were used in an 
attempt to diagnose aTCMR in a minimally invasive way. Five proteins (CD5, CD8A, 
NCR1, TNFRSF4 and TNFRSF9) were associated with aTCMR and had good positive and 
negative predictive values. These proteins are strongly associated with effector lymphocytes 
of adaptive and innate immune systems, i.e. the classical CD8+ cytotoxic T cells and NK 
cells. These cells have important roles in AR23. After activation, these cells release cytotoxic 
molecules like perforin and granzyme, which can result in donor cell lysis and allograft 
damage. The observations of our study in serum of patients with AR are in accordance with 
the biology of AR found in kidney allografts24. The top molecular transcripts found in AR 
biopsies reflected the presence and actions of effector T cells, antigen presenting cells, NK 
cells, and γ-interferon-inducible genes25. 
The protein panel tested in this study also contained several other biomarkers that have 
been associated with AR. For instance, IFN-γ, CXCL9, CXCL10, CXCL11, granzyme 
B, PD ligand 1, FASLG and NK cell marker KLRD124,26. Here, these markers were not 
significantly different between the belatacept-treated patients with and without aTCMR. 
However, AR is a process of time-dependent events involving different combinations of 
proteins. It is, therefore, better not to look at a single protein but at a panel of proteins. 
In this study, cluster analysis of all proteins showed a distinct clustering of sera with and 
without aTCMR. 
Prediction of AR might help to stratifying immunosuppressive therapy of kidney transplant 
recipients. Therefore, pre-rejection samples (after the first month of transplantation) were 
compared with samples of patients without rejection in the first year. No protein profile 
could be identified that predicted aTCMR, and the 5 proteins that were significantly higher 
in rejection samples were not higher in pre-rejection samples compared with samples without 
rejection. A possible explanation for this is the timing of measurements: expression of these 
proteins might increase shortly before AR. One protein, IFN-γ, was found to be lower in 
pre-rejection samples compared with samples of patients without rejection. Although IFN-γ 
is a proinflammatory cytokine, it can also exert immunoregulatory activities27. Xu et al. 
also reported decreased IFN-γ levels in serum of kidney transplant patients with aTCMR 
compared with samples of patients without rejection. They postulated that IFN-γ is secreted 
from Th1-like regulatory T cells and thereby negatively modulates aTCMR28.
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Only one study in solid organ transplant recipients was performed with PEA before. This 
study shows promising results to discriminate AR from no rejection in serum of heart 
transplant recipients29. Ten proteins, mainly associated with T cell and NK cells (CCL19, 
CD244, CSF1, CXCL9, CXCL10, CXCL11, IL-6, IL-12B, LTA, SLAMF1) were expressed 
significantly higher in heart transplant recipients with AR compared to patients without 
AR29. An explanation for the discrepancy between our results and theirs may be that AR 
of a heart allograft is most often recognized at an earlier stage compared with a kidney 
allograft. In heart transplantation, diagnosing AR is mainly based on the histopathologic 
examination of protocol endomyocardial biopsies. In contrast, in kidney transplantation, 
AR is usually diagnosed in a for-cause biopsy. This can delay the diagnosis of AR in kidney 
transplant recipients and making the diagnosis at a later stage of rejection and subsequently 
differences in the proteome. 
The advantages of PEA are that it is a fast method (results within 24 hours and 3 hours 
hands-on time), with high sensitivity and specificity, and only a very low sample volume (1 
µL) is required. Furthermore, different types of samples (plasma, serum, urine, saliva, dried 
blood spot etc.) can be tested and low-abundant (below pg/mL) proteins can be measured19. 
We, therefore, believe that PEA is a candidate screening tool for acute kidney transplant 
rejection. This assay can potentially reduce the burden of kidney biopsies, especially in 
patients with a high risk for biopsy-related complications and in children. 
We acknowledge the limitations of this pilot study. First, the number of included patients 
was limited and therefore, no validation study was performed. However, expansion of the 
sample size is currently impossible, because of a manufacturing delay of belatacept30. Despite 
the limited sample size, a clear distinction in the protein profile was seen between serum 
samples from patients with aTCMR and those without aTCMR. Second, a selection of 
proteins was analyzed, thereby excluding other possibly relevant proteins. Third, with PEA, 
no absolute levels of the proteins are measured and therefore comparison with other studies 
is difficult. Fourth, in this study only patients treated with a belatacept-based regimen were 
analyzed. The low number of patients with an AR (n=2) in the tacrolimus group of our RCT 
precluded a meaningful analysis. Currently, we are collecting samples of tacrolimus-treated 
patients with an AR for a proteomic analysis. This study will include n = 225 patients and is 
expected to be completed at the end of 2019. Lastly, it would be of interest to analyze PEA in 
serum of patients with other types of rejection (e.g. antibody-mediated rejection), rejections 
occurring longer after transplantation (as opposed to early AR), and other common kidney 
6
138
PART II
pathology in kidney transplant recipients (like delayed graft function, acute tubular necrosis, 
pyelonephritis, BK nephropathy, and recurrent glomerulonephritis).
CONCLUSION
Targeted proteomic analysis with PEA of serum of kidney transplant recipients appears 
to be a promising minimally invasive technique to diagnose aTCMR additionally to 
histopathological examination. The encouraging results from this pilot study warrant 
further study with the inclusion of a larger group of patients and different types of kidney 
diseases. 
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ABSTRACT
The introduction of immunosuppressant belatacept, an inhibitor of the CD28-80/86 
pathway, has improved 1-year outcomes in kidney transplant recipients with pre-existent 
diabetes mellitus and has also reduced the risk of posttransplant diabetes mellitus. So far, 
no studies have compared a tacrolimus-based to a belatacept-based immunosuppressive 
regimen with regard to improving glucose tolerance after kidney transplantation. Here, 
we present the case of a 54-year-old male with type 2 diabetes mellitus who was converted 
from belatacept to tacrolimus 1 year after a successful kidney transplantation. Thereafter, 
he quickly developed severe hyperglycemia, and administration of insulin was needed 
to improve metabolic control. Six months after this episode, he was converted back to 
belatacept because of nausea, diarrhea, and hyperglycemia. After switching back to 
belatacept and within 4 days after stopping tacrolimus glucose tolerance improved and 
insulin therapy could be discontinued. Although belatacept is considered less diabetogenic 
than tacrolimus, the rapid improvement of glucose tolerance after switching to belatacept 
is remarkable. In this article, the potential mechanisms of this observation are discussed.
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INTRODUCTION
Kidney transplant recipients who have pre-existent diabetes mellitus (DM) or who develop 
DM after transplantation (posttransplant DM [PTDM]) have a worse survival and suffer 
from more cardiovascular morbidity than those without1-3. The calcineurin-inhibitors 
(CNI), cyclosporine A (CsA) and tacrolimus, may decrease insulin secretion and increase 
insulin resistance4. The latter is characterized by a decreased insulin sensitivity, that is, more 
insulin is needed to maintain serum glucose within the reference range5. 
Belatacept, an inhibitor of the CD28-CD80/86 pathway6, does not induce hyperglycemia 
nor PTDM. Despite the higher acute rejection risk observed in belatacept-treated patients7-9, 
it improves 1-year allograft survival and renal function in kidney transplant recipients with 
pre-existent DM compared with CsA-treated patients3. 
 In addition, belatacept-based therapy decreases the risk of developing PTDM. A meta-
analysis which included 729 belatacept-treated and 320 CsA-treated patients showed a 
relative risk of 0.61 (95%-confidence interval, 0.40 - 0.93) to develop PTDM with belatacept 
compared to CsA10. Tacrolimus is, nowadays, the most-widely used CNI, and treatment 
with tacrolimus carries a higher risk of developing PTDM than CsA11,12. 
Belatacept may be a therapeutic option for kidney transplant recipients that develop 
PTDM or for those with pre-existent DM who develop a worsening of metabolic control 
after starting a CNI-based regimen. Glucose metabolism has not been compared between 
belatacept- and tacrolimus-treated patients. In addition, no data on the safety and 
efficacy regarding insulin sensitivity of conversion from CNIs to belatacept after kidney 
transplantation have been reported. 
Here, a kidney transplant recipient with DM is described, who after conversion from 
belatacept to tacrolimus developed severe hyperglycemia. Glucose control was difficult 
and did not improve despite high doses of insulin. Within 4 days after stopping tacrolimus 
and reintroducing belatacept, a marked improvement of glucose tolerance was observed. 
The purpose of this case report is to discuss the possible pathophysiologic mechanisms 
explaining this observation and the role of immunosuppressive therapy therein.
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CASE DESCRIPTION
A 54-year-old Caucasian male received a preemptive, living-unrelated donor kidney 
transplant in October 2013 because of hypertensive and diabetic nephropathy. His 
medical history included hypertension since 1992; type 2 DM since 2002; and since 
2008, histologically confirmed diabetic and hypertensive nephropathies. The transplant 
was 2-2-1 mismatched (for HLA-A, HLA-B and HLA-DR, respectively). Peak and actual 
panel reactive antibodies were 0%. 
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Figure 1. Overview of the dose of tacrolimus and prednisolone. The depicted doses of tacrolimus and 
prednisolone are oral daily doses per time period. Tacrolimus was adjusted to whole blood predose con-
centrations (C0). Prednisolone was given as an intravenous dose of 100 mg on days 0-3. From day 4 until 
day 18 the prednisolone dose was 20 mg/d; in weeks 3-4 the prednisolone dose was 15 mg/d; in weeks 5-6 
the prednisolone dose was 10 mg/d; in weeks 7-10 the prednisolone dose was 7.5 mg/d; thereafter pred-
nisolone dose was 5 mg/d. De dashed vertical lines indicate the time points when belatacept was discon-
tinued and restarted.
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The patient was treated with belatacept according to the less-intensive regimen of the 
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression 
(BENEFIT) trials during the first posttransplantation year as part of a randomized-
controlled trial13,14. This trial compared belatacept to tacrolimus and its main findings were 
described previously14,15. In addition to belatacept, he also received induction therapy with 
20 mg/kg basiliximab (day 0 and 4) and maintenance therapy with mycophenolate mofetil 
(targeted to pre-dose concentrations of 1.5-3.0 mg/mL), and prednisolone, tapered to 5 mg/d 
by month 3 and maintained at 5 mg/d thereafter (Figure 1). The clinical course of the first 
posttransplant year was uneventful. Belatacept was not reimbursed by the health insurance 
companies in the Netherlands at the time the patient was 1 year after transplantation 
(October 2014). Belatacept was discontinued, and he was switched to tacrolimus (Advagraf ®; 
Astellas Pharma, Tokyo, Japan) targeted to predose concentrations of 5-7 ng/mL (Figure 1). 
At the time of transplantation, his DM was well-controlled: glycated hemoglobin (HbA1c) 
was 44 mmol/mol with 24 International Units (IU) of long-acting insulin-glargine (Lantus®; 
Sanofi, Paris, France) daily. Before transplantation, he was taken care of by a nephrologist 
in a local hospital. Initially, his diabetes was managed with metformin only. When his 
renal function deteriorated, metformin was stopped, and he was started on long-acting 
insulin. After transplantation and in an attempt to take patient off insulin, he was started on 
metformin and glimepiride. Insulin-glargine was initially continued (mean dose, 28 IU/d). 
In addition, during the first month after transplantation, he received short-acting insulin-
aspart (NovoRapid®; Novo Nordisk, Bagsværd, Denmark, mean dose 18 IU/day). Four 
months after his transplantation and when prednisolone had been tapered to 5 mg daily, 
insulin could be discontinued completely. Figure 2 gives an overview of diabetes-related 
events, glucose and HbA1c concentrations, and glucose lowering medication. We believe 
that the combination of improved kidney function, possibly increased physical activity, the 
introduction of metformin and glimepiride and the tapering of prednisolone to 5 mg daily 
(Figure 2) allowed for the complete withdrawal of insulin therapy.
Within 14 days after conversion to tacrolimus, the patient developed severe hyperglycemic 
episodes (Figure 2). Glimepiride and metformin were increased to 6 mg and 3000 mg 
daily, respectively, without improvement of glucose control (Figure 2). Insulin therapy was 
restarted (Figure 2). The patient needed up to 50 IU of short- and long-acting insulin on 
a daily basis to improve metabolic control. Despite the high insulin dose, hyperglycemia 
persisted. During these hyperglycemic episodes, no infections or changes in bodyweight 
were observed.
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Figure 2. Overview of diabetes-related events, measurements and glucose-lowering medication. A timeline 
is depicted indicating important events related to changes in glucose concentrations. The presented glu-
cose and HbA1c concentrations were measured in hospital at the outpatient clinic. The maximum target 
concentration of HbA1c was 53 mmol/mol. Glucose concentrations measured at home are not included. 
The daily doses per time period are given for metformin, glimepiride, insulin-glargine and insulin-aspart. 
From day 12 to 48 after transplantation, doses of insulin-aspart were adjusted to target a premeal glucoses 
concentration of <10 mmol/L (average dose was 18 IU/d). De dashed vertical lines indicate the time points 
when belatacept was discontinued and restarted.
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In addition, the patient developed tremors of the hands, nausea, and diarrhea that were 
all considered as side effects of tacrolimus. Clinically, no signs of tacrolimus-associated 
nephrotoxicity were observed. No (protocol) kidney biopsy was performed after conversion 
to tacrolimus. Because of these side effects, 6 months after conversion, belatacept (5 mg/kg 
bodyweight monthly) was restarted. Tacrolimus was discontinued overnight. Four days after 
discontinuing tacrolimus, the patient’s blood glucose concentrations improved tremendously 
and insulin therapy could be stopped. During the 2-year follow up period, the patient 
has remained in good clinical condition. No acute rejection occurred and his eGFR has 
remained stable (55 mL/min per 1.73 m2; Figure S1). His current glucose-lowering treatment 
consists of metformin and glimepiride. 
DISCUSSION
In this patient, a marked improvement in glucose tolerance was observed after switching 
from belatacept to tacrolimus. Improvement of glucose control occurred immediately after 
withdrawal of tacrolimus and exogenous insulin could be stopped within 4 days. The 
improvement in glucose was not related to changes in BMI (Figure S1). Although it is well 
known that belatacept is less diabetogenic than CNIs10, the rapid improvement of glucose 
tolerance was remarkable and unexpected. 
Tacrolimus may induce DM by several mechanisms. First, tacrolimus reduces insulin 
secretion by the pancreatic β cells via decreasing insulin mRNA expression through 
inhibition of 2 pathways (nuclear factor of activated T cells and cAMP response element-
binding protein)16-19. Second, the insulin content of the β cell is diminished by tacrolimus17. 
Third, the glucose-induced insulin release is inhibited by tacrolimus through reduced 
glucokinase activity17,20. Fourth, tacrolimus directly induces β cell apoptosis and reduces 
islet cell proliferation19,21. Altogether, these effects lead to a reduction of insulin secretion. 
Furthermore, CNIs may induce insulin resistance by stimulating endocytic removal of 
glucose transporter type 4 (Glut-4) from the cell membrane of adipocytes and muscle cells22. 
The induction of hypomagnesemia is another mechanism by which tacrolimus may directly 
influence glucose tolerance23. Tacrolimus can downregulate the magnesium absorbing 
channel transient receptor of potential melastatin (TRPM6) in the distal collecting tubule 
and thereby induce hypomagnesemia via renal magnesium wasting24. Hypomagnesemia may 
contribute to insulin resistance by decreasing autophosphorylation of the β subunits of the 
insulin receptor25. Besides, hypomagnesemia may reduce insulin secretion25. Unfortunately, 
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it is unknown if hypomagnesemia played a role in our case, since magnesium concentrations 
were not measured. 
We think that the fast improvement of glucose control after switching to belatacept in our 
patient was mainly related to (1) the discontinuation of tacrolimus and/or (2) a direct effect 
on insulin resistance by CD80-86 blockade by belatacept. Several animal studies have 
described the effects of discontinuation of tacrolimus on glucose metabolism. Redmon et 
al17 observed reversibility of insulin secretion 72 hours after discontinuation of tacrolimus 
in hamster β cells (HIT-T15). Another in vitro study using rat β cells found similar results26. 
In an in vivo study, reversibility of rat β cells insulin gene expression, insulin content, and 
insulin secretion was observed 7 days after discontinuing tacrolimus27. Another study in 
rats showed that the insulin resistance improved 5 days after the last dose of tacrolimus28. 
All these studies show reversibility of impaired glucose tolerance after discontinuation of 
tacrolimus. However, these studies are limited by the short duration of tacrolimus treatment. 
Prolonged administration could possibly lead to a more severe reduction of functional β 
cell mass and irreversibility of impaired glucose control. Furthermore, to the best of our 
knowledge, no studies in humans have analyzed directly the effects of insulin secretion 
and resistance after discontinuation of tacrolimus. Boots et al29 described the effect of 
tacrolimus dose reduction on insulin secretion. In 15 kidney transplant recipients without 
DM, a 33% reduction in the tacrolimus predose concentrations resulted in a 36% increase 
in β cell secretion capacity29.
The fast improvement of glucose tolerance in this case may also have been caused by 
the introduction of belatacept (rather than the withdrawal of tacrolimus).One study 
has suggested that CD86 may play a role in insulin resistance via interaction with the 
adiponectin axis30.
Interestingly, a case report of a patient with rheumatoid arthritis reported an improvement 
of insulin resistance 4 weeks after treatment with abatacept, which is considered a lower-
affinity version of belatacept31. In another study, improved insulin sensitivity was observed 
in 15 patients 6 months after the start of abatacept treatment32. 
In contrast to the findings of the studies described above, Zhong et al33 found in mice and 
humans that a higher CD80/86 expression was negatively correlated with insulin resistance. 
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No effect of adiponectin on CD80/86 expression was noted on human macrophages in 
another study34. 
The main limitation of this case report is that the mechanistic evidence of the effect of 
belatacept and tacrolimus on glucose tolerance is lacking. We did not examine endogenous 
insulin secretion and insulin resistance. 
In conclusion, a kidney transplant recipient with pre-existing type 2 DM is described 
who showed a rapid improvement of glucose tolerance after switching from tacrolimus to 
belatacept. Such a strategy may be beneficial in comparable cases although high-quality 
evidence of the safety of this intervention in terms of rejection is currently lacking. 
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SUPPORTING INFORMATION
Additional supporting information may be found in the online version of this article:
Figure S1. Body mass index, blood pressure, lipids and graft function during 2-year follow-up 
Chol, total cholesterol; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; 
HDL, high-density lipoproteins; LDL, low-density lipoproteins; SBP, systolic blood pressure; TG, 
triglycerides
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ABSTRACT
Background
T cell depleting antibody therapy with rabbit anti-thymocyte globulin (rATG) is the 
treatment of choice for glucocorticoid-resistant acute kidney allograft rejection (AR) and 
is used as first-line therapy in severe AR. Almost all studies investigating the effectiveness of 
rATG for this indication were conducted at the time when cyclosporine A and azathioprine 
were the standard of care. Here, the long-term outcome of rATG for AR in patients using 
the current standard immunosuppressive therapy (i.e. tacrolimus and mycophenolate 
mofetil), is described.
Methods
Between 2002 to 2012, 108 patients were treated with rATG for AR. Data on kidney 
function in the year following rATG and long-term outcomes were collected.
Results
Overall survival after rATG was comparable to overall survival of all kidney transplant 
patients (p = 0.10). Serum creatinine 1 year after rATG was 179 µmol/L (interquartile range 
(IQR) 136-234 µmol/L) and was comparable to baseline serum creatinine (p = 0.22). Early 
AR showed better allograft survival than late AR (p = 0.0007). In addition, 1 year after 
AR, serum creatinine was lower in early AR (157 mol/L; IQR 131-203) compared to late 
AR (216 mol/L; IQR 165-269; p < 0.05). The Banff grade of rejection, kidney function at 
the moment of rejection, and reason for rATG (severe or glucocorticoid resistant AR) did 
not influence the allograft survival.
Conclusion
Treatment of AR with rATG is effective in patients using current standard immunosuppressive 
therapy, even in patients with poor allograft function. Early identification of AR followed 
by T cell depleting treatment leads to better allograft outcomes.
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INTRODUCTION
T cell depleting antibody therapy with rabbit anti-thymocyte globulin (rATG) is the 
treatment of choice for glucocorticoid-resistant or recurrent acute rejection (AR)1. In 
addition, many physicians use rATG as first-line therapy for severe acute T cell-mediated 
rejection (aTCMR, Banff grade IIA or higher) or as a component of treatment directed 
against acute antibody-mediated rejection (aABMR)2.
The evidence of the efficacy of rATG therapy for AR dates from the era when azathioprine 
and cyclosporine A (CsA) were the standard of care. However, there is little evidence 
to guide the type of anti-rejection therapy in kidney transplant recipients treated with 
the current standard maintenance immunosuppressive therapy, consisting of tacrolimus 
(TAC) and mycophenolate mofetil (MMF)3. The advice on anti-rejection therapy in the 
KDIGO guideline1 is based on a systematic review with meta-analysis4, which was recently 
updated5. This review compared T cell depleting therapy (ATG, both horse and rabbit, 
anti-lymphocyte globulin and muromonab-CD3) to pulse glucocorticoids as treatment of 
the first episode of kidney transplant AR. ATG therapy showed less failure of reversal of 
AR compared with pulse glucocorticoids (relative risk (RR) 0.40; 95%-confidence interval 
(CI) 0.22-0.74). Furthermore, allograft loss 18 months after AR was significantly less in the 
ATG group compared with patients treated with pulse glucocorticoids (RR 0.63, 95%-CI 
0.44-0.89)5.
The studies included in this systematic review had a wide variation in definition of 
outcomes. Not all studies reported the immunization status of the patients, details about 
trial methodology were often incompletely reported and most studies included only small 
numbers of patients5. Most importantly, because the studies were performed more than 2 
decades ago, all patients received maintenance immunosuppressive treatment consisting of 
CsA and/or azathioprine. No patients received TAC plus MMF-based therapy.
The lack of data on the effectiveness of rATG in kidney transplant patients using TAC plus 
MMF-based immunosuppressive therapy and the availability of several new options to treat 
aTCMR, such as anti-CD52 therapy (alemtuzumab) and anti-CD20 therapy2,6,7, prompted 
us to analyze the results of rATG for AR after kidney transplantation at our center. The 
objectives of this study were to: 1) investigate the long-term outcomes (patient survival, 
allograft survival and adverse events) and 2) characterize which patients were at greater risk 
for adverse outcome after rATG therapy for AR. The outcomes presented here could serve 
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as a basis for future studies that describe other anti-rejection therapies in patients treated 
with TAC and MMF.
MATERIALS AND METHODS
Study design and inclusion criteria
A retrospective analysis was conducted of all kidney transplant recipients who received 
rATG (Thymoglobulin®, Sanofi Genzyme, United States) because of AR between 2002 and 
2012 in the Erasmus Medical Center. This specific period was chosen because from 2000 
onwards, patients received TAC as the standard maintenance immunosuppression. After 
2012, the anti-rejection protocol was changed and ever since patients have been treated 
with alemtuzumab in case of glucocorticoid-resistant or severe aTCMR. According to 
Dutch law, the present study did not require formal approval of the local medical ethical 
review board8. All AR episodes were proven by biopsy except for one. In this patient, no 
biopsy was performed. This case was included in all analyses except the analyses with the 
Banff classification. For the present study, all kidney allograft biopsies were revised by an 
experienced renal-pathologist (M.C.C-v.G) and categorized according to the Banff 2015 
classification9.
In the period 2002-2012, 1463 patients received a kidney transplantation at our center. 
Patients treated with rATG were identified by means of our kidney transplant registry and 
the electronic medication prescription system of our hospital pharmacy. Sixteen patients 
with blood group ABO-incompatible kidney transplantations who received rATG were 
excluded from the analysis.
Immunosuppressive protocol
The standard immunosuppressive regimen after 2009 included induction therapy with 
basiliximab (Simulect®, Novartis Pharma, Basel, Switzerland) 20 mg intravenously on 
days 0 and 4 after transplantation. Before 2009, induction therapy was not given in our 
center on a routine basis except to recipients of a deceased-after-circulatory-death donor 
kidney. The standard maintenance immunosuppressive regimen consisted of TAC (Prograf ®, 
Astellas Pharma, Leiden, the Netherlands), MMF (Cellcept®, Roche Pharmaceuticals, Basel, 
Switzerland) and glucocorticoids.
Dosing of TAC was based on pre-dose concentrations (C0). Target C0 for tacrolimus were 
10-15 µg/L (week 1-2), 8-12 µg/L (week 3-4), 5-10 µg/L (week 4-12), and 4-8 µg/L from 
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month 4 onwards. MMF was started at 1000 mg twice daily. Before 2010, the dose of 
MMF was adjusted if the patient experienced side effects, like gastro-intestinal complaints 
and leucopenia. From 2010, dosing of MMF was based on C0, aiming for target C0 of 1.5 
– 3.0 mg/L. Glucocorticoids were given as an intravenous dose of 100 mg on days 0-3 and 
thereafter were started in a dose of 20 mg/day (days 4 – 20). Thereafter, glucocorticoids 
were tapered and completely withdrawn around month 4. Patients using other experimental 
immunosuppressive drugs as part of clinical studies were included in the current analysis.
Treatment of AR
Patients with AR were initially treated with intravenous methylprednisolone 1000 mg 
(Solu-Medrol®, Pfizer, New York, United States) daily for 3 consecutive days. Treatment 
with rATG was left at the discretion of the attending physician and was based on the effect 
of pulse glucocorticoids, severity of the AR (Banff category), previous transplant rejection, 
medical history, and patient immunization status. For a subgroup analysis, two reasons 
for rATG therapy were distinguished: 1) glucocorticoid-resistant and (2) severe AR. In 
glucocorticoid-resistant AR, patients were initially treated with pulse glucocorticoids. If 
the effect was not satisfactory, rATG therapy was administered subsequently. In patients 
with severe AR (based on Banff category and kidney function) rATG was given as first-
line therapy or shortly after pulse glucocorticoids (without awaiting the full effect of 
glucocorticoids).
Rabbit ATG was administered in a high flow vein or central venous catheter as a single 
bolus (4 mg/kg [actual bodyweight, no maximum dose limit]) during 6 hours. The aim 
was an absolute whole blood CD3+ T cell count below 200 x 106/L for a duration of 2 
weeks. If CD3+ T cell counts increased during this period, a repeat dose of rATG (4 mg/
kg) was administered. Patients with an aABMR or a mixed type AR might be treated 
additionally with intravenous immunoglobulins, rituximab, or plasma-exchange, according 
to the KDIGO guideline and local protocol 1.
All patients received pre-medication prior to rATG administration: prednisolone 50 
mg intravenously, 4 mg clemastine and 1000 mg acetaminophen. For 3-6 months, 
patients received Pneumocystis jirovecii prophylaxis (sulfamethoxazole/trimethoprim) and 
cytomegalovirus (CMV) prophylaxis ([val]ganciclovir or CMV immunoglobulins).
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Outcomes
The following data were collected: baseline characteristics, anti-rejection therapy, rejection 
type and severity according to the Banff 2015 classification9, allograft function (serum 
creatinine and estimated glomerular filtration rate (eGFR; Chronic Kidney Disease 
Epidemiology Collaboration [CKD-EPI]10 and proteinuria), allograft survival (censored for 
death) and serious adverse events. Baseline serum creatinine was defined as the lowest serum 
creatinine in the 3 months before AR. Baseline eGFR was defined as the highest eGFR in 
the 3 months before AR. Data on serum creatinine and eGFR were included in the analysis 
when the patient had a functioning allograft. The follow-up period for infection was from 
rATG administration until death, loss to follow-up, or re-transplantation. Malignancies 
and mortality were evaluated until last follow-up, which could be after a subsequent kidney 
transplantation. Allograft loss was defined as the need for dialysis or re-transplantation. In 
all patients who received a kidney transplant between 2002 and 2012 in our center, allograft- 
and patient survival were analyzed and compared with that of patients suffering from AR 
and requiring rATG therapy. The hospital information system, NKR (Netherlands Cancer 
Registry, https://www.cijfersoverkanker.nl/) and NOTR (Netherlands Organ Transplant 
Registry, https://www.transplantatiestichting.nl/) were used for data retrieval regarding the 
occurrence of malignancies. Infections were considered serious if the infection necessitated 
hospitalization or occurred during hospital admission for another reason. Viral infections 
were recorded. BK viremia was tested on indication. Unexplained fever, chills, hypotension, 
rash, dyspnea, lymphadenopathy, arthralgia or myalgia were considered serum sickness.
Statistical methods
Categorical variables are presented as number (percentage). Continuous variables are 
presented as mean with standard deviation for parametric variables or median with 
interquartile range (IQR) for non-parametric variables. For differences between paired 
samples the paired two-sample t-test or Wilcoxon signed rank test were used. For unpaired 
non-parametric continuous data, the Kruskal-Wallis test and Mann-Whitney U test 
were used. Allograft survival between groups was analyzed by means of Kaplan-Meier 
survival analysis. The influence of independent variables was analyzed with univariate 
Cox proportional hazard regression analysis. Because of the number of events (49 allograft 
losses), it was only possible to test a maximum number of variables mounting up to 5 degrees 
of freedom per analysis in the multivariate Cox proportional hazard regression analysis. The 
influence of the most significant variable was tested in the presence of all the other variables 
one by one in order of increasing p-values. Variables were eliminated from the model by 
backward elimination. They were replaced by other variables so that at last all variables 
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had been present in the model. A two-sided p-value < 0.05 was considered statistically 
significant. For statistical analysis, GraphPad Prism, version 5 (San Diego, CA, USA) and 
SPSS version 21 (SPSS Inc., Chicago, IL, USA) were used.
RESULTS
Patient demographics
A total of n = 108 episodes of AR requiring rATG therapy were identified in 103 patients 
(Table 1). Five patients were diagnosed with a second episode of AR in the same kidney 
transplant, which also required rATG treatment. Most rejections were aTCMR (Table 1).
Forty-five patients received induction therapy (Table 1). At the time of AR, the majority of 
patients were treated with combination therapy consisting of TAC, MMF, with or without 
glucocorticoids (72.2%). Six patients (5.6%) used a TAC-based immunosuppressive regimen 
and 20 patients (18.5%) were treated with a MMF-based immunosuppressive regimen 
(without TAC) at the time of rejection. TAC and glucocorticoid dosing was stable during 
the 2002-2012 study period. In contrast, MMF dosing, was significantly lower in the period 
2010-2012 compared with 2002-2006: 1000 mg (IQR 1000-2000 mg) versus 2000 mg 
(IQR 1250-2000 mg; p = 0.04).
Efficacy
Allograft survival
Allograft survival and event-free survival (survival free from allograft loss or death) in 
rATG treated patients was significantly worse than in the total group of kidney transplant 
recipients without rATG treatment (p < 0.0001, HR 3.9, 95%-CI 2.6-5.8 and p < 0.0001, 
HR 15.9, 95%-CI 9.2-27.4, respectively; Figure 1A). In the year after rATG treatment, 
28 patients (25.9%) experienced allograft loss, 5 of whom had primary non-functioning 
allografts (Figure 1A). In the full observation period (median 6.8 years, IQR 4.9-9.1) 49 
patients lost their allograft. Median allograft survival of the total group was 7.0 years 
(Figure 1A).
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Table 1. Baseline characteristics of patients requiring rATG because of AR
Characteristic
Patients - no. 103
Kidney transplantations - no. 107
Recipient age - yr. 46 (35-56)
Donor age - yr. 54 (46-61)
Female sex - no. (%) 64 (62.1)
Cause of ESRD - no.
DM/HTN/GN/PKD/reflux/other/unknown 23/10/18/16/17/16/3
Ethnic distribution - no.
Caucasian/Black/Asian/Arab/other 70/16/5/5/7
Transplant number - no.
1/2/3/4 76/25/5/1
Preemptive kidney transplantation - no. (%) 25 (23.4)
Donor type - no.
LR/LUR/DBD/DCD 35/47/15/10
HLA mismatch
HLA A: 0/1/2 21/60/23
HLA B: 0/1/2 11/55/38
HLA DR: 0/1/2 13/50/41
PRA actual - no. (%)
0-5% 81 (77.1)
6-83% 21 (20)
84-100% 3 (2.9)
PRA peak - no. (%)
0-5% 62 (59)
6-83% 32 (30.5)
84-100% 11 (9.5)
CMV IgG serostatus recipient
Positive / negative 75/31
EBV IgG serostatus recipient
Positive / negative 90/7
Induction therapy - no.
None 62
Basiliximab/ ATG/ Daclizumab 33/10/2
Maintenance immunosuppression - no. (%)
TAC/MMF/glucocorticoids 58 (53.7)
TAC/MMF 20 (18.5)
TAC + other (non-MMF) 6 (5.6)
MMF + other (non-TAC) 20 (18.5)
Other combinations 4 (3.7)
rATG administration - no. 108
DGF during rejection episode - no. (%) 19 (17.6)
Primary non-function - no. (%) 5 (4.6)
Time to rejection - days 24 (8-339)
Early rejection (<1 month) - no. (%) 56 (51.9)
Intermediate rejection (1-3 months) - no. (%) 8 (7.4)
Late rejection (>3 months) - no. (%) 44 (40.7)
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Table 1. (Continued)
Characteristic
Banff 2015 classification - no.*
aTCMR
aTCMR IA 6
aTCMR IB 8
aTCMR IIA 21
aTCMR IIB 20
aTCMR III 1
ABMR
a/aABMR 12
c/aABMR 3
Mixed aTCMR with a/aABMR
aTCMR IA 1
aTCMR IB 7
aTCMR IIA 2
aTCMR IIB 8
Mixed aTCMR with c/aABMR
aTCMRIIA 1
C4d positive ABMR 18
C4d negative ABMR 10
No diagnosis after reclassification* 18
Anti-rejection therapy
Methylprednisolone prior to rATG - no. (%) 93 (86.1)
Cumulative dose of methylprednisolone, mg
1000/2000/3000/6000 2/9/79/3
Cumulative dose of rATG per patient, mg 555 (250-715)
Cumulative dose of rATG per patient, mg/kg 7.4
rATG number of gifts - no.
1/2/3/4 30/62/15/1
Necessity for additional anti-rejection therapy < 3 months - no.
Methylprednisolone 10
Intravenous immunoglobulins 6
Rituximab 3
Plasma exchange 3
Muromonab-CD3 1
Data are numbers (%) or median (interquartile range). Other kidney diseases included focal segmental glomerulosclerosis, 
hemolytic uremic syndrome, nephronophtisis, tuberous sclerosis or tubulo-interstitial nephritis. TAC + other regime contained 
combinations of TAC, glucocorticoids, sirolimus, everolimus, AEB071, or FTY720. MMF + other regime contained 
combinations of MMF, glucocorticoids, sirolimus, cyclosporine A, everolimus, or CP-690550. Other combinations existed of 
a combination of azathioprine, glucocorticoids, everolimus, cyclosporine A, AEB071, or FTY720.* Banff 2015 re-classification 
in 18 biopsies was not possible. Fifteen patients’ biopsies were either missing from archives or there was insufficient material 
to allow for reclassification. In 3 patients, no histologic diagnosis of AR was made (although the clinical picture was strongly 
suspect for AR). ABMR antibody mediated rejection; a/aABMR acute/active antibody mediated rejection; aTCMR acute T 
cell mediated rejection; c/aABMR chronic/active antibody mediated rejection; CMV cytomegalovirus; DBD donation after 
brain death; DCD donation after circulatory death; DGF Delayed graft function (need for dialysis in the first week after 
transplantation); DM diabetes mellitus; EBV Epstein-Barr virus; ESRD end stage renal disease; GN glomerulonephritis; HTN 
hypertensive nephropathy; LR living related; LUR living unrelated; MMF mycophenolate mofetil; PKD polycystic kidney 
disease; PRA panel reactive antibody; rATG rabbit anti-thymocyte globulin; TAC tacrolimus.
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In univariate Cox proportional hazard analysis, two variates had a significant influence 
on death-censored allograft survival: timing of AR and glucocorticoid use during AR 
(Table 2). Allograft survival was significantly better in the patients with early AR (<1 
month) than in patients with late AR (>3 months; p < 0.0001, HR 3.64, 95%-CI 1.97-
6.72) (Table 2 and Figure 2A). Allograft survival was not significantly different between 
intermediate (1-3 months after transplantation) and late AR (p = 0.50; data not shown). 
Allograft survival was better in patients using glucocorticoids as part of the maintenance 
immunosuppressive therapy during AR (p < 0.0001, HR 0.40, 95%-CI 0.22-0.72; Table 
2). Glucocorticoids were significantly more often used during AR in patients with early 
rejections (98%) compared to late rejections (42%; p < 0.001).
 
Table 2. Results of the univariate cox proportional hazards analysis 
Variable (reference category) Exp (B) 95% CI for Exp (B) p-value
Patient characteristics
Recipient age at transplantation (per yr) 0.99 0.97-1.01 0.32
Recipient age at acute rejection (per yr) 0.99 0.97-1.01 0.47
Donor age (per yr) 0.99 0.97-1.02 0.54
Gender (female) 0.95 0.54-1.68 0.86
Race (Caucasian) 0.86 0.46-1.59 0.63
Transplant number (1) 0.84 0.45-1.57 0.59
PRA current (<6%) 1.13 0.58-2.20 0.73
PRA (per %) 1.00 0.99-1.01 1.00
Transplant characteristics
Type donor (living donor) 1.36 0.69-2.68 0.37
HLA mismatch (per HLA mismatch) 0.94 0.78-1.14 0.54
Therapy characteristics
Induction therapy (no) 0.90 0.50-1.63 0.74
Maintenance therapy (TAC+MMF) 0.70 0.38-1.27 0.23
Glucocorticoid maintenance (no) 0.40 0.22-0.72 <0.0001
Rejection characteristics
Timing rejection (< 1 month) <0.0001
1-3 months 1.54 0.45-5.22 0.49
>3 months 3.64 1.97-6.72 <0.0001
Type rejection (aTCMR I) 0.55
CKD at time rejection (CKD 3b) 0.64
Reason rATG (GC resistant rejection) 0.88 0.50-1.54 0.65
Univariate analysis of the risk of allograft loss with hazard ratio (Exp(B), 95% confidence interval and p-value. Race is caucasian 
or non-caucasian. Transplant number is 1 or >1. PRA current is < 6% or ≥6%. Type donor is living or postmortal. Maintenance 
therapy is TAC+MMF or TAC+other and MMF+other. Glucocorticoid use at the time of rejection. Type rejection is aTCMR I, 
aTCMR II+III, ABMR, or mixed. CDK at time rejection is CKD3b, CKD4, CKD5, or delayed graft function. Reason rATG 
is glucocorticoid (GC) resistant or severe rejection.
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Figure 2
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Figure 2. Allograft survival curves of different subgroups of patients treated with rATG for AR. (A) 
Death-censored allograft survival in early (< 1 month after transplantation), intermediate (1-3 months) 
and late AR (> 3 months). (B) Death-censored allograft survival of patients using the combination of 
maintenance immunosuppression TAC/MMF versus patients using other combinations of immunosup-
pression. (C) Death-censored allograft survival of patients after rATG therapy grouped by the categories 
of the Banff 2015 classification. aTCMR I = acute T cell mediated rejection grade IA+IB, aTCMR II and 
III = acute T cell mediated rejection grade II and III. ABMR = acute and chronic active antibody medi-
ated rejection, mixed = patients with a mixed AR (aTCMR and aABMR). (D) Death-censored allograft 
survival grouped by chronic kidney disease (CKD) stage. CKD3b = 30-45 mL/min, CKD4 = 15-30 mL/
min, CKD5 = < 15 mL/min. DGF - Delayed graft function (need for dialysis in the first week after trans-
plantation) NS - not significant
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Death-censored allograft survival of patients using TAC/MMF (± glucocorticoids) and 
patients using other combinations of immunosuppressive drugs was comparable (p = 0.23, 
HR 0.70, 95%-CI 0.38-1.27; Table 2 and Figure 2B). Furthermore, no difference in allograft 
survival was seen between aTCMR grade I, aTCMR grade II+III, aABMR and mixed-
type AR (Figure 2C; p = 0.55; Table 2). Remarkably, death-censored allograft survival was 
comparable between all CKD stages (CKD 3b, CKD 4, CKD 5) and delayed graft function 
(DGF; Figure 2D and Table 2, p = 0.64).
Sixty-two patients (57.4%) received rATG because of glucocorticoid-resistant AR, whereas 
46 patients (42.6%) were treated with rATG because of severe AR. Death-censored allograft 
survival were comparable between the 2 groups (p = 0.65, HR 0.88, 95%-CI 0.50-1.54; 
Table 2 and Supplementary Figure 1).
In a multivariate analysis, the influence of timing of AR on allograft survival in presence of 
each variable was tested. Apart from timing of AR, no other variables showed a significant 
influence on allograft survival. This means that the final result of multivariate analysis is 
the same as that of univariate analysis of the influence of timing of AR (Table 2).
Allograft function
Rabbit ATG efficacy was also reflected in kidney function. One year after rATG therapy, 
kidney function (median serum creatinine) in the patients without allograft loss in the 
first year was comparable to baseline kidney function (p = 0.22; Figure 3). Twelve months 
after rATG, 33.9% of patients had a serum creatinine comparable to baseline level (± 25%), 
43.5% of patients showed an increase of serum creatinine of more than 25%, and 22.6% 
of patients showed a decrease in serum creatinine of more than 25% compared to baseline 
(data not shown). The urine protein/creatinine ratio (UPCR) was significantly higher at 
the moment of rejection compared to baseline level (p < 0.001, Figure 3C). However, the 
UPCR had normalized to baseline level at 3 months after transplantation (Figure 3C).
Besides better allograft survival, the patients with early AR also had a significantly lower 
serum creatinine 12 months after AR compared to the patients with late AR (157 µmol/L 
[IQR 131-203] versus 216 µmol/L [IQR 165-269], respectively, p < 0.05; Table 3). In patients 
with late AR, serum creatinine 12 months after AR did not return to baseline: 216 µmol/L 
versus 148 µmol/L, respectively (p < 0.001; Table 3).
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Table 3. Serum creatinine of the subgroups 
Baseline rATG M12
Subgroups Median (IQR) Number Median (IQR) Number Median (IQR) Number
Banff classification
aTCMR IA and IB 148 (208-299) 13 299 (229,5-382)a 13 248 (182-372)b 8
aTCMR IIA, IIB and III 165 (132-223) 39 270 (212-412)a 39 144 (132-190) 31
ABMR 153 (114-182) 11 224 (186-274)a 10 203 (140-320) 13
Mixed 143 (111-163) 19 211 (166-245)a 13 205 (140-239) 15
Reason for rATG therapy
GC-resistant rejection 152 (111-176) 55 247 (198-367)a 55 180 (142-237)a 42
Severe rejection 163 (132-223) 35 285 (222-445)a 33 171 (129-223) 33
CKD stage
CKD 3b 148 (116-162) 18 182 (165-200)acd 18 182 (131-208) 15
CKD 4 164 (124-207) 37 247 (224-276)ad 37 186 (140-252)a 25
CKD 5 157 (132-255) 19 428 (367-626)a 19 157 (122-203) 15
DGF DGF 19 DGF 19 170 (137-212) 14
Timing of rejection
<1 month 165 (141-220)ef 37 270 (223-420)a 37 157 (131-203)f 49
1-3 months 130 (98-152) 7 210 (193-412)a 7 182 (135-234) 4
>3 months 148 (109-174) 42 247 (200-340)a 40 216 (165-269)a 22
Data are median (interquartile range) and number of patients with available serum creatinine (µmol/l) at that specific time 
point. a Significantly different (p < 0.05) compared with baseline, b Significantly different (p < 0.05) compared with aTCMR 
II and III at M12, c Significantly different (p < 0.05) compared with CKD4, d Significantly different (p < 0.05) compared with 
CKD5, e Significantly different (p < 0.05) compared with 1-3 months, f Significantly different (p < 0.05) compared with > 3 
months. aTCMR I= Acute T cell mediated rejection grade IA+IB; aTCMR II and III= Acute T cell mediated rejection grade 
IIA, IIIB and III; ABMR = acute and chronic active antibody mediated rejection; Mixed = Patients with a mixed rejection 
(aTCMR and aABMR); M12 - 12 months (±8 weeks) after rATG therapy; GC Glucocorticoid-resistant
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Serum creatinine was comparable between patients with various types of AR at baseline 
and at time of diagnosis (Table 3). Twelve months after rATG therapy, serum creatinine 
in patients aTCMR grade I was significantly higher than in patients with aTCMR grade 
II and III: 248 µmol/L versus 144 µmol/L, respectively (p < 0.05; Table 3) in the patients 
without allograft loss in the first year. Allograft function at 12 months was comparable 
between the other groups (Table 3). The interval between pulse glucocorticoids and rATG 
was significantly longer in patients with aTCMR grade I than in patients with aTCMR 
grade II and III: 31 days (IQR 23-92) versus 8 days (IQR 3-15; p < 0.05).
In patients with glucocorticoid-resistant AR, serum creatinine after 12 months did not 
return to baseline (180 µmol/L versus 152 µmol/L, p = 0.04) in the patients without allograft 
loss in the first year after rejection (Table 3). The interval between pulse glucocorticoids and 
rATG was significantly longer in patients with glucocorticoid-resistant AR than in patients 
with severe AR (15 days (IQR 5-27) versus 4 days (1-9); p = 0.0003).
Serum creatinine in the patients with a functioning allograft 1 year after rATG was 
comparable between all CKD stages (CKD 3b, CKD 4, CKD 5) and DGF (Table 3). In 
the DGF group, all patients had a functioning allograft after 1 year and median serum 
creatinine was 170 µmol/L.
Complications
Adverse events and mortality
The overall survival of the patients treated with rATG for AR was similar to the overall 
survival of all patients who received a kidney transplantation between 2002 and 2012 in 
our center after exclusion of those treated with rATG (p = 0.10, HR 1.4, 95%-CI 0.3-2.1; 
Figure 1B).
Median length of hospital stay after rATG infusion was 15 days (IQR 13-19). Five (7.4%) 
patients were transferred to the intensive care unit because of hemodynamic instability (Table 
4). None of these patients died during the intensive care unit stay. Six (5.6%) experienced 
serum sickness after rATG treatment and one patient cytokine release syndrome.
A significant drop in hemoglobin, thrombocytes and leukocytes was seen after rATG 
therapy (Supplementary Figure 2). T cells dropped from 0.54 x 109/L to a minimum of 
0.01 x 109/L in the first week (p = 0.01). After 4 weeks, T cell count was still significantly 
lower than before rATG therapy (0.11 x 109/L, p = 0.001; data not shown).
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Table 4. Adverse events 
Adverse events
Serum sickness - no. (%) 6 (5.6)
Cytokine release syndrome - no. (%) 1 (0.9)
Fever - no. (%) 42 (61.8)
Interventions - no. (%)
Transfer to ICU 5 (4.6)
Infection in the first year after rATG - no. 124
Viral 19
Fungal 8
Bacterial 97
CMV infections
CMV reactivation - no. (%) 27 (25)
Primary CMV infection - no. (%) 0 (0)
EBV infections
EBV reactivation - no. (%) 4 (3.7)
Primary EBV infection - no. (%) 1 (0.9)
BK infections
BK viremia - no. (%) 6 (5.6)
Malignancy
Number 14
Time after rATG therapy - months 63 (45)
Data are numbers (percentage), median (IQR), or mean (standard deviation) *Clinical data of the first 24 hours after rATG 
administration was retrieved from 67 patients. Fever was defined as temperature above 38.5°C. CMV cytomegalovirus; EBV 
Epstein-Barr virus. The types of malignancies were endometrial carcinoma, adenocarcinoma of the lung, non-seminoma testis, 
colon carcinoma, renal carcinoma, meningeoma, prostatic cancer, non-Hodgkin lymphoma and EBV related lymphoma. The 
EBV-related lymphoma was in an IgG seropositive patient and occurred fourteen months after treatment with rATG and was 
treated with irradiation.
Infections
A total of 124 serious infections were recorded in the first year following rATG therapy 
(median time after rATG 44 days, IQR 10-157). The most common infections were urinary 
tract infections and pneumonia (Table 4). In 4 of 15 patients with pneumonia, Pneumocystis 
jiroveci was the causative pathogen. One patient died of Pneumocystis jiroveci pneumonia 
and one patient died of Candida sepsis 6 months after rATG therapy.
Median duration of follow-up for viral infections was 4.7 years (IQR 2-6.9). CMV 
reactivation occurred in 25% of patients (Table 4). One patient was diagnosed with CMV 
colitis and another with CMV retinitis. Four reactivations and 1 primo infection of Epstein-
Barr virus (EBV) occurred (Table 4).
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Malignancy
Median duration of follow-up for malignancies was 6.8 years (IQR 4.9-9.1). Twelve primary 
solid tumors occurred in 11 patients and two patients developed a lymphoma after a 
mean follow up of 63 months (standard deviation 45; Table 4). In addition, 11 basal cell 
carcinomas and 4 squamous cell carcinomas were diagnosed in 6 patients after a median 
of 107 months (IQR 60-117).
DISCUSSION
Rabbit ATG is a purified polyclonal immunoglobulin fraction obtained from sera of rabbits 
immunized with human thymocytes11. Administration of rATG leads to a fast and profound 
depletion of T cells and to a lesser extent, B cells which lasts for several months11,12. Rabbit 
ATG also modulates T cell activation by downregulation of molecules that control T cell 
activation12. Repopulation of lymphocytes occurs through homeostatic proliferation of 
CD4+ and CD8+ memory cells with a senescent and exhausted functional profile13,14.
Here, the long-term outcomes and adverse events are described of treatment of AR with 
rATG in patients using the current standard immunosuppressive therapy. In this cohort, 
overall 5-year patient survival after rATG treatment for AR was 89% and was similar to the 
overall survival of all kidney transplant patients transplanted in our center between 2002-
2012 and who did not receive treatment with rATG. In comparison, literature reported a 
5-year patient survival (with and without AR) after deceased donor kidney transplantation 
and living donor kidney transplantation of 91.8% and 95.6%, respectively15. In a systematic 
review, ATG therapy for AR was not associated with increased mortality after one year 
compared to therapy with pulse glucocorticoids5. Our findings support the notion that 
survival is not affected by rATG in everyday clinical practice.
One year after rATG therapy, 78.2% of all patients had a functioning allograft and 5-year 
allograft survival was 55.6%. The allograft survival reported here is inferior to that described 
in 4 other studies where rATG was used as anti-rejection therapy. Two studies describing 
patients who received rATG as first-line anti-rejection therapy (cumulative dose of rATG 
10.5-21 mg/kg)16 and for glucocorticoid-resistant AR (cumulative dose of rATG 7.5 mg/
kg)17 showed one-year allograft survival rates of 83% and 89%, respectively. Two other 
studies demonstrated 5-year allograft survival rates of 78% (cumulative dose rATG 40 
mg/kg)18 and 74% (cumulative dose of rATG not reported)19 in patients treated with ATG 
as first-line treatment for AR. These studies are not entirely comparable to ours because 
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in these studies, patients were mainly treated with azathioprine and CsA, rATG was used 
as first-line therapy in three of the four studies, and the cumulative dose of rATG was not 
similar (being lower in the present study with a cumulative dose of 7.4 mg/kg). Because 
the efficacy of rATG is dose-dependent20,21, the differences in the cumulative dose of rATG 
between the other studies and the present study can influence allograft survival, Given the 
favorable outcomes of these older studies, perhaps we should have used rATG sooner and 
in higher dose.
Various parameters of AR determined the risk for allograft loss and recovery of kidney 
function 1 year after rATG treatment, including timing, Banff grade of rejection and the 
reason for rATG therapy (severe or glucocorticoid-resistant AR). Allograft survival and 
serum creatinine at 12 months were superior in patients with early AR versus late AR. This 
has also been described by others22-25. Late AR is different from early AR for two reasons. 
First, late AR occurs in patients who visit the outpatient clinic less frequently and with 
intervals of 1-4 months, likely leading to a delay in diagnosis. Second, a major proportion of 
late AR may have been related to non-adherence to immunosuppressive drugs. Furthermore, 
late AR is associated with the formation of de novo donor-anti-HLA antibodies and the 
development of aABMR for which no proven therapy exits26-28.
Death-censored allograft survival was comparable for aTCMR I, aTCMR II+III, ABMR 
and mixed-type rejection. Surprisingly, kidney function after 12 months in patients with 
aTCMR grade II+III was superior to those with aTCMR grade I. Allograft survival rates 
according to Banff grade rejection have been described by others29,30 and showed better 
allograft survival in patients with aTCMR I than in patients with aTCMR II and III. Our 
surprising finding may have resulted from a longer interval between pulse glucocorticoids 
and rATG in patients with aTCMR grade I. This may have been caused by reluctance of 
nephrologists to treat with rATG because of fear for complications. This delay may have 
resulted in more irreversible damage due to ongoing AR. Other possible explanations are 
that the attending physician did not intensify the maintenance immunosuppression after 
rATG treatment in the group with aTCMR grade I leading to ongoing and subclinical AR. 
Based on these results, we suggest treatment of patients with aTCMR grade I in whom 
kidney function does not improve after pulse glucocorticoids should be more aggressive 
and the administration of rATG not to be delayed too long. The choice to prescribe rATG 
may be guided by a repeat kidney transplant biopsy. However, in this study, no data were 
collected of patients with aTCMR grade I treated with pulse glucocorticoids only, so we 
may have excluded the population with the most favorable prognosis.
8
178
PART III
The allograft survival of patients with ABMR is worse compared with patients experiencing 
TCMR31. In this study, no significant difference was seen in the allograft survival of patients 
with aTCMR or ABMR. A possible explanation for this surprising finding may be the fact 
that the number of patients with ABMR was small which may have resulted in limited 
statistical power to detect any difference in allograft survival.
Serum creatinine was significantly higher in patients with glucocorticoid-resistant AR 
compared to patients with severe AR. The interval between pulse glucocorticoids and 
rATG in patients with a glucocorticoid-resistant AR was 15 days. Possibly, kidney function 
may have been better if rATG had been given sooner. A multivariate prediction model, 
using intra-graft mRNA expression of immune and non-immune biomarkers, designed to 
predict which patients will not respond to pulse glucocorticoid therapy may serve as a tool 
to guide the type of anti-rejection therapy32.
Despite the efficacy of rATG for AR, treatment with rATG is associated with considerable 
toxicity and morbidity. In this study, 5 patients were transferred to the intensive care unit 
and 6.5% of patients experienced serum sickness. Other studies described an incidence of 
serum sickness between 1.7 and 28%17,33-36. These infusion-related side-effects are the reason 
that certain patients cannot be treated with rATG (e.g., those with cardiac failure or fluid 
overload). Alternative treatment, such as alemtuzumab, is indicated in these patients37,38. 
Besides the infusion-related events, the rATG-treated patients experienced 124 serious 
infections in the first year after rATG treatment and 25% of patients suffered from CMV-
related complications.
Although this is the largest cohort of patients treated with rATG for AR in the era of 
current standard immunosuppressive medicine, we realize that this study is heterogeneous 
and single-center. However, and unlike in clinical trials, this study illustrates the long-
term outcomes in real life and not in highly selected subpopulations. We think this study 
provides more insight in the long-term outcomes of rATG therapy for AR in de modern era 
of immunosuppressive therapy. Future prospective studies should include a comparator and 
focus on the optimal dosing of rATG to better weigh the benefits and risks3.
This study has limitations. Due to its retrospective character, not all patients treated with 
rATG may have been included. Since patients were identified by means of our institution’s 
transplant database and the hospital pharmacy records; we believe not many patients were 
missed. Second, some clinical parameters could not be retrieved and data on long-term 
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outcomes may have been missed if patients were admitted to other hospitals. Third, in 
the first period of the study, DSA (donor-specific antibodies) were not routinely tested in 
patients with AR in our hospital. Because of the incomplete data on the presence or absence 
of DSA, no meaningful analysis into the role of DSA could be performed. Fourth, follow-
up biopsies after rATG therapy to evaluate for post-AR treatment changes, like ongoing 
inflammation or interstitial fibrosis, were not routinely performed. Finally, although all 
patients received the current gold standard immunosuppression (TAC plus MMF), subtle 
changes may have occurred over the study period. At the beginning of the 21st century, many 
of our patients received immunosuppression-minimizing treatment39-41, whereas in the more 
recent era and with the recognition of aABMR as an important cause of allograft loss, we 
may have aimed for higher TAC exposure and have become more careful when considering 
glucocorticoid minimization. The median dose of MMF was lower in the period 2010-
2012 compared with the period 2002-2006. Possibly, the introduction of therapeutic drug 
monitoring for mycophenolic acid in our clinic led to the difference in MMF dosing42. The 
retrospective design of the present study precluded a meaningful analysis of any such trend.
CONCLUSION
Rabbit ATG is an effective anti-rejection treatment in patients using current standard 
immunosuppressive therapy, even in patients with poor allograft function. Treatment 
with rATG for AR does not seem to be associated with increased mortality although it is 
associated with considerable toxicity, especially CMV-related complications. Timing of 
rATG therapy is important. Early recognition of severe and /or glucocorticoid-resistant AR 
followed by aggressive treatment leads to better allograft function and allograft survival. 
When this window of opportunity is used, the benefits may outweigh the risks.
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SUPPLEMENTALS
SDC Figure 1. Death-censored allograft survival of glucocorticoid-resistant 
AR versus severe AR. GC Glucocorticoid
Numbers at risk
GC resistant rejection 61 44 35 33 31 25 18 9 6 5 3 3 3 2
Severe rejection 42 36 30 27 22 19 17 13 12 11 5 3
SDC Figure 1. Death-censored allograft survival of glucocorticoid-resistant AR versus severe AR. GC 
Glucocorticoid
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SDC Figure 2. Laboratory parameters of hemoglobin (a.), thrombocytes (b.), 
leukocytes (c.) and lymphocytes (d.). Data are median and interquartile range. 
0 = the day of rATG. W0-1 = the lowest measured value in the first week after 
rATG. W1 = the value 1 week after ATG ± 3 days. W2 = the value of 2 weeks 
after rATG ± 4 days. W4 = 4 weeks after rATG ± 7 days. M3 = 3 months after 
rATG ± 4 weeks. *Significant different compared with T=0 (p < 0.05). N = number 
of patients with laboratory parameters at that specific time point.
a. b.
c. d.
SDC Figure 2. Laboratory parameters of hemoglobin (a.), thrombocytes (b.), leukocytes (c.) and lym-
phocytes (d.). Data are median and interquartile range. 0 = the day of rATG. W0-1 = the lowest mea-
sured value in the first week after rATG. W1 = the value 1 week after ATG ± 3 days. W2 = the value of 
2 weeks after rATG ± 4 days. W4 = 4 weeks after rATG ± 7 days. M3 = 3 months after rATG ± 4 weeks. 
*Significant different compared with T=0 (p < 0.05). N = number of patients with laboratory parameters 
at that specific time point.
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ABSTRACT
Rabbit anti-thymocyte globulin (rATG) is currently the treatment of choice for 
glucocorticoid-resistant, recurrent or severe acute allograft rejection (AR). However, rATG 
is associated with severe infusion-related side effects. Alemtuzumab is incidentally given 
to kidney transplant recipients as treatment for AR. In the current study, the outcomes 
of patients treated with alemtuzumab for AR were compared with that of patients treated 
with rATG for AR. The patient-, allograft-, and infection-free survival and adverse events 
of 116 alemtuzumab-treated patients were compared with those of 108 patients treated 
with rATG for AR Propensity scores were used to control for differences between the 
two groups. Patient- and allograft survival of patients treated with either alemtuzumab or 
rATG were not different (hazard ratio [HR] 1.14, 95%-confidence interval [CI] 0.48-2-69, 
p=0.77, and HR 0.82, 95%-CI 0.45-1.5, p=0.52, respectively). Infection-free survival after 
alemtuzumab treatment was superior compared with that of rATG-treated patients (HR 
0.41, 95%-CI 0.25-0.68, p<0.002). Infusion-related adverse events occurred less frequently 
after alemtuzumab treatment. Alemtuzumab therapy may therefore be an alternative therapy 
for glucocorticoid-resistant, recurrent or severe acute kidney transplant rejection.
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INTRODUCTION
Alemtuzumab is incidentally used to treat acute kidney allograft rejection (AR)1-5. 
Alemtuzumab is a humanized monoclonal rat antibody directed against the cell surface 
glycoprotein CD526. Treatment with alemtuzumab causes a long-lasting depletion of various 
cells of the adaptive (T- and B cells) and innate immune system (NK cells, dendritic 
cells, monocytes and granulocytes)6. The drug is registered for the treatment of relapsing-
remitting multiple sclerosis7. The Campath® Distribution Program offers off-label treatment 
with alemtuzumab for other indications, including therapy for kidney transplant recipients 
and patients with chronic lymphocytic leukemia8.
Currently, rabbit anti-thymocyte globulin (rATG) is the treatment of choice for 
glucocorticoid-resistant, recurrent or severe (Banff grade IIA or higher) acute T cell-
mediated rejection (aTCMR)9. Although effective, rATG has several limitations, for instance 
infusion-related side effects10-12. Alemtuzumab might be an alternative T cell-depleting 
therapy for AR with fewer infusion-related side effects1-5.
The outcomes of alemtuzumab therapy for AR in kidney transplant recipients have only 
been reported in five small case series (with a cumulative number of 88 patients), concluding 
that patients with AR responded well to therapy with alemtuzumab1-5. However, in only 
one of these reports, alemtuzumab was compared to rATG therapy and none of them 
were randomized controlled trials1. Our center participated in one of these case series1. In 
this case series, 11 patients with AR and a contra-indication for rATG were treated with 
alemtuzumab. The incidence of the composite endpoint ‘treatment failure’ was comparable 
between both groups (alemtuzumab 27% versus rATG 40%, p = 0.89) and treatment with 
alemtuzumab was associated with fewer infusion related side effects and reduced costs1.
Since 2012 and after our initial positive experience with alemtuzumab, it became the 
treatment of choice for all patients with glucocorticoid-resistant, severe or recurrent AR 
in the Erasmus MC1. Here, we present further data on patient- and allograft outcome on 
subsequent patients treated with alemtuzumab for AR in our center. Factors that influenced 
allograft survival were investigated, and we focused on the occurrence of infections, 
malignancies and autoimmune diseases. Patient-, allograft-, and infection-free survival of 
alemtuzumab-treated patients were compared with those of patients treated with rATG 
for AR10.
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MATERIALS AND METHODS
Study design
A retrospective analysis was performed on data of kidney transplant recipients who were 
treated in the Erasmus MC, University Medical Center Rotterdam, with alemtuzumab 
(Campath®, Sanofi Genzyme, United States) because of AR between January 2012 and 
January 2018. The study was approved by the medical ethical review board of the Erasmus 
MC (number 2018-1430). The patients were identified by the electronic medication 
prescription system of our hospital pharmacy. Patients with blood group AB0-incompatible 
kidney transplantations were excluded from the analysis, because they receive alemtuzumab 
as induction therapy13.
The outcomes were compared to those of a cohort of patients treated with rATG 
(Thymoglobulin®, Sanofi Genzyme, United States) for AR between January 2002 and 
January 2012. The characteristics and outcomes of this cohort were described in detail 
previously10.
All AR episodes (including recurrent AR) were biopsy-proven and biopsies were re-evaluated 
according to the Banff 2015 (for rATG-treated patients) and Banff 2017 classification 
(for alemtuzumab-treated patients) by one dedicated renal-pathologist (M.C.C-v.G.)14-16. 
The presence of donor-specific anti-HLA antibodies (DSA) and non-donor-specific 
HLA antibodies against HLA-A, HLA-B, HLA-DR, and HLA-DQ were examined in 
alemtuzumab-treated patients using the single-antigen bead Luminex assay on serum 
samples collected at the time of AR. DSA directed against Cw and DP HLA molecules 
were not tested. The presence of DSA was not routinely tested in the period 2002-2012 
when rATG still was the therapy of choice10. Therefore, the biopsies of the rATG-treated 
patients could not be reclassified according to the Banff 2017 criteria14.
Of patients treated with alemtuzumab, patient survival, allograft function (estimated 
glomerular filtration rate (eGFR; Chronic Kidney Disease Epidemiology Collaboration 
[CKD-EPI]17), allograft survival (censored for death), variables that could influence allograft 
survival (patient and donor characteristics, type of immunosuppressive therapy, and type 
and grade of rejection), and adverse events were assessed. Baseline eGFR was defined as the 
highest eGFR in the three months prior to AR. Delayed graft function (DGF) was defined 
as the need for dialysis in the first week after transplantation. Allograft loss was defined 
as the need for dialysis or retransplantation. The follow-up period for allograft loss and 
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infection was from the day of T cell-depleting therapy until death, retransplantation, or 
loss to follow-up. Malignancies and mortality were evaluated until the last follow-up visit, 
which could be after subsequent kidney transplantation. The Dutch national pathology 
archive PALGA (Pathologisch-Anatomisch Landelijk Geautomatiseerd Archief, https://
www.palga.nl/) was used for collecting of data relating to the occurrence of malignancy. 
Infections were considered serious if the infection necessitated hospitalization or occurred 
during hospital admission for another reason.
The allograft- and patient survival data of patients who had received a kidney transplant in 
the same time periods in our center and were not treated with T cell-depleting therapy was 
also compared to the patients treated with T cell-depleting therapy for AR.
Maintenance immunosuppressive therapy
The standard immunosuppressive regimen included induction therapy with basiliximab 
(Simulect®, Novartis Pharma, Basel, Switzerland) 20 mg intravenously on days 0 and 4 
after transplantation, followed by maintenance therapy with tacrolimus (Prograf ®, Astellas 
Pharma, Leiden, the Netherlands), mycophenolate mofetil (MMF; Cellcept®, Roche 
Pharmaceuticals, Basel, Switzerland) and glucocorticoids.
Basiliximab became part of our standard immunosuppressive regimen in 2009. Dosing of 
tacrolimus and MMF was based on pre-dose concentrations (C0). Target C0 for tacrolimus 
was respectively 10-15 µg/L (week 1-2), 8-12 µg/L (week 3-4), 5-10 µg/L (week 5-12), and 
4-8 µg/L from month 4 onwards. MMF was started at 1,000 mg twice daily and subsequent 
dosing was based on C0 (target C0 was 1.5-3.0 mg/L). Glucocorticoids were given as an 
intravenous dose of 100 mg on days 0-3 and followed by a dose of 20 mg/day (days 4-14). 
Thereafter, glucocorticoids were tapered off and completely withdrawn around month 4.
Treatment of AR
The first-line treatment of aTCMR was methylprednisolone 1,000 mg (Solu-Medrol®, Pfizer, 
New York, the United States) intravenously daily for three consecutive days, followed by 
a second-line treatment with alemtuzumab or rATG in case of a glucocorticoid-resistant, 
recurrent or severe aTCMR (Banff grade IIA or higher). rATG was administered as a 
single bolus (4 mg/kg [actual bodyweight, no maximum dose limit]) intravenously10. 
Alemtuzumab was administered subcutaneously18. The first 14 patients were treated with 
alemtuzumab (30 mg) daily for two consecutive days. Since T cell-depletion already 
occurred after one dose of alemtuzumab, the next patients received a single dose (30 mg). 
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To prevent infusion-related side effects patients were premedicated with glucocorticoids 
(50 mg intravenously), acetaminophen (4 times daily 1,000 mg) and clemastine (4 mg 
intravenously). The alemtuzumab-treated patients were discharged the same day if no severe 
side-effects were noted. T- and B cell counts were measured with BD FACSCantoTM software 
every three months until the T cell count was >200 x 106/L. In the patients treated with 
rATG, a CD3+ T cell count <200×106/L was aimed for a duration of two weeks during 
which patients were hospitalised10. If CD3+ T cell counts increased during this period, a 
repeat dose of rATG was administered. All patients received prophylaxis for Pneumocystis 
jirovecii (sulfamethoxazole/trimethoprim) and cytomegalovirus (CMV; valganciclovir, 
except for CMV seronegative recipients with CMV seronegative donors) until the T cell 
count was >200 x 106/L. Patients with aABMR or mixed type AR could additionally be 
treated with intravenous immunoglobulins (IVIg), plasma-exchange, or both according to 
the Kidney Disease: Improving Global Outcomes (KDIGO) guideline9.
Statistical methods
Categorical variables are presented as number (percentage). Continuous variables are 
presented as mean with standard deviation for normally distributed variables or median 
with interquartile range (IQR) for non-normally distributed variables. For differences 
between unpaired non-normally distributed continuous data or unpaired categorical data, 
the Kruskal-Wallis and Mann-Whitney U tests, and the Chi-squared and Fisher’s exact 
tests were used. Kaplan-Meier survival analysis was used to examine subgroups (e.g. age 
categories and rejection types) within the alemtuzumab group and to compare allograft- 
and patient survival between alemtuzumab-treated patients and patients transplanted in 
the same period and who were not treated with alemtuzumab.
The influence of predictor variables on allograft survival in alemtuzumab-treated patients 
was analyzed with multivariable Cox proportional hazard regression analysis. Due to the 
number of events (41 allograft losses), the number of variables that could be included per 
analysis was limited. The influence of the most significant variable was tested in the presence 
of all the other variables one by one, and the non-significant variables were eliminated from 
the model by backward elimination.
Propensity scores were used to control for baseline differences between the patients treated 
with rATG and alemtuzumab19. They were acquired by performing a logistic regression with 
therapy type as the outcome variable. Covariates included in the logistic model were: age 
of the patient at time of AR, gender, primary kidney disease, donor type (living/deceased), 
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induction therapy (43% of patients treated with rATG received induction therapy, versus 
97.3% of alemtuzumab treated patients), maintenance therapy, time to AR, and type of 
AR. The resulting propensity score was used as a covariate in Cox proportional hazards 
regression models (for calculation of the patient-, allograft-, and infection-free survival), in 
linear regression models (for continuous outcomes), and in logistic regression models (for 
categorical outcomes).
A two-sided p-value <0.05 was considered statistically significant. GraphPad Prism, version 
5 (San Diego, CA, USA), SPSS version 21 (SPSS Inc., Chicago, IL, USA), and R (R 
Foundation for Statistical Computing, Vienna, Austria, version 3.5.1) were used for the 
statistical analysis.
RESULTS
Patient demographics
Between January 2012 and January 2018, 1,214 patients received a kidney transplant at 
our center. Of these, 113 patients (9.3%) were treated with alemtuzumab for AR. Three 
patients were treated with alemtuzumab twice because of two separate rejection episodes 
of the same kidney transplant. Between January 2002 and January 2012, 1,107 patients 
were transplanted with a kidney and 108 patients of these (9.8%) were treated with rATG 
for AR10. The median cumulative dose of rATG per patient was 7.4 mg/kg. Baseline 
characteristics of patients treated with either alemtuzumab or rATG for AR are presented 
in Table 1.
Induction therapy with basiliximab was given to 303 (27.4%) of all patients transplanted 
between 2002 and 2012 (the rATG period) and to 1065 (87.8%) of all patients between 2012 
and 2018 (the alemtuzumab period). As a result, significantly more patients treated with 
alemtuzumab (93.8%) had previously received basiliximab induction therapy compared 
to rATG-treated patients (29.2%; p<0.0001 [Table 2]). A tacrolimus- and MMF-based 
maintenance therapy was given to 81% of alemtuzumab-treated patients and to 72.2% of 
rATG-treated patients (p=0.08; Table 2). First line therapy for AR was methylprednisolone 
in 94.8% of alemtuzumab-treated patients, and to 86.1% or rATG-treated patients (Table 
2).
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Table 1. Baseline characteristics of patients treated with either alemtuzumab or rATG 
Characteristic Alemtuzumab (n=113) rATG (n=108) p-value
Recipient age at transplantation- yr. 56 (39-63) 45 (34-55) 0.0001
Recipient age at rejection- yr. 56 (40-63) 46 (35-56) 0.0002
Donor age - yr. 54 (43-63) 54 (46-61) 0.82
Female sex - no. (%) 47 (40.5) 40 (37.0) 0.69
Cause of ESRD - no.
DM/HTN/GN/PKD/reflux/other*/unknown 26/22/21/9/7/27/4 23/10/18/16/17/16/3 0.04
Ethnic distribution - no.
Caucasian/Black/Asian/Arab/other 79/17/8/11/1 70/16/5/5/7 0.12
Transplant number - no.
1/2/3 88/22/6 76/25/5 0.71
Preemptive kidney transplantation - no. (%) 41 (35.3) 25 (23.4) 0.06
Donor type - no.
LR/LUR/DBD/DCD 27/55/12/22 35/47/15/10 0.12
HLA mismatch
HLA A: 0/1/2 26/61/29 21/60/23 0.75
HLA B: 0/1/2 10/53/53 11/55/38 0.39
HLA DR: 0/1/2 21/55/40 13/50/41 0.48
PRA actual - no. (%) 0.52
0-5% 93 (80.2) 81 (77.1)
6-83% 22 (19.0) 21 (20)
84-100% 1 (0.8) 3 (2.9)
PRA peak - no. (%) 0.15
0-5% 69 (59.5) 62 (59)
6-83% 31 (26.7) 32 (30.5)
84-100% 16 (13.8) 11 (9.5)
CMV IgG serostatus recipient - no. (%)
Positive 83 (73.6) 75 (70.8) 0.76
EBV IgG serostatus recipient - no. (%)
Positive 106 (93.8) 90 (92.8) 0.78
Data are numbers (%) or median (interquartile range). *Other kidney diseases included focal segmental glomerulosclerosis, 
vascular disease, septic shock, kidney dysplasia /nephrectomy, congenital nephrotic syndrome, Alport syndrome, nephronophtisis, 
drug intoxication, RCAD syndrome, or tubulointerstitial nephritis. Data of rATG-treated patients are prescribed previously10. 
CMV cytomegalovirus; DBD donation after brain death; DCD donation after circulatory death; DM diabetes mellitus; EBV 
Epstein-Barr virus; ESRD end stage renal disease; GN glomerulonephritis; HLA human leucocyte antigen; HTN hypertensive 
nephropathy; LR living related; LUR living unrelated; PKD polycystic kidney disease; PRA panel reactive antibody; rATG 
rabbit anti-thymocyte globulin.
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Table 2. Immunosuppressive therapy in patients treated with alemtuzumab or rATG
Immunosuppressive therapy Alemtuzumab (n=113) rATG (n=108) p-value
Induction therapy - no. (%) <0.0001
None 3 (2.7)* 62 (57.4)
Basiliximab 106 (93.8) 33 (29.2)
rATG 2 (1.8) 10 (8.8)
Rituximab 2 (1.8) 0 (0)
Daclizumab 0 (0) 2 (1.9)
Maintenance immunosuppression - no. (%) 0.08
TAC/MMF/glucocorticoids 78 (67.2) 58 (53.7)
TAC/MMF 16 (13.8) 20 (18.5)
TAC + other (non-MMF) 11 (9.5) 6 (5.6)
MMF + other (non-TAC) 11 (9.5) 20 (18.5)
Anti-rejection therapy - no. (%)
Methylprednisolone prior to T cell-depleting therapy 110 (94.8) 93 (86.1) 0.04
Cumulative dose of methylprednisolone, mg 0.004
1000 0 (0) 2 (2.2)
2000 1 (0.9) 9 (8.2)
3000 96 (87.3) 79 (71.8)
4000 1 (0.9) 0 (0)
6000 12 (10.9) 3 (2.7)
Additional anti-rejection therapy in patients with ABMR
Intravenous immunoglobulins 10 1
Plasma-exchange + intravenous immunoglobulins 3 2
Additional anti-rejection therapy in patients with mixed AR
Intravenous immunoglobulins 8 4
Plasma-exchange + intravenous immunoglobulins 0 4
Data are numbers (%).*In three patients no induction therapy was administered because of an HLA-identical donor. TAC + 
other regime contained combinations of TAC, glucocorticoids, everolimus, or azathioprine. Other combinations existed of a 
combination of azathioprine, glucocorticoids, everolimus, cyclosporine A, AEB071, or FTY720. MMF + other regime contained 
combinations of MMF, glucocorticoids, cyclosporine A, everolimus, or belatacept. Data of rATG-treated patients are prescribed 
previously10. MMF mycophenolate mofetil; TAC tacrolimus.
 
Sixty-four alemtuzumab-treated patients (55.2%) and 64 (59.3%) rATG-treated patients 
had an early AR (within three months after transplantation; Table 3). The distribution of 
the Banff grade of AR was not different between the patients treated with alemtuzumab 
or rATG (p=0.89; Table 3). In 18 patients (15.5%), a second kidney allograft biopsy was 
performed after the initial treatment with methylprednisolone and immediately before 
alemtuzumab treatment to confirm ongoing AR (Table S1).
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Table 3. Rejection characteristics
Rejection characteristic Alemtuzumab (n=116)$ rATG (n=108) p-value
Time to rejection - days 32 (2-1644) 24 (8-339) 0.83
Early rejection (<3 months) - no. (%) 64 (55.2) 64 (59.3) 0.59
Late rejection (>3 months) - no. (%) 52 (44.8) 44 (40.7) 0.59
Delayed graft function during AR 33 (28) 19 (17.6) 0.06
Banff classification - no.* 0.89
aTCMR
aTCMR IA/IB 1/9 6/8
aTCMR IIA/IIB/III 29/23/2 21/20/1
Borderline aTCMR 3 0
ABMR
aABMR 17 12@
DSA+ and C4d+ 7
DSA+ and C4d- 0
DSA- and C4d+ 7
C4d+, no DSA tested 2
Histologic features of ABMR, no DSA/C4d 1¥
c/aABMR 1§ 3
Mixed aTCMR with aABMR
aTCMR I/II/III 9/7/2 8/10/0@
DSA+ and C4d+ 5
DSA+ and C4d- 6
DSA- and C4d+ 4
C4d+, no DSA tested 3
Mixed aTCMR with c/aABMR 1$ 1
Data are numbers (%) or median (interquartile range). $A total of 113 patients were treated with alemtuzumab, however three 
patients were treated with alemtuzumab twice because of two separate rejection episodes of the same kidney transplant *Banff 
classification of aTCMR, ABMR and mixed AR were compared. Re-classification in 12 biopsies of alemtuzumab-treated 
patients and 18 biopsies of rATG-treated patients was not possible because the biopsies were missing from archives. The primary 
pathological diagnosis of these biopsies was aTCMR in five patients, ABMR in two patients, and mixed AR in five patients. Data 
of rATG-treated patients are prescribed previously10. ¥Histologic features of ABMR with glomerulitis and peritubular capillaritis, 
but C4d staining was negative and no DSAs were present. §The patients with c/aABMR had no DSAs and C4d staining was 
positive in the peritubular capillaries. $The patient with mixed c/aABMR had DSAs and C4d staining was negative. @DSAs were 
not routinely measured in the rATG-treated patients. ABMR antibody mediated rejection; aABMR active antibody mediated 
rejection; aTCMR acute T cell mediated rejection; c/aABMR chronic/active antibody mediated rejection; DGF Delayed graft 
function (need for dialysis in the first week after transplantation); DSA de novo donor specific antibodies.
Patient survival
Patient survival of patients treated with either alemtuzumab or rATG for AR is depicted 
in Figure 1A. Compared with the historical rATG cohort, the patient survival of the 
alemtuzumab group was not different (hazard ratio [HR] 1.14, 95%-confidence interval 
[CI] 0.48-2.69, p=0.77; Figure 1A), also when only those patients who were treated with 
basiliximab induction therapy were included (HR 1.74, 95%-CI 0.68-4.46, p=0.25; Figure 
2A).
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The patient survival of alemtuzumab-treated patients was significantly lower compared with 
the patients transplanted in the same period and who were not treated with alemtuzumab 
(HR 2.38, 95%-CI 1.25-4.54, p=0.0036, Figure S1A). In the total follow-up period 
(median 2.8 years [IQR 1.3-3.8 years]), 18 patients died after a median of 1.45 years 
(IQR 0.92-2.93; Table S2). A univariable Cox proportional hazard regression analysis was 
performed to investigate which variables influenced the risk of death in patients treated 
with alemtuzumab. The only variable that was associated with the risk of death was age of 
the recipient (HR per year 1.09, 95%-CI 1.04-1.14, p<0.0001; Table S3). This increased 
risk of death was seen in alemtuzumab-treated patients older than 50 years at the time of 
transplantation (Figure S2).
A comparison between the patient survival of rATG-treated and patients transplanted in 
the same period and who were not treated with rATG is shown in Figure S1C and was 
described previously10.
Kidney allograft survival
Death-censored kidney allograft survival of alemtuzumab-treated patients was not different 
compared to that of patients who received rATG for AR (HR 0.82, 95%-CI 0.45-1.50, 
p=0.52; Figure 1B). A similar survival was also observed when only those patients who 
were treated with basiliximab induction therapy were included (HR 1.10, 95%-CI 0.57-
2.10, p=0.78; Figure 2B). Additional information about the kidney allograft function after 
alemtuzumab or rATG therapy for AR is provided in Figure S3.
The allograft survival of alemtuzumab-treated patients was significantly worse compared 
to the allograft survival of patients that were transplanted in the same period and who 
were not treated with alemtuzumab (HR 258.0, 95%-CI 112.0-591.3, p<0.0001; Figure 
S1B). During the follow-up (median 2.2 years, IQR 1-3.5), 41 (35.3%) patients lost their 
kidney allograft after alemtuzumab therapy for AR, of which six never had a functioning 
graft (primary non-function [PNF]). To investigate which variables influenced allograft 
survival in alemtuzumab-treated patients, a Cox proportional hazard regression analysis 
was performed. In the univariable model, age of the recipient, number of HLA mismatches, 
glucocorticoid maintenance treatment, timing of AR, and the Δ eGFR (percentage change 
between baseline eGFR and eGFR at the moment of AR) significantly influenced the risk 
for death-censored allograft loss (p<0.05, Table S4) in alemtuzumab-treated patients. The 
variables glucocorticoid use and timing of rejection were related because all patients with 
an early acute rejection used glucocorticoids as maintenance therapy, while only 56.6% 
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of patients with a late acute rejection used glucocorticoids (p<0.0001). The Banff grade of 
rejection did not influence allograft survival (p=0.19). Allograft survival of alemtuzumab-
treated patients suffering from either aTCMR or aABMR is shown in Figure S4.
The final multivariable model showed that patients with actual panel reactive antibodies 
(PRA) >6%, and patients with a Δ eGFR of more than 50% had an inferior allograft 
survival after alemtuzumab therapy (Figure 3). Patients using glucocorticoids at time of 
AR, and patients with more HLA mismatches, showed a superior allograft survival after 
alemtuzumab therapy (Figure 3). Several variables were compared between patients with 
an HLA mismatch of 0-3 and an HLA mismatch of 4-6 (Table S5). One variable was 
significantly different: 42 (72%) recipients with 4-6 HLA mismatches received a living 
unrelated donor kidney (Table S5), while 13 (23%) recipients with 0-3 HLA received a 
living unrelated donor kidney (p<0.001; Table S5).
 
Hazard ratio (95%-CI)
HLA mismatch (per mismatch)
∆ eGFR Baseline-rejection
25-50% vs. <25% 
>50% vs. <25% 
Glucocorticoid use: yes vs. no
PRA actual: >6% vs. <6%
Subgroup
0.21 (0.09-0.46)
0.63 (0.49-0.81)
0.90 (0.33-2.47)
3.99 (1.49-10.71)
3.65 (1.31-10.12)
<0.001
<0.001
0.003
0.84
0.006
0.013
p-value
Figure 3
50.5 1 100.1 20.2
Figure 3. Multivariable Cox proportional hazard regression analysis of risk for allograft loss in alemtu-
zumab-treated patients. Multivariable analysis of the risk of allograft loss with hazard ratio (Exp(B), 
95%-confidence interval and p-value). Delta (Δ) eGFR baseline-moment of rejection is the percentage 
change between the baseline eGFR and eGFR at the moment of rejection. Glucocorticoid use means 
maintenance therapy with glucocorticoids during the rejection. PRA Panel reactive antibodies.
 
The allograft survival of patients treated with survival of rATG was worse compared to that 
of patients who were not treated with rATG and transplanted in the same time period (HR 
15.9, 95%-CI 9.2-27.4, p < 0.0001; Figure S1D). A multivariable Cox proportional hazard 
regression analysis was performed for patients treated with rATG for AR and reported 
previously10. This analysis demonstrated that allograft survival was superior in patients with 
an early AR compared with a late AR10.
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Adverse events
Infusion-related side effects also occurred less frequently in alemtuzumab-treated patients 
compared with the patients treated with rATG (Table 4). No alemtuzumab-treated 
patients experienced serum sickness versus five patients in the rATG group (p=0.02). No 
patients experienced cytokine release syndrome or pulmonary edema after alemtuzumab. 
The median duration of hospitalization was three days (IQR 1-6) in patients treated with 
alemtuzumab and 15 days (IQR 13-19) in rATG-treated patients.
 
Table 4. Adverse events after therapy with alemtuzumab or rATG
Adverse events Alemtuzumab rATG p-value
Fever* - no. (%) 10 (8%) 42 (61.8%) <0.001
Systolic blood pressure <90 mmHg - no. (%) 1 (0.8% 7 (10.4%) 0.003
Tachycardia >100/minute - no. (%) 18 (15.5%) 44 (69.8%) <0.001
Interventions - no.    
Transfer to ICU 1 (0.9%) 5 (4.6%) 0.11
Supplemental oxygen 1 (0.9%) 9 (13.4%) 0.03
Volume resuscitation 0 6 (9.0%) 0.06
Data are numbers (percentage) and median (interquartile range). Fever, blood pressure, tachycardia and interventions were 
registered in the 24 hours after therapy. Under-reporting of the incidence of infusion-related adverse events is possible in 37 
patients who were dismissed on the day of alemtuzumab therapy. Data of rATG-treated patients are prescribed previously10. 
*Fever was defined as temperature above 38.5°C. 
 
The infection-free survival (excluding CMV, EBV and BK virus infections) in the first year 
after alemtuzumab treatment was significantly better compared with the infection-free 
survival of the rATG-treated patients (HR 0.41, 95%-CI 0.25-0.68, p<0.002; Figure 4). 
CMV reactivation occurred in 25 patients (21.6%) treated with alemtuzumab (Table S6), 
compared to 27 patients (25%) in the rATG group (p=0.10). In both the alemtuzumab- 
and rATG-treated groups, two patients experienced a primary CMV infection (p=0.50). 
Additional information on the occurrence of infections is presented in Table S6.
Secondary autoimmune events have been described after administration of alemtuzumab6. 
In the current study, two patients developed inflammatory polyneuropathy (one case 
of Guillain-Barre syndrome and one case of chronic inflammatory demyelinating 
polyneuropathy) after alemtuzumab treatment20. No patients were diagnosed with 
autoimmune thyroid disorders, idiopathic thrombocytopenic purpura or autoimmune 
nephropathy.
Repopulation of T cells >200x106/L occurred in 55.7% of alemtuzumab-treated patients in 
the first year after administration (Figure S5A and B). In 40.2% of the patients, repopulation 
of B cells >100x106/L (Figure S5C and D) was seen at 1 year.
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Figure 4
No. at risk
Alemtuzumab 116 100 90 83 77 71 65 59 52 51
rATG 108 67 60 57 52 49 46 43 43 42
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Figure 4. Infection-free survival in the first year after treatment for acute rejection. Infection-free survival 
(excluding CMV, EBV and BK virus infections) of patients with AR and treated with alemtuzumab (2012-
2018) and patients treated with rATG for AR between 2002-2012.
Solid tumors were diagnosed in seven alemtuzumab-treated patients during the total follow-
up (median 2.8 years [IQR 1.3-3.8]; Table S7). The incidence of solid tumors was 2.3 
per 100 person-years with a median time after alemtuzumab therapy of 28 months (IQR 
9-38), and the age at the time of diagnosis was 65 years (IQR 60-76). Seven patients were 
diagnosed with skin cancer: 21 basal cell carcinomas and 12 squamous cell carcinomas. In 
the rATG treated patients, 14 malignancies were diagnosed after a mean time of 63 months 
(standard deviation 45 months) during the follow-up of 6.8 years (IQR 4.9–9.1; Table S8)10.
DISCUSSION
In the current study, the largest cohort of patients treated with alemtuzumab for AR is 
described. The results of this study suggest that alemtuzumab could be an alternative to 
rATG for the treatment of glucocorticoid-resistant, severe or recurrent AR. Compared 
to rATG, allograft- and patient survival of patients treated with alemtuzumab was not 
different. Moreover, adverse events and infections seemed to occur less frequently in patients 
treated with alemtuzumab compared with rATG-treated patients.
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Alemtuzumab seems as effective as rATG for the prevention of allograft loss after AR. 
Five case series have described allograft outcome in patients treated with alemtuzumab for 
AR1-5. The results of these case series are difficult to compare with our study. Four of the 
five studies were performed more than 15 years ago and patients in these studies were not 
treated with the current gold standard therapy (induction therapy in combination with 
tacrolimus and MMF)2-5. Furthermore, these case series were of heterogeneous design. 
First, alemtuzumab was prescribed as first line treatment for AR in two studies4,5, and in 
one study alemtuzumab was prescribed to patients with AR resistant to ATG or OKT32. 
Second, the dose of alemtuzumab ranged from 15 mg1 to 93 mg2. Third, the follow-up 
period of these studies ranged from three months1 to ten years4. Compared with treatment 
with methylprednisolone or rATG, allograft survival in alemtuzumab-treated patients was 
similar1,4. The result of our study supports this conclusion.
Treatment with alemtuzumab is associated with serious side effects and therefore the 
assessment of the benefit-risk balance in the individual patient before initiation of treatment 
is necessary. We investigated which clinical factors influenced allograft survival. Factors that 
were associated with a good response were a low Δ eGFR between baseline and the moment 
of AR, glucocorticoid maintenance therapy at the time or AR, and an actual PRA below 
6%. The use of glucocorticoid maintenance therapy and timing of rejection were related, 
because all patients with an early acute rejection used glucocorticoids as maintenance 
therapy. Therefore, we are not sure if glucocorticoid use is a protective factor, or that an 
early rejection is associated with a better allograft outcome compared with a late rejection. 
Late rejections occur in patients who visit the outpatient clinic less frequently and with 
intervals of 1–4 months, likely leading to a delay in diagnosis.
Surprisingly, patients with more HLA mismatches had a better response to alemtuzumab 
therapy compared with those with less HLA mismatches. Analysis of all factors showed 
that patients with more HLA mismatches (4-6) more often received a kidney from a living 
unrelated donor. How this is related to a better response to alemtuzumab treatment is 
unclear. It is known that results of living donor kidney transplantation are better compared 
to deceased donor transplantation, even with higher numbers of HLA mismatches21. 
Taken together, based on these results, we treat patients with an early AR aggressively with 
alemtuzumab and are more reluctant to administer alemtuzumab in patients with a late 
AR who also have a considerable loss of renal function.
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Seventeen patients with aABMR were treated with alemtuzumab. Treatment options for 
aABMR are limited and no specific drugs have received US Food and Drug Administration 
approval. Currently, the therapy for aABMR consists of glucocorticoids, IVIg and/or plasma-
exchange, although the evidence for this treatment is not strong22,23. Since alemtuzumab 
causes lysis of T- and B cells, as well as antigen presenting cells, alemtuzumab may be 
considered in patients with aABMR. In our study, patients with aABMR showed a good 
response to alemtuzumab therapy. However, larger studies are necessary to confirm our 
results and analyze the best therapeutic strategy.
Although T cell-depletion after alemtuzumab therapy lasts longer than after rATG24, 
the infection-free survival was better after therapy with alemtuzumab compared with 
rATG. The biggest difference in the number of infections in patients treated with rATG or 
alemtuzumab occurred in the first few weeks after therapy (Table S6). A possible explanation 
for this is the longer duration of hospitalization after therapy for AR in rATG-treated 
patients compared with alemtuzumab-treated patients. A longer hospitalization is associated 
with a higher risk for health care-associated infections25. The occurrence of CMV disease or 
reactivation was similar between patients treated with alemtuzumab or rATG. In literature, 
similar results (lower frequency of infections and no difference in CMV infections) are seen 
when alemtuzumab or rATG are used as induction therapy26.
In contrast to reports investigating the occurrence of autoimmune disorders in patients 
suffering from multiple sclerosis and treated with alemtuzumab, we observed no clinically 
apparent autoimmune thyroid disorders or idiopathic thrombocytopenic purpura in the 
present cohort27. Possibly, the follow-up period of the present study was too short for these 
autoimmune events to occur. Another reason could be that patients with multiple sclerosis 
are susceptible to autoimmune disorders because of their genetic constitution.
The administration of rATG is associated with serious infusion-related side effects and 
the drug is relatively contra-indicated in patients with cardiac failure or fluid overload11,12. 
Infusion-related side effects in our study were less prevalent in patients treated with 
alemtuzumab compared with rATG therapy and subcutaneous administration of 
alemtuzumab therefore appears to be safe in frail patients and patients with cardiac 
morbidity. In this study, rATG was given as a bolus of 4 mg/kg. We cannot exclude the 
possibility that another dosing regimen such as a repeated, standard dose of rATG may 
have resulted in fewer infusion-related side effects28.
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We acknowledge the limitations of the current study. First, this was a retrospective 
single-center study. Second, several variables (including time period, the use of induction 
therapy and others) were different between the patients treated with alemtuzumab and 
the patients treated with rATG. A propensity score analysis was performed to correct for 
potential differences between the alemtuzumab and rATG group, but we cannot exclude 
the possibility that other (unmeasured) confounding factors influenced the outcomes of this 
analysis. Currently, these data offer the best available evidence for the treatment of AR with 
alemtuzumab as it is unlikely that a randomized controlled trial comparing alemtuzumab 
with other anti-rejection therapies will be performed anytime soon. Third, the allograft 
survival of patients who were treated with alemtuzumab seemed (although not significant) 
to be worse compared with rATG-treated patients. Again, we cannot exclude the possibility 
that inclusion of more patients may have resulted in a significant difference between the 
two groups. Fourth, in our study 93.8% of alemtuzumab-treated patients were treated 
with basiliximab induction therapy. In the United States, only 33.8% of kidney transplant 
recipients are treated with basiliximab, whereas 65.9% of patients receive induction therapy 
with T cell-depleting antibodies29. We don’t know the influence of this difference on the 
outcomes after alemtuzumab therapy for AR. Fifth, due the unavailability of data on DSAs 
in the rATG-treated patients, it was not possible to apply the Banff 2017 classification on 
biopsies of these patients which may have biased the diagnosis of ABMR.
To conclude, alemtuzumab therapy could be an alternative therapy to rATG for 
glucocorticoid-resistant or severe AR. This may be especially relevant for patients with 
a relative contraindication for rATG, including patients suffering from fluid overload or 
previous rATG treatment. Further studies, preferably multicenter randomized controlled 
trials, are necessary to explore the potential advantages of alemtuzumab for severe rejection.
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Figure S1. Survival plots of allograft- and patient survival in the period between 2002-2012 and 
2012 -2018. a. Kaplan-Meier patient survival curve of patients treated with alemtuzumab for AR (2012-
2018) and patients transplanted in the same period and not treated with alemtuzumab. From time point 
of acute rejection (alemtuzumab group) and time point of kidney transplantation (patients not treated 
with alemtuzumab). b. Kaplan-Meier allograft survival curve (event = allograft loss, censored for death) 
of patients treated with alemtuzumab for AR (2012-2018) and patients transplanted in the same period 
and not treated with alemtuzumab. From time point of acute rejection (alemtuzumab group) and time 
point of kidney transplantation (patients not treated with alemtuzumab). c. Kaplan-Meier patient surviv-
al curve of patients treated with rATG for AR (2002-2012) and patients transplanted in the same period 
and not treated with rATG. From time point of acute rejection (rATG group) and time point of kidney 
transplantation (patients not treated with rATG). d. Kaplan-Meier allograft survival curve (event = allograft 
loss, censored for death) of patients treated with rATG for AR (2002-2012) and patients transplanted in 
the same period and not treated with rATG. From time point of acute rejection (rATG group) and time 
point of kidney transplantation (patients not treated with rATG).
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SDC Figure 2
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Figure S2. Kaplan-Meier survival curves of patient survival of different age categories. a. Patient 
survival of patients (<50 years at time of transplantation) treated with alemtuzumab for AR (2012-2018) 
and patients (<50 years at time of transplantation) transplanted in the same period and not treated with 
alemtuzumab. b. Patient survival of patients (50-65 years at time of transplantation) treated with alemtu-
zumab for AR (2012-2018) and patients (50-65 years at time of transplantation) transplanted in the same 
period and not treated with alemtuzumab. c. Patient survival of patients (>65 years at time of transplan-
tation) treated with alemtuzumab for AR (2012-2018) and patients (>65 years at time of transplantation) 
transplanted in the same period and not treated with alemtuzumab. 
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Figure S3. The creatinine clearance (mL/min/1.73m2) of patients treated with alemtuzumab or rATG 
for AR. The boxes represent median and IQR and the whiskers 5th and 95th percentile. n=number of 
patients with an eGFR. Baseline = best serum creatinine or eGFR in three months before AR, 0 = serum 
creatinine or eGFR on day of AR, M3 = 3 months after alemtuzumab (±4 weeks), M6 = 6 months (±6 
weeks) after alemtuzumab, M12 = 12 months after alemtuzumab (±8 weeks). *p<0.05, **p=not significant
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SDC Figure 4
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Figure S4. Kaplan-Meier survival curve of allograft survival of alemtuzumab-treated patients with aTCMR 
or aABMR
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SDC Figure 5
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Figure S5. T- and B cells after alemtuzumab therapy. T- and B cells were measured every three 
months, until T cells were >200 x 106/L. a. Scatter dot plot of all measured T cells on different time 
points after alemtuzumab therapy. The horizontal line depicts the median. b. Percent of patients 
with repopulation of T cells >200 x 106/L in the year after alemtuzumab therapy. c. Scatter dot 
plot of all measured B cells on different time points after alemtuzumab therapy. The horizontal line 
depicts the median. d. Percent of patients with repopulation of B cells >100 x 106/L in the year after 
alemtuzumab therapy.
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SDC Table 1. Patients with a second biopsy between methylprednisolone and alemtuzumab to confirm 
ongoing rejection.
Patient 
no.
1st Banff diagnosis Treatment Days between 1st 
and 2nd biopsy
2nd Banff diagnosis
1 aABMR Methylprednisolon 3 x 1000 mg 8 aTCMRIIA
2 aABMR Methylprednisolon 3 x 1000 mg + IVIg 50 aABMR
3 aABMR Methylprednisolon 6 x 1000 mg 7 aTCMRIIB
4 aTCMRIB Methylprednisolon 3 x 1000 mg 85 aTCMRIB
5 aTCMRIIA Methylprednisolon 6 x 1000 + IVIg 16 aTCMRIIA
6 aABMR Methylprednisolon 3 x 1000 mg + IVIg 61 aABMR
7 aTCMRIIB Methylprednisolon 3 x 1000 mg + IVIg 111 chronic active TCMR
8 aTCMR (biopsy missing) Methylprednisolon 3 x 1000 mg 77 aTCMRIB
9 aTCMRIA Methylprednisolon 3 x 1000 mg + IVIg 52
c/aABMR, borderline 
TCMR
10 aTCMRIB Methylprednisolon 3 x 1000 mg 80 aTCMRIIA, aABMR
11 aTCMRIB Methylprednisolon 6 x 1000 mg 17 borderline TCMR
12 aTCMRIB Methylprednisolon 3 x 1000 mg 54 aTCMRIB
13 borderline aTCMR Methylprednisolon 3 x 1000 mg 86 Acute tubular necrosis
14 aABMR Methylprednisolon 3 x 1000 mg + IVIg 33 aABMR
15 aTCMRIA Methylprednisolon 3 x 1000 mg 126 chronic active TCMR
16 aTCMRIIA Methylprednisolon 3 x 1000 mg 9 aTCMRIIA
17 aTCMRIB Methylprednisolon 3 x 1000 mg 111 chronic active TCMR
18 aTCMRIIB Methylprednisolon 3 x 1000 mg + IVIg 7 ABMR (biopsy missing)
aABMR active antibody mediated rejection; aTCMR acute T cell mediated rejection; IVIg intravenous immunoglobulins
SDC Table 2. Cause of death after therapy with alemtuzumab or rATG
Adverse events Alemtuzumab rATG
Patient death - no (%) 18 (15.5) 17 (16.5)
Time after therapy - yr. 1.45 (0.92-2.93) 3.1 (1-6.3)
Cause of death - no.
Infectious 7 5
Carcinoma 4 2
Cardiovascular 2 3
Hepatic failure 1 1
Allograft failure 2 0
Unknown 2 6
Data are numbers (percentage) and median (interquartile range).
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SDC Table 3. Univariable Cox proportional hazard regression analysis for risk of death within patients 
treated with alemtuzumab
Variable (reference category) Exp (B) 95% CI for Exp (B) p-value
Patient characteristics
Recipient age at transplantation (per yr) 1.09 1.04-1.14 <0.0001
Recipient age at acute rejection (per yr) 1.09 1.04-1.14 <0.0001
Donor age (per yr) 1.00 0.97-1.03 1.00
Gender (female) 0.44 0.29-1.73 0.44
Ethnicity (Caucasian) 0.40 0.12-1.37 0.14
Transplant number (1) 0.55 0.16-1.88 0.34
PRA current (<6%) 1.07 0.36-3.23 0.90
Transplant characteristics
Type donor (living) 1.20 0.46-3.16 0.71
HLA mismatch (per HLA mismatch) 0.88 0.64-1.19 0.40
Therapy characteristics
Maintenance therapy (TAC+MMF±glucocorticoids) 5.70 0.76-42.83 0.09
Glucocorticoid maintenance (no) 1.63 0.47-5.60 0.44
Rejection characteristics
Timing rejection (< 3 months) 0.52 0.20-1.32 0.17
Type rejection 0.41
DSA vs no DSA 0.40 0.11-1.44 0.16
CKD at time rejection (CKD 3) 0.30
Δ eGFR Baseline- moment of rejection 0.99
Interval methylprednisolon-alemtuzumab 1.00 0.99-1.02 0.83
Allograft loss 1.18 0.47-2.94 0.72
T cells after 3 months 1.00 0.99-1.01 0.85
Increasing age at time of transplantation or AR resulted in increased risk of death. Ethnicity is caucasian or non-caucasian. 
Transplant number is 1 or >1. PRA current is < 6% or ≥6%. Type donor is living or deceased. Maintenance therapy is 
TAC+MMF± glucocorticoids or the other combinations of drugs. Glucocorticoid maintenance is use at the time of rejection. 
Timing of the rejection is <3 or > 3months after transplantation. Type rejection is aTCMR, ABMR, or mixed. CDK at time 
rejection is CKD1+2+3, CKD4, CKD5, and delayed graft function+ primary non-function. Interval between methylprednisolon 
and alemtuzumab is days. T cells three months after alemtuzumab is a continue variable. Data of rATG-treated patients were 
described previously10. CKD chronic kidney disease; MMF mycophenolate mofetil; PRA panel reactive antigen; TAC tacrolimus
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SDC Table 4. Univariable Cox proportional hazard regression analysis for allograft loss in patients treated with 
alemtuzumab
Variable (reference category) Exp (B) 95%-CI for Exp (B) p-value
Patient characteristics
Recipient age at transplantation (per yr) 0.97 0.95-0.99 0.002
Recipient age at acute rejection (per yr) 0.97 0.95-0.99 0.003
Donor age (per yr) 0.99 0.97-1.01 0.27
Gender (female) 0.99 0.53-1.86 0.97
Ethnicity (Caucasian) 1.11 0.57-2.15 0.77
Transplant number (1) 1.1 0.53-2.23 0.81
PRA actual (<6%) 1.35 0.64-2.87 0.43
Transplant characteristics
Type donor (living) 1.48 0.77-2.85 0.24
HLA mismatch (per HLA mismatch) 0.72 0.58-0.89 0.002
HLA mismatch (0-3) 0.34 0.17-0.65 0.001
Therapy characteristics
Maintenance therapy (TAC+MMF± glucocorticoids) 1.19 0.55-2.60 0.66
Glucocorticoid maintenance (no) 0.32 0.17-0.60 <0.0001
Frequency alemtuzumab (1) 1.19 0.56-2.54 0.65
Rejection characteristics
Timing rejection (< 3 months) 1.39 1.01-1.91 0.04
Type rejection (aTCMR) 0.19
DSA vs no DSA 1.36 0.66-2.81 0.40
CKD at time rejection (CKD1-3) 0.20
Δ eGFR baseline-moment of rejection 0.004
25 till 50% drop versus <25% drop 0.91 0.33-2.53 0.81
>50% drop versus <25% drop 3.36 1.29-8.75 0.008
Interval methylprednisolone-alemtuzumab 1.00 0.99-1.01 0.49
Transplant number is 1 or >1. PRA current is < 6% or ≥6%. Type donor is living or deceased. Maintenance therapy is 
TAC+MMF± glucocorticoids or the other combinations of drugs. Glucocorticoid maintenance is use at the time of rejection. 
Frequency of alemtuzumab is 1 or >1. Timing of the rejection is <3 or > 3 months after transplantation. Type rejection is 
aTCMR, ABMR, or mixed. CDK at time rejection is CKD1+2+3, CKD4, CKD5+ delayed graft function+ primary non-
function. Interval between methylprednisolone and alemtuzumab is days. Data of rATG-treated patients were described 
previously10. CKD chronic kidney disease; DSA de novo donor specific antibodies; MMF mycophenolate mofetil; PRA panel 
reactive antibodies; TAC tacrolimus
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SDC Table 5. Characteristics and statistical analysis of alemtuzumab-treated patients with HLA mismatch 
of 0-3, and patients with HLA mismatch of 4-6
Characteristic HLA MM 0-3 (n=57) HLA MM 4-6 (n=58) p-value
Recipient age at transplantation- yr. 54 (38-63) 57 (40-63) 0.31
Recipient age at rejection- yr. 54 (38-63) 58 (42-64) 0.28
Donor age - yr. 54 (40-63) 54 (40-63) 0.59
Female sex - no. (%) 25 (43) 22 (38) 0.71
Cause of ESRD - no.
DM/HTN/GN/PKD/reflux/other/unknown 12/9/12/4/5/16/0 14/13/9/5/2/11/4 0.28
Ethnic distribution - no.
Caucasian/Black/Asian/Arab/other 40/8/4/6/0 39/9/4/5/1 1.00
Transplant number - no.
1/2/3 41/12/5 47/10/1 0.22
Preemptive kidney transplantation - no. (%) 22 (38) 19 (32.8) 0.70
Donor type - no.
LR/LUR/DBD/DCD 24/13/6/15 3/42/6/7 <0.001
Living/deceased 37/21 45/13 0.15
HLA mismatch - no.
HLA A: 0/1/2 22/33/3 4/28/26 <0.001
HLA B: 0/1/2 10/43/5 0/10/48 <0.001
HLA DR: 0/1/2 19/36/3 2/19/37 <0.001
PRA actual - no. (%) 0.35
0-5% 44 (75.9) 49 (84.4)
6-83% 13 (22.4) 9 (15.5)
84-100% 1 (1.7) 0 (0)
PRA peak - no. (%) 0.29
0-5% 33 (56.9) 36 (62.1)
6-83% 14 (24.1) 17 (29.3)
84-100% 11 (19.0) 5 (8.6)
De novo DSA (ABMR and mixed type rejections)
DSA+/non-donor HLA antibodies/no DSA/not tested 6/4/2/2 14/1/3/3 0.24
Class I/II/I+II 1/3/2 3/9/2 0.62
CMV IgG serostatus recipient - no. (%)
Positive 43 (74) 41 (71.9) 0.84
EBV IgG serostatus recipient - no. (%)
Positive 52 (91.2) 55 (96.5) 0.44
Maintenance therapy (TAC+MMF± glucocorticoids) - no. (%) 49 (84.4) 47 (79.3) 0.63
Glucocorticoid maintenance - no. (%) 44 (75.9) 49 (84.5) 0.35
Timing rejection (< 3 months) - no. (%) 31 (53.4) 32 (55.2) 1.00
Type rejection 34/6/8 32/10/11 0.54
CKD at time rejection 17/21/20 20/18/19 0.80
Interval methylprednisolone-alemtuzumab 6 (4-24) 7 (4-22) 0.80
Data are numbers (%) or median (interquartile range). Type rejection is aTCMR, ABMR, or mixed. CDK at time rejection 
is CKD1+2+3, CKD4, CKD5+ delayed graft function+ primary non-function. Interval between methylprednisolone and 
alemtuzumab is days. CMV cytomegalovirus; DBD donation after brain death; DCD donation after circulatory death; 
DM diabetes mellitus; DSA de novo donor specific antibodies; EBV Epstein-Barr virus; ESRD end stage renal disease; GN 
glomerulonephritis; HLA human leucocyte antigen; HTN hypertensive nephropathy; LR living related; LUR living unrelated; 
MMF mycophenolate mofetil; PKD polycystic kidney disease; PRA panel reactive antibody; rATG rabbit anti-thymocyte 
globulin; TAC tacrolimus
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SDC Table 6. Infections during the total follow-up after alemtuzumab and rATG treatment
Infections Alemtuzumab rATG
Infection in the first year - no. 96 124
Viral 14 19
Fungal 3 8
Bacterial 79 97
Blood 3 8
Urinary tract/urosepsis 47 51
Skin and soft tissue 5 9
Lung 16 15
Tuberculosis 2 0
Other/unknown 6 14
Infection in the first 15 days 9 29
CMV infections
CMV reactivation - no. (%) 25 (21.6) 27 (25)
CMV disease - no. (%) 2 (1.7) 0
Primary CMV infection - no. (%) 2 (1.7) 2 (1.9)
CMV, time after therapy 76 (52-167) 32 (19-74)
EBV infections - no. (%) 0 1 (9)
BK infections
BK viremia - no. (%) 20 (17.2) 6 (5.6)
BK viremia, time after therapy 106 (59-186)  458 (322-844)
Data are numbers (%) or median (interquartile range). CMV, EBV and BK virus infections were scored apart from the infections 
during the total follow-up, in the first year, and after the first year.
SDC Table 7. Malignancies after alemtuzumab treatment
Malignancy Months after alemtuzumab Months after transplantation Age of patient
Lung cancer 9 10 57
Lung cancer 27 38 61
Pancreatic cancer 37 43 73
Breast cancer 28 32 65
Prostate carcinoma 43 44 80
Adenocarcinoma of unknown primary* 38 46 60
Colon cancer** 8 58 76
Age of patient is at the time of malignancy. *No biopsy of the metastasis was taken. **This patient had pre-transplantation 
colon cancer and developed metastasis of colon cancer after alemtuzumab.
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SDC Table 8. Malignancies after rATG treatment
Malignancy Months after rATG Months after transplantation Age of patient
Endometrial carcinoma 67 69 57
Adenocarcinoma lung 68 157 61
Non seminoma testis 17 23 44
Colon carcinoma 21 21 45
Rectal carcinoma 17 62 52
Meningioma 28 44 62
Renal carcinoma 107 107 34
Renal carcinoma 77 77 69
Renal carcinoma 140 140 55
Renal carcinoma 144 144 56
Prostatic carcinoma 10 35 54
Prostatic carcinoma 77 77 69
Non-Hodgkin lymphoma 78 79 56
EBV related B-lymphoma 14 14 65
Age of patient is at the time of malignancy. The Epstein-Barr virus (EBV)-related lymphoma was in an IgG seropositive patient 
and occurred fourteen months after treatment with rATG and was treated with irradiation.
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INTRODUCTION
Alemtuzumab is approved for the treatment of relapsing-remitting multiple sclerosis and 
is used off-label for patients with chronic lymphocytic leukemia and as induction- and 
anti-rejection therapy in kidney transplant recipients1. Guillain-Barré syndrome (GBS) 
or chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) complicating 
alemtuzumab treatment was reported in nine patients with hematologic malignancy or 
multiple sclerosis1-3. The risk of GBS or CIDP in solid organ transplant recipients treated 
with alemtuzumab is unknown.
Rabbit anti-thymocyte globulin (rATG) is another T cell-depleting drug used to treat acute 
kidney allograft rejection. Only one patient was reported who developed GBS after rATG 
treatment for aplastic anemia4. We found no reports of GBS or CIDP complicating rATG 
treatment in kidney transplant recipients. Here, we investigated the frequency, type, and 
outcome of GBS and CIDP in a single-center cohort of kidney transplant recipients treated 
with either alemtuzumab or rATG.
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PATIENTS AND METHODS
Study design
A retrospective analysis was performed of a cohort of kidney transplant recipients who 
received either alemtuzumab (Campath, Sanofi-Genzyme, Cambridge, Massachusetts, 
USA) or rATG (Thymoglobulin, Sanofi-Genzyme) between 2002 and 2018 in the Erasmus 
MC, Rotterdam. Alemtuzumab was administered as a single dose of 30 mg subcutaneously 
and rATG in a dose of 4 mg/kg intravenously.
Statistical methods
Continuous variables are presented as median and interquartile ranges (IQRs). The 
95%-confidence intervals (CI) were calculated with the modified Wald method. For 
statistical analysis, SPSS version 21 (SPSS Inc., Chicago, IL, USA) was used.
Standard protocol approval, registrations and patient consents
The study was approved by the Erasmus MC Medical Ethical Review Board (number 
2018-1430).
RESULTS
Between 2002 and 2018, 2,788 patients received a kidney transplant at our center. 
Alemtuzumab was administered to 143 (5.1%) patients and rATG to 108 (3.9%) patients. 
The total follow-up period of patients treated with alemtuzumab was 3.0 years (IQR 1.7-
4.1) for a total of 444.3 person-years. A tacrolimus-based immunosuppressive regimen was 
given to 92% of patients. Three patients (2.1%, 95%-CI 0.4%-6.3%) developed GBS or 
CIDP after alemtuzumab. Two patients fulfilled the diagnostic criteria for GBS and one 
fulfilled the diagnostic criteria for CIDP. The clinical presentation and diagnostic findings 
of these patients are presented in Table 1. Laboratory tests, including clinical chemistry, 
serology and virology demonstrated no alternative diagnoses, and there was no recent 
Campylobacter jejuni or cytomegalovirus infection (PCR negative for cytomegalovirus). 
The total follow-up period for rATG-treated patients was 8.2 (IQR 6.3-11) years for a 
total of 829.4 person-years. Seventy-eight percent of patients received a tacrolimus-based 
immunosuppressive regimen. None of the patients treated with rATG (0%, 97.5%-CI 
0-4.1%) developed GBS or CIDP.
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Table 1. Clinical characteristics, diagnosis and outcome of patients with GBS and CIDP after alemtuzumab
Case 1 (GBS) 2 (GBS) 3 (CIDP)
Gender Male Female Male
Age at onset symptoms (years) 54 57 63
Primary kidney disease Polycystic kidney disease Reflux nephropathy Polycystic kidney 
disease
CMV status at transplantation Seropositive Seronegative Seropositive
Induction therapy Alemtuzumab (30 
mg, 30 days before 
transplantation, IVIg 
(0.4g/kg on day of 
transplantation), 
immunoabsorption
Basiliximab Basiliximab
Anti-rejection therapy None Alemtuzumab (30 mg) Alemtuzumab (30 mg)
Immunosuppressive treatment at onset 
symptoms
Tacrolimus/ MMF/ 
prednisolone 5 mg/day
Tacrolimus/ MMF/ 
prednisolone 2.5 mg/day
Tacrolimus/ MMF/ 
prednisolone 5 mg/day
Diagnosis GBS, level 2 of Brighton 
classification (No 
electrophysiological 
studies available)
GBS (AIDP), level 1 of 
Brighton classification
CIDP (fulfillment 
of clinical criteria 
and definite 
electrophysiological 
criteria EFNS/PNS 
2010)
Interval between alemtuzumab treatment 
and symptoms (months)
4 8 42
Onset to maximum severity (days) 21 10 90
Maximum mRS (range 0-6) 4 5 4
Maximum GBS disability score (range 0-6) 4 5 -
EGOS (range 0-7) 3.5 6.5 -
Treatment IVIg (0.4 g/kg) for 5 
days
IVIg (0.4 g/kg) for 5 
days
2x IVIg (0.4 g/kg) 
for 5 days, 4 sessions 
of plasma-exchange, 
methylprednisolone 
(3x1000mg), 
prednisone 5mg daily 
(maintenance)
mRS after treatment 1 6 1
GBS disability score after treatment for GBS 1 6 -
Neurologic outcome at the last follow-up Partial recovery (follow 
up 1 year)
Death (6 months later, 
due to malignancy)
Full recovery (follow-up 
3 years)
AIDP, acute inf lammatory demyelinating polyradiculoneuropathy; CIDP, chronic inf lammatory demyelinating 
polyradiculoneuropathy; EGOS, Erasmus GBS outcome score; GBS, Guillain-Barre syndrome; IVIg, intravenous 
immunoglobulins; MMF mycophenolate mofetil; mRS modified Rankin Scale
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DISCUSSION
This study shows that 2.1% of patients treated with alemtuzumab developed GBS or CIDP. 
This is higher than the incidence rate of these neuropathies in the general population and of 
kidney transplant recipients not treated with alemtuzumab5-7. Secondary autoimmunity after 
alemtuzumab appears to be mainly B cell-driven. A mismatched reconstitution of T and B 
cells after alemtuzumab can lead to an expansion of B cells in the absence of appropriate 
T cell regulation. This may enable the escape of autoreactive B cells and production of 
pathogenic autoantibodies to self-antigens which can lead to secondary autoimmunity, such 
as thyroiditis, idiopathic thrombocytopenic purpura, GBS or CIDP1.
None of the patients treated with rATG developed GBS or CIDP. A possible explanation 
for the difference in the risk of developing these neuropathies with alemtuzumab is that 
the depletion of immune cells lasts longer after alemtuzumab1. Alternatively, rATG may 
protect from GBS and CIDP.
Limitations of the current study are that we were unable to define the frequency of GBS 
and CIDP in kidney transplant recipients not treated with T cell-depleting therapy. Second, 
no causality between alemtuzumab and the risk of GBS or CIDP was demonstrated, and 
our findings may therefore relate to chance. Third, cytomegalovirus could have played 
a role in the development of GBS or CIDP because patients 1 and 3 were seropositive 
for cytomegalovirus at the time of transplantation. However, no signs of a reactivation 
were observed at the time the patients were diagnosed with GBS and CIDP. Fourth, we 
cannot exclude that the increased incidence of GBS and CIDP among alemtuzumab-
treated patients may relate to the fact that in this group, more patients used tacrolimus as 
maintenance immunosuppression compared with the rATG cohort. Fifth, this observation 
is based on kidney transplant recipients who have several reasons to have an underlying 
neuropathy (i.e., renal insufficiency and diabetes mellitus) and it is uncertain whether it is 
also applicable to patients with multiple sclerosis.
In conclusion, alemtuzumab therapy in kidney transplant recipients may be associated 
with the development of GBS and CIDP. Clinicians should be alert for these neurological 
complications in kidney transplant recipients treated with alemtuzumab.
10
226
PART III
REFERENCES
1. van der Zwan M, Baan CC, van Gelder T, Hesselink DA. Review of the Clinical Pharmacokinetics 
and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. Clin 
Pharmacokinet. 2018;57(2):191-207.
2. Avivi I, Chakrabarti S, Kottaridis P, et al. Neurological complications following alemtuzumab-
based reduced-intensity allogeneic transplantation. Bone Marrow Transplant. 2004;34(2):137-142.
3. Hradilek P, Woznicova I, Slonkova J, Lochmanova A, Zeman D. Atypical acute motor axonal 
neuropathy following alemtuzumab treatment in multiple sclerosis patient. Acta Neurol Belg. 
2017;117(4):965-967.
4. Kaya B, Davies CE, Oakervee HE, et al. Guillain Barre syndrome precipitated by the use of 
antilymphocyte globulin in the treatment of severe aplastic anaemia. J Clin Pathol. 2005;58(9):994-
995.
5. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet. 2016;388(10045):717-
727.
6. Ostman C, Chacko B. Guillain-Barre syndrome post renal transplant: A systematic review. Transpl 
Infect Dis. 2019;21(1):e13021.
7. Echaniz-Laguna A, de Seze J, Chanson JB. Chronic inf lammatory demyelinating 
polyradiculoneuropathy in solid organ transplant recipients: a prospective study. J Neurol Neurosurg 
Psychiatry. 2012;83(7):699-705.
227
CHAPTER 10 | GBS AND CIDP AFTER ALEMTUZUMAB THERAPY
10

Marieke van der Zwan 
Frank W.G. Leebeek 
Yorick Sandberg 
Marieke J.H.A. Kruip 
Dennis A. Hesselink
Haemophilia 2020; Jul
CHAPTER
Acquired 
hemophilia A after 
alemtuzumab 
therapy 
11
230
PART III
To the editor:
Treatment with alemtuzumab leads to a prolonged depletion of T- and B cells, natural killer 
cells, dendritic cells and monocytes1. Alemtuzumab therapy is associated with secondary 
auto-immune disorders, including auto-immune thyroid disease, immune thrombocytopenia 
and inflammatory neuropathy1. Here, two patients with acquired hemophilia A (AHA) are 
described who were previously treated with alemtuzumab.
Patient 1 was a 24-year-old male who received a kidney transplant because of end-stage 
kidney disease caused by Alport syndrome. One year after transplantation he was treated 
for a mixed-type kidney transplant rejection. He received methylprednisolone (total dose 
3,000 mg) and intravenous immunoglobulins (2 g/kg) followed by alemtuzumab (30 mg, 
subcutaneously on two consecutive days). Four years after treatment for rejection, he presented 
with spontaneous bruising. He did not experience unintentional weight loss, fever, infection 
or night sweats. His immunosuppressive regimen at that time consisted of tacrolimus and 
prednisolone (5 mg/day). Physical examination at presentation revealed multiple large 
hematomas on all extremities and on his thorax. Laboratory testing demonstrated an isolated 
prolonged activated partial thromboplastin time (aPTT) of 80 seconds (Table 1). The aPTT 
did not correct after mixing with normal pooled plasma (46 seconds). Factor VIII coagulation 
activity (FVIII:C) was strongly reduced (0.02 U/mL; normal 0.60-1.40 U/mL). A Factor VIII 
inhibitor was confirmed and quantified with the Nijmegen modification of the Bethesda 
assay (10 Bethesda Units [BU/ml]; Table 1 and Figure 1A). Additional work-up showed 
repopulation of T- and B-lymphocytes (Table 1). The patient was diagnosed with AHA and 
was treated with a single administration of activated prothrombin complex concentrate (factor 
eight inhibitor bypassing activity [FEIBA®] 50 U/kg) to stop bleeding of a severe bleeding 
in his arm resulting in pain and impairment of joint mobility of the elbow (Figure 1A). 
Immunosuppressive therapy was immediately started with prednisolone (1 mg/kg/day, i.e. 80 
mg/day) and cyclophosphamide (100 mg/day). The aPTT shortened and FVIII:C increased 
within two weeks whereupon cyclophosphamide was discontinued (Figure 1A). The patient 
achieved complete remission of the AHA after six weeks with normalization of FVIII:C and no 
detectable Factor VIII inhibitor (Figure 1A). Prednisolone was tapered to 5 mg over a period 
of six months. Thereafter, prednisolone was continued (5 mg/day) as immunosuppressive 
therapy for the kidney transplantation.
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Table 1.
Parameter Patient 1 Patient 2 Reference range
Hemoglobin (g/dL) 10.3 10.8 13.7-17.7
Platelets (x109/L) 391 217 150-400
Leukocytes (x109/L) 15.6 5.8 4-10
Lymphocytes (x109/L) 0.84 0.80 0.50-5.00
B-lymphocytes (x109/L) 0.21 - -
T-lymphocytes (x109/L) 0.63 - -
CD4/CD8 ratio 3.9 - -
aPTT (seconds) 80 62 25-31
PT (seconds) 11.3 13.1 9.5-13-5
aPTT mix (seconds) 46 54 25-31
Factor VIII (U/mL) 0.02 0.02 0.60-1.40
vWF antigen (U/mL) 1.79 2.31 0.60-1.40
vWF activity (U/mL) 1.67 2.94 0.60-1.40
Bethesda VIII (BU/ml) 10 24.6 <0.3
Laboratory testing of the hemostasis parameters at presentation. aPTT, activated partial thromboplastin time; PT, prothrombin 
time; vWF, von Willebrand Factor
Patient 2 was a 42-year-old male who received alemtuzumab (intravenously, 12 mg/day for 
five days and one year later 12 mg/day for three days) for relapsing-remitting multiple sclerosis. 
Fourteen months after the last dose, he presented with a spontaneous large hematoma on his 
back without other complaints. He did not use any medications at the time of presentation. 
Physical examination revealed a large hematoma in the lumbar region which extended to his 
right upper leg, which was illustrated earlier2. Laboratory testing revealed an isolated prolonged 
aPTT of 62 seconds which did not normalize after mixing with normal pooled plasma (54 
seconds; Table 1). FVIII:C was strongly reduced (0.02 U/mL) and a Factor VIII inhibitor was 
present (24.6 BU/ml; Table 1). The lymphocyte count was normal (Table 1). A diagnosis of 
AHA was made and he was treated because of severe bleeding with a hemoglobin drop to 10.8 
g/dL with FEIBA® 100 U/kg on the first day followed by 50 U/kg two times daily for six days. 
He was also treated with prednisolone (1 mg/kg/day, i.e. 90 mg/day) and cyclophosphamide 
(200 mg/day) as immunosuppressive therapy (Figure 1B). Complete remission of AHA 
was achieved after six weeks (Figure 1B). Cyclophosphamide was stopped ten weeks after 
presentation and prednisolone was tapered over a period of seven months.
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AHA is a rare auto-immune disorder caused by autoantibodies directed against Factor VIII. It 
occurs mainly at (very) high age, or in young women after pregnancy. It is usually idiopathic 
(50% of cases) but AHA may also be associated with malignancies, auto-immune diseases, 
infections, pregnancy and drugs3-5. In our patients, additional investigations, including auto-
immune serology (for systemic lupus erythematosus and rheumatoid arthritis), virology (of 
hepatitis B and C, and Epstein Barr virus) and a CT scan of the thorax and abdomen, 
did not reveal any underlying cause of AHA in our patients. There was no monoclonal 
gammopathy, white blood cell and platelet counts were normal, nor were there other signs of 
a hematological malignancy. Currently, both patients (three and one year after presentation) 
are still in remission of AHA after treatment with glucocorticoids and cyclophosphamide and 
no other auto-immune disorders or malignancies have occurred6.
In literature, an association between alemtuzumab and AHA has been described in four 
patients7-11. The indication for alemtuzumab was multiple sclerosis in three cases7-10 and anti-
neutrophil cytoplasmic antibody-associated vasculitis in one case11. The interval between 
alemtuzumab therapy and the diagnosis of AHA ranged from 11 months9,10 to 5 years8,11. 
Depletion of regulatory T cells, natural killer and dendritic cells and escape of auto-reactive 
B cells after alemtuzumab therapy have been proposed to contribute to the increased 
susceptibility of secondary autoimmunity1. Because of the lack of another explanation and 
the remarkable young age of our patients, we believe that AHA in our patients was related to 
the administration of alemtuzumab. Therefore, AHA should be considered in the differential 
diagnosis of an alemtuzumab-treated patients presenting with an acquired bleeding disorder.
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SUMMARY
Kidney transplantation is a lifesaving procedure. However, transplantation of a foreign 
organ leads to transplant rejection if the kidney transplant recipient is not treated with 
immunosuppressive drugs. Kidney transplant rejection still occurs in approximately a 
quarter of kidney transplant recipients and is associated with a high burden of morbidity 
and mortality1. The quote:
“An ounce of prevention is worth a pound of cure.”
Benjamin Franklin (1705-1790)
therefore can be applied to the care of kidney transplant recipients. Minimizing or 
preventing adverse events related to the current standard immunosuppressive maintenance 
therapy will aid in improvement of patient- and allograft kidney transplant outcomes. 
In addition, early detection and optimal treatment of acute rejection are important to 
prevent irreversible allograft injury. This thesis explores ways to optimize maintenance 
immunosuppressive treatment, and diagnosing and treating kidney transplant rejection.
Prevention of acute rejection
Current immunosuppressive regimens consist of induction therapy and maintenance 
therapy. Induction therapy is administered during transplant surgery. Maintenance therapy 
is initiated directly after surgery and must be continued life-long2. The current standard 
of care maintenance therapy in most kidney transplant centers includes tacrolimus (a 
calcineurin inhibitor [CNI]) and mycophenolic acid (MPA, an anti-proliferative agent). 
With this regimen, the short-term kidney allograft survival is good3. However, this 
immunosuppressive regimen has limitations that impact long-term patient- and allograft 
survival: i) harmful adverse events, including nephrotoxicity, infection, malignancy, diabetes 
mellitus, hypertension and dyslipidemia, and ii) incomplete prevention of acute kidney 
transplant rejection still occurs in a significant proportion of patients4.
The current standard immunosuppressive maintenance therapy also is a “one size 
fits all” protocol. Almost all kidney transplant recipients are currently treated with a 
combination of CNI, MPA and/or glucocorticoids3. This disregards the fact that each 
patient has individual needs. Patient- or donor-related factors such as co-morbidity, organ 
quality and immunological risk are in general not considered when choosing a specific 
immunosuppressive regimen5. The last few years only a few of novel immunosuppressive 
241
CHAPTER 12 | SUMMARY, GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
drugs have been tested in kidney transplant recipients3,6-11. One group of drugs that has 
the potential to be part of the immunosuppressive regimen in the future are biologicals 
that intervene with the costimulatory pathway between T cells and antigen-presenting 
cells (APCs).
In Chapter 2, we provide an overview of costimulation blockade therapies that are 
currently in use or being developed for kidney transplantation. Belatacept, a biological 
that inhibits the interaction between the antigens CD28 and CD80/86, is currently the only 
costimulation blockade drug that is approved by the U.S. Food and Drug Administration 
for the prevention of acute kidney transplant rejection12. Belatacept therapy is associated 
with a superior kidney function and reduced incidence of de novo donor-specific anti-
HLA antibodies (DSA; Chapter 2) in comparison with CNI-based immunosuppression. 
However, the use of this drug in the clinic is not widespread because of the associated 
increased risk of acute rejection (Chapter 2). A better understanding of the pathogenesis of 
belatacept-resistant acute rejection and identification of patients with a low risk of belatacept-
resistant acute rejection will likely expand the use of belatacept. This was investigated in 
Chapter 5. We compared kidney transplant biopsies with acute T cell-mediated rejection 
(aTCMR) of patients treated with belatacept maintenance immunosuppressive therapy to 
that of patients treated with tacrolimus. We could not detect a difference in the expression 
of 209 genes known to be involved in acute kidney transplant rejection. There was also 
no difference in immunophenotypic analysis by immunohistochemistry between patients 
treated with belatacept or tacrolimus. These findings suggest that patients treated with either 
belatacept- or tacrolimus-based immunosuppressive therapy share a common pathway of 
aTCMR.
Therefore, we questioned if it was possible to identify belatacept-treated patients with a low 
risk of acute rejection (Chapter 6). We analyzed the concentrations of 92 inflammation-
related proteins in prerejection serum samples of belatacept-treated patients and compared 
them with serum samples of belatacept-treated patients without rejection. No difference 
was observed between the two groups, which implies that this proteomic analysis does 
not predict acute rejection. To conclude, no clinical tests are currently available to reliably 
predict the risk of belatacept-resistant rejection besides the conventional pre-transplant 
assessment of DSAs and HLA mismatch.
In Chapter 2 we discussed the current position of belatacept as maintenance 
immunosuppressive therapy in kidney transplant recipients. We concluded that belatacept 
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still is a promising drug. Kidney transplant recipients that appear to benefit the most of 
belatacept therapy are those with a low risk of acute rejection and/or have contraindications 
to CNI, for instance CNI-induced nephrotoxicity, impaired allograft function, delayed 
graft function, CNI-mediated thrombotic microangiopathy, atypical hemolytic uremic 
syndrome and poorly controlled type 2 diabetes mellitus. In Chapter 7 we describe an 
example of such a patient. This kidney transplant recipient had severe hyperglycemia and 
neurotoxicity (tremor) during tacrolimus maintenance therapy, both well-known side effects 
of tacrolimus. After conversion to belatacept a rapid and profound improvement of glucose 
tolerance was noted. In addition, the patient reported that the tremor disappeared after 
withdrawal of tacrolimus.
Diagnosis of acute rejection
Despite improvement in the maintenance therapy of kidney transplant recipients, acute 
rejection still occurs in a significant proportion of patients. Currently, the gold standard 
test to diagnose acute kidney transplant rejection is the histopathologic examination of a 
kidney biopsy. However, this is an invasive procedure and interobserver variability and 
sampling error occur frequently13,14. At present, multiple approaches are being developed 
to improve the diagnosis of acute kidney transplant rejection, for example integration of 
molecular analysis into the conventional histomorphologic examination of a kidney biopsy, 
and minimally invasive screening of acute rejection biomarkers in blood or urine. The Banff 
(2017) report introduced the molecular analysis of genes associated with kidney transplant 
rejection as a criterion for antibody-mediated rejection (ABMR)15. Interestingly, only limited 
recommendations were made regarding the implementation of molecular analysis for the 
diagnosis of aTCMR.
In Chapter 5 we analyzed the expression of the genes presented in the Banff 2017 report 
in biopsies with and without aTCMR. The gene signature of biopsies with aTCMR was 
different compared to those without aTCMR. Moreover, a significant increased expression 
of 78 genes was seen in biopsies with aTCMR. These genes were primarily associated with 
T cell-associated genes, γ-interferon-inducible genes and effector genes. Importantly, one 
patient with an isolated vascular lesion was diagnosed with aTCMR grade IIA. However 
the gene profile was comparable to that of biopsies without aTCMR and the patient did 
not have a clinical picture of acute rejection. Therefore, we conclude from these preliminary 
data that implementation of molecular analysis to the conventional examination of a kidney 
transplant biopsy could help in improving diagnostics of aTCMR in challenging cases. For 
instance, an isolated vascular lesion may not always be a sign of aTCMR.
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As described in Chapter 6 we tested a minimally-invasive assay to diagnose aTCMR in 
the serum of kidney transplant recipients. In this pilot study the concentrations of 92 
inflammation-related proteins were tested in sera of patients with and without aTCMR. 
A significant difference was noted between the two groups: Five proteins (T-cell surface 
glycoprotein CD5 [CD5], T cell surface glycoprotein CD8 [CD8a], Natural cytotoxicity 
triggering receptor 1 [NCR1], TNF receptor superfamily member 4 [TNFRSF4], and TNF 
receptor superfamily member 9 [TNFRSF9]) were significantly higher in sera at the time 
of aTCMR. Moreover, the protein profile of patients with aTCMR was also different from 
that of patients without aTCMR. These findings implicate that this proteomic analysis is a 
promising minimally-invasive tool to screen for aTCMR in the blood of kidney transplant 
recipients.
Treatment of acute rejection
The treatment of choice for glucocorticoid-resistant, severe or recurrent acute kidney 
transplant rejection is, according to the international guideline, the T cell-depleting 
drug rabbit anti-thymocyte globulin (rATG)2. However, the guideline is based on studies 
performed more than 25 years ago when induction therapy was not routinely administered 
and kidney transplant recipients were mainly treated with azathioprine and ciclosporin. 
None of these patients were treated with current standard of care therapy consisting of 
tacrolimus and MPA. Therefore, we investigated the long-term patient- and allograft 
outcomes of rATG treatment for acute rejection in 108 patients treated with tacrolimus- 
and MPA-based immunosuppressive therapy (Chapter 8). We observed that rATG is an 
effective therapy for glucocorticoid-resistant, severe or recurrent acute kidney transplant 
rejection, especially in patients with an early acute rejection (in the first month post-
transplantation). In addition, patients with tubulointerstitial rejection (aTCMR grade I) had 
an inferior kidney function one year after therapy compared with patients with a vascular 
rejection (aTCMR grade II or III). The interval between methylprednisolone treatment and 
rATG administration was the longest in the aTCMR grade I group suggesting that the 
clinicians were reluctant to prescribe rATG to these patients, which seems to have resulted 
in more irreversible damage to the kidney transplant. rATG therapy was not associated 
with increased mortality compared with patients not treated with rATG. However, severe 
infusion-related adverse events frequently occurred.
Alemtuzumab is another T cell-depleting agent and is sometimes used off-label in kidney 
transplant recipients as induction therapy (mostly in highly sensitized kidney transplant 
recipients) or as anti-rejection therapy. Chapter 3 reviews the current literature on the 
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application of alemtuzumab in kidney transplant recipients. Since 2012, in the Erasmus 
MC, patients are treated with alemtuzumab for glucocorticoid-resistant, severe or recurrent 
acute kidney transplant rejection. In Chapter 9 the patient- and allograft outcomes and 
adverse events of patients treated with either alemtuzumab (n = 113) or rATG (n = 108) in 
the Erasmus MC were compared. The main conclusions of this study were that the patient- 
and allograft survival was similar between the two therapies. However, infusion-related side 
effects and infection occurred less frequently after alemtuzumab therapy and the length 
of hospital stay was 12 days shorter in the group of patients treated with alemtuzumab.
Alemtuzumab is associated with secondary auto-immune events, such as autoimmune 
thyroid disorders, immune thrombocytopenia and anti-glomerular basement membrane 
disease. Alemtuzumab-associated auto-immunity can occur even years after treatment 
(Chapter 3)16. We analyzed the kidney transplant recipients treated with alemtuzumab in 
the Erasmus MC for the occurrence of such auto-immune events. Three kidney transplant 
recipients treated with alemtuzumab (2.1% of all patients treated with alemtuzumab) 
developed an inflammatory polyneuropathy (Chapter 10). Other causes of inflammatory 
polyneuropathy were excluded and alemtuzumab may therefore have played a crucial role in 
the development of inflammatory polyneuropathy. In Chapter 11, we describe two patients 
who developed acquired hemophilia A after therapy with alemtuzumab. Alemtuzumab 
may have played a role in the formation of auto-antibodies to factor VIII in these patients.
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GENERAL DISCUSSION AND FUTURE DIRECTIONS
Prevention of acute rejection
Eight years after the drug was first approved for the prevention of kidney transplant 
rejection, belatacept remains a promising immunosuppressive drug. Because of the increased 
rejection risk associated with belatacept compared to tacrolimus-based immunosuppression, 
many transplant physicians are reluctant to prescribe this drug. Unfortunately, at this 
moment, no biomarker(s) exists that can predict the risk of belatacept-resistant acute kidney 
transplant rejection. In Chapter 6, we described that identification of belatacept-treated 
patients with a low risk of kidney transplant rejection was not possible. In that study, we 
compared (prerejection) serum samples taken on day 30 after transplantation with serum 
samples on the time of rejection. However, the time between the prerejection samples and 
the time of rejection ranged between 10 and 90 days and this may have influenced the 
results. A proteomic study with serial monitoring in these patients, for instance every two 
weeks, may show protein alterations in the blood before the rejection becomes clinically 
overt and may provide further information on the pathogenesis of rejections occurring 
under belatacept-based immunosuppression.
Because no clinical test is available that can predict the risk of belatacept-resistant acute 
kidney transplant rejection, belatacept is currently reserved for subgroups of patients. In 
Chapter 2 we suggest an approach to the selection of patients who may benefit from 
belatacept and discuss possible treatment protocols and strategies to monitor belatacept 
treatment. As shown in Chapter 7, patients with post-transplantation diabetes mellitus 
can benefit from conversion from tacrolimus to belatacept. One of the explanations for this 
improvement in diabetes control is that tacrolimus can induce hypomagnesemia via renal 
magnesium wasting, which can cause insulin resistance and decreased insulin secretion17-19. 
In addition to a higher risk of diabetes mellitus, hypomagnesemia is one of the factors 
that contribute to progression of arterial stiffness and increased cardiovascular risk in 
kidney transplant recipients treated with CNIs20. There is some evidence that CNI sparing 
immunosuppressive regimens based on belatacept are associated with a positive effect on 
cardiovascular risk20. In two small retrospective studies, belatacept therapy resulted in a 
small improvement in arterial stiffness compared with CNIs21,22. In the BENEFIT trials, 
belatacept therapy was associated with a superior cardiovascular and metabolic profile, 
including lower blood pressure, improved serum lipids concentrations and a decreased 
incidence of post-transplantation diabetes mellitus one year after transplantation compared 
with ciclosporin23. However, the extension BENEFIT study (seven-year evaluation) did not 
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report these outcomes24. Furthermore, no studies compared the cardiovascular risk between 
patients treated with belatacept or tacrolimus. Whether belatacept therapy leads to superior 
long-term outcomes compared with tacrolimus therapy with respect to cardiovascular and 
metabolic risk remains to be seen and warrants further investigation.
Although the risk of T cell-mediated rejection is increased in belatacept-treated patients, 
the formation of de novo DSAs is reduced compared with ciclosporin-treated patients25. 
Two reasons for the reduced formation of DSAs may be that 1) costimulation blockade with 
belatacept leads to more effective prevention of DSA formation by B cells and 2) intravenous 
administration of belatacept ensures better drug adherence and lower day to day variability 
in immunosuppressive drug exposure compared with CNI-based regimens26. DSAs are a risk 
factor for the development of chronic active antibody-mediated rejection (c-aABMR) which 
is an important cause of late kidney transplant loss27. However, whether belatacept therapy 
leads to a decreased rate of c-aABMR is not known and is an interesting research question.
Diagnosis of acute rejection
Molecular analysis of acute rejection biopsies
The combination of molecular diagnostics with the conventional histomorphologic 
examination of a kidney biopsy improves the accuracy of transplant rejection diagnosis15. 
In Chapter 5 we used the Nanostring® assay to evaluate gene expression in kidney biopsies. 
An increasing number of studies use Nanostring® in solid organ transplant recipients, 
and recently Nanostring® released a commercially-available 770-gene expression panel in 
collaboration with the Banff community named the Banff-Human Organ Transplant (B-
HOT) panel28. We showed that the gene signature of biopsies with aTCMR was different 
compared with those without aTCMR with the Nanostring® assay (Chapter 5). These 
findings suggest that a logical next step is to investigate if gene expression differs between 
the different grades of aTCMR (including borderline aTCMR, isolated vascular lesions 
[aTCMR IIA] and mixed type rejections) and if these differ in frequently occurring disorders 
after kidney transplantation, such as CNI-related nephrotoxicity, BK virus nephropathy, 
pyelonephritis or recurrence of the primary kidney disease. This could aid in tailored 
therapeutic regimens resulting in improved renal allograft outcome.
A possible next step in the application of molecular diagnostics to kidney transplant biopsies 
could be to evaluate whether gene expression profiles can predict if a patient with aTCMR 
will respond to anti-rejection treatment and in this way guide therapy. This could lead 
to improved outcomes after aTCMR and prevent (unnecessary) side effects of the anti-
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rejection therapy. These gene profiles could then for example be integrated with clinical 
factors of patients who respond to alemtuzumab and result in a risk prediction score to 
evaluate which patients with a glucocorticoid-resistant, recurrent or severe acute rejection 
may benefit from alemtuzumab.
Minimally-invasive biomarkers of acute rejection
In our proof-of-concept study we identified a specific protein profile in serum of patients 
with aTCMR by the use of a targeted proteomic assay (Chapter 6). Several steps must 
be performed before this assay can be used as a reliable tool to screen for acute kidney 
transplant rejection. As described in the introduction of this thesis (Chapter 1), the 
standard-of-care therapy is a tacrolimus-based immunosuppressive regimen, and in our 
study we investigated serum taken form belatacept-treated patients. It is not expected that 
large differences between the two treatment groups exist, because the gene expression in 
the aTCMR biopsies was also similar between tacrolimus- and belatacept-treated patients 
(Chapter 5). Additionally, a larger number of patients need to be tested, and it would be 
of additional value to include other types of rejection. Our study analyzed a small patient 
cohort (n = 20) and only patients with aTCMR were included in our study. Influence of 
factors such as age, the severity of chronic kidney disease, the type of induction therapy 
and disorders with immune activation (auto-immune disease and infection) also need to 
be taken into consideration and investigated29-32.
The timing of the rejection is also an important aspect to consider. In our study, only 
patients with a rejection between three days and four months after transplantation were 
analyzed. Due to a limited number of samples, we could not investigate if the time after 
transplantation influenced the protein expression in the serum. Of interest, in a pilot study 
that we presented at a the Banff 2019 conference, the gene expression of three interferon-
γ-inducible chemokines (chemokine [C-X-C motif ] ligand 9 [CXCL9], CXCL10 and 
CXCL11) in aTCMR biopsies at different time points after transplantation were compared33. 
These three chemokines are important for the recruitment of T lymphocytes during kidney 
transplant rejection and are promising biomarkers to diagnose kidney transplant rejection. 
A significant difference was seen in the gene counts of these chemokines between early 
aTCMR (rejection in the first two weeks after transplantation) and late aTCMR (rejection 
after two weeks; Table 1)33. Additionally, these findings were strengthened through urine 
analysis on a different patient population, in which we also found a difference in these 
genes when comparing them in early and late rejection, These results seem to indicate a 
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different immunologic mechanism of rejection early after transplantation and warrants 
further investigation.
Table 1. Gene counts (median and interquartile range) of CXCL9, CXCL10 and CXCL11. 
Early aTCMR (n=6) Late aTCMR (n=9) No rejection (n=5)
CXCL9 4017 (2440-9822) 968 (638-2180)* 52 (11-194)**
CXCL10 6027 (2560-9181) 680 (439-1758)* 23 (13-147)**
CXCL11 3581 (2120-6802) 453 (204-1152)* 19 (13-55)**
*Significantly different (P<0.003) compared with early aTCMR. **Significantly different compared with early aTCMR 
(P<0.004) and late aTCMR (P<0.002)
We also found that certain proteins that are associated with acute rejection in other studies, 
such as IFN- g, CXCL9, CXCL10, CXCL11, granzyme B, and PD ligand 1, were not 
different between the sera of patients with and without aTCMR in our study (Chapter 
6)34-36. Two possible explanations for this are: i) rejection is a time-dependent process that 
involves immune activation, tissue injury and tissue repair and the protein expression may 
differ during these events and ii) rejections located in the tubulointerstitial space may show 
a different protein profile in the blood compared with rejections involving the arteries 
(aTCMR with vasculitis or ABMR). Perhaps this may also be the case for protein profiles 
in the urine of kidney transplant recipients.
A concluding remark is that thorough validation is necessary, for instance in a multi-
center setting, before this assay can be implemented into the routine clinical care of kidney 
transplant recipients.
Treatment of acute rejection
Alemtuzumab and rATG are both effective drugs to treat glucocorticoid-resistant, severe or 
recurrent acute kidney transplant rejections (both aTCMR and ABMR). The advantage of 
alemtuzumab above rATG is that alemtuzumab is associated with less severe infusion-related 
side effects (Chapter 8 and 9). In addition, rATG must in general be administered through a 
central venous catheter, while alemtuzumab is injected subcutaneously. Another advantage is 
that the length of hospitalization was 12 days shorter in patients treated with alemtuzumab. 
In the Erasmus MC, the costs for a day of hospitalization on an internal medicine ward are 
€ 700,-, and therefore € 8.400,- can be saved with alemtuzumab. Alemtuzumab is used off-
label in kidney transplant recipients and is free of charge via the Campath Access program37. 
The administration of alemtuzumab is therefore more cost-effective than rATG therapy. 
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The outcomes (infusion-related side effects and cost-effectiveness) may be different when a 
low-dose rATG regimen is administered.
A disadvantage of alemtuzumab treatment is that the depletion of T and B cells is much 
longer than after rATG therapy (Chapter 8 and 9). We found, rather surprisingly, that this 
does not cause an increased incidence of infections in the first year after T cell-depleting 
therapy. The infection-free survival in the first year after alemtuzumab was lower compared 
with rATG therapy (Chapter 9). The largest difference between the two groups was seen in 
the first few weeks after T cell-depletion therapy. Because the duration of hospitalization 
after rATG was longer than after alemtuzumab therapy, these patients were exposed to a 
higher risk of nosocomial infection. The influence of alemtuzumab on the immune system 
persists much longer than after rATG therapy. We do not know the consequence of this on 
the incidence of infections occurring more than one year after T cell-depleting therapy. The 
longer duration of T and B cell depletion after alemtuzumab therapy may cause an increased 
rate of secondary auto-immune diseases (Chapter 2, 10 and 11). Another disadvantage 
of alemtuzumab is that it is not indicated, approved or marketed for kidney transplant 
recipients. As described in Chapter 3, alemtuzumab is registered for the treatment of 
multiple sclerosis and through the Campath Access Program available for off-label use 
in other indications37. Therefore, the future of alemtuzumab in kidney transplantation 
is uncertain. Funding agencies are reluctant to fund studies that includes off-label use of 
drugs and this will limit further development of alemtuzumab as anti-rejection therapy. 
It is therefore unlikely that additional large studies, such as a randomized, controlled trial 
comparing alemtuzumab to rATG as anti-rejection therapy, will be performed anytime 
soon.
The depletion of T and B cells can be long-lasting (up to 36 months). In our study with 
alemtuzumab (Chapter 9), in only 55.7% of alemtuzumab-treated patients T cells 
repopulated above 200x106/L one year after therapy. Such a long and profound depletion 
may not be required to successfully treat acute rejection and may unnecessarily increase the 
risk of infection, malignancy and auto-immunity. The dose of alemtuzumab (a single dose 
of 30 mg) in kidney transplant recipients was based on the maximum dose used in patients 
with chronic lymphocytic leukemia. No dose-finding studies have been performed in kidney 
transplant recipients38. A lower dose of alemtuzumab for acute rejection could potentially 
lead to a shorter T- and B cell-depletion and fewer complications. In our study, the first 
14 patients were treated with alemtuzumab (30 mg) daily for two consecutive days (for a 
total of 60 mg). Since T cell-depletion already occurred after one dose of alemtuzumab, 
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the next patients received a single dose (30 mg). No difference in the allograft survival 
was seen between patients treated with either one or two injections with alemtuzumab 
(Hazard ratio 1.19, 95% confidence-interval 0.56-2.54, p = 0.65; Chapter 9). One study 
compared different dosages of alemtuzumab in kidney transplant patients39. Willicombe 
et al. compared induction therapy with a fixed dose alemtuzumab (30 mg) to a weight-
adjusted dose (0.4 mg/kg) 39. One year after therapy, a significant difference was observed 
in lymphocyte count (fixed dose 1.1x109/L [1.03-1.14] and weight-adjusted dose 1.27x109/L 
[1.17-1.38], p < 0.0001). Fewer episodes of urosepsis occurred in the weight-adjusted dose 
group (HR 1.38, 95%-CI 1.03-1.85, p = 0.037). However, the infection-free survival 
after one year was similar (fixed dose 63.8% and weight-adjusted dose 67.4%, p = 0.14)39. 
Although this study shows that an adjusted dose is associated with earlier lymphocyte 
repopulation, alemtuzumab dosing based on the bodyweight may still be suboptimal. In 
children undergoing hematopoietic stem cell transplantation, bodyweight-adjusted dosing 
of alemtuzumab leads to a highly variable exposure40. Recently, a pharmacokinetic model 
was published for individualized dosing in pediatric patients41. We believe that such a 
pharmacokinetic model also needs to be developed for kidney transplant recipients treated 
with alemtuzumab to determine the optimal dose and improve the clinical outcomes after 
alemtuzumab.
As described in Chapter 2, 10 and 11 alemtuzumab is associated with rare and sometimes 
fatal secondary auto-immune diseases, such as inflammatory polyneuropathy (Guillain-
Barré syndrome and chronic inflammatory demyelinating polyneuroradiculopathy) and 
acquired hemophilia A) that can occur even years after therapy and despite the repopulation 
of lymphocytes. Besides, alemtuzumab therapy exposes patients to a higher risk of 
(opportunistic) infections and malignancy. Because of these adverse events, alemtuzumab 
therapy for patient with multiple sclerosis is only available via the Risk Evaluation and 
Mitigation Strategy program in the United States42. This program informs health care 
professionals about the risks of alemtuzumab and an advice is included to monitor auto-
immune events until four years after treatment (Table 2). Besides, several patient support 
tools, including smartphone applications, are developed to educate patients and send 
reminders for doctor’s appointments and blood tests43.
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Table 2. Data derived from Lemtrada Risk Education and mitigation website42
Condition Activity Timing
Immune thrombocytopenia Complete blood count and 
differential
- Prior to treatment
- Monthly until 48 months after last infusion
Glomerular nephropathies, 
including anti-GBM disease
Urine protein to creatinine 
ratio
Prior to treatment
Serum creatinine - Prior to treatment
- Monthly until 48 months after last infusion
Urinalysis - Prior to treatment
- Monthly until 48 months after last infusion
Thyroid disorders Thyroid function tests - Prior to treatment
- Monthly until 48 months after last infusion
Autoimmune hepatitis Serum transaminases and 
total bilirubin
- Prior to treatment
- Monthly until 48 months after last infusion
Melanoma Skin examinations - Prior to treatment
- Yearly
As alemtuzumab is used off-label in kidney transplant recipients a safety monitoring program 
is not mandatory for this population. After the promising results of alemtuzumab as anti-
rejection therapy, the nephrologists in Erasmus MC continue to administer alemtuzumab 
in patients with glucocorticoid-resistant, severe or recurrent acute rejection. Since 2012 a 
total of 197 kidney transplant recipients have been treated with alemtuzumab for these types 
of acute rejection. Furthermore, alemtuzumab is also administered in the Erasmus MC as 
induction therapy in highly sensitized kidney transplant recipients and in patients with a 
blood group incompatible kidney transplantation. Although most of these above-mentioned 
tests are already implemented into the clinical care of kidney transplant recipients, the 
introduction of a prospective registry with a safety monitoring program in the Erasmus 
MC (to be expanded to a national scale) will lead to increased alertness for the occurrence 
of rare adverse events even long after therapy. An improved understanding of the risks of 
alemtuzumab in kidney transplant recipients is important to inform patients and balance 
the risks and benefits of this therapy in the future.
Conclusions and future perspectives
Kidney transplant rejection is complex clinical problem with long-lasting consequences for 
the patient. The focus of this thesis is optimization of the maintenance immunosuppressive 
therapy, diagnosis and treatment of kidney transplant rejection. The conclusions of this thesis 
are: i) belatacept remains a promising immunosuppressive drug for subgroups of kidney 
transplant recipients, for instance in patients with post-transplantation diabetes mellitus, but 
a more tailored strategy in the selection of kidney transplant recipients, treatment regimen 
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and post-conversion monitoring is necessary to expand the use, ii) novel applications, such 
as gene expression profiling of kidney transplant biopsies and a proteomic assay in the 
blood have the ability to improve the diagnosis of acute kidney transplant rejection, iii) 
alemtuzumab and rATG are both effective drugs to treat glucocorticoid-resistant, severe 
or recurrent acute kidney transplant rejections (both aTCMR and ABMR). The advantage 
of alemtuzumab above rATG is that alemtuzumab is associated with less severe infusion-
related side effects, a shorter hospital stay and lower costs, and iv) the use of alemtuzumab 
is associated with secondary auto-immune disorders, such as inflammatory polyneuropathy 
and acquired hemophilia A, and this risk may be higher compared with the use of rATG. 
The outstanding recommendations for future research are summarized in Table 3.
Table 3. Recommendations for future research
To identify kidney transplant recipients with a high risk for belatacept-resistant transplant rejection, for instance through serial 
testing of molecular or protein markers in peripheral blood and urine of belatacept-treated patients
To investigate if gene expression differs between the different grades of aTCMR and of frequently occurring kidney transplant 
diseases after kidney transplantation, in order to improve the accuracy of transplant rejection diagnosis and subsequent 
tailored treatment options
To evaluate if an integrated risk prediction score consisting of clinical variables and gene expression profiles of transplant 
biopsies can predict if a patient with aTCMR will respond to anti-rejection treatment
To investigate the following aspects of a targeted proteomic assay to diagnose kidney transplant rejection minimally-invasive:
• Inclusion of a larger number of kidney transplant recipients
• Patients treated with the current standard-of-care immunosuppressive therapy
• Influence of age, the severity of chronic kidney disease, type of induction therapy and disorders with immune activation
• The effect of time between transplantation and rejection on the protein expression of CXCL9, CXCL10 and CXCL11
• Test peripheral blood and urine
• Validation of the data in an independent cohort of patients and thereafter a prospective study
To conduct a randomized controlled trial comparing rATG to alemtuzumab for acute kidney transplant rejection
To implement a prospective registry with a safety monitoring program for kidney transplant recipients treated with 
alemtuzumab to screen for the occurrence of adverse events
To investigate the incidence, pathogenesis and risk factors of secondary auto-immune diseases after alemtuzumab therapy in 
kidney transplant recipients
To develop a pharmacokinetic model to determine the optimal dose of alemtuzumab in kidney transplant recipients
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De nieren zijn onmisbare organen en hebben veel functies, zoals het filteren van 
afvalstoffen uit het bloed, het regelen van de bloeddruk, het op peil houden van de vocht- 
en zouthuishouding, de productie van het hormoon erytropoëtine wat belangrijk is voor 
de aanmaak van rode bloedcellen, en ze spelen een belangrijke rol in de calcium en fosfaat 
stofwisseling. Indien de nieren zeer ernstig beschadigd zijn en hierdoor onvoldoende werken 
heet dit eindstadium nierfalen. Bij eindstadium nierfalen moet de nierfunctie kunstmatig 
worden overgenomen door een kunstnier en dit wordt ook wel dialyse genoemd. Dialyse 
heeft grote gevolgen voor het dagelijkse leven en veel patiënten ervaren een lage kwaliteit van 
leven; zij moeten vaak een streng dieet volgen, mogen niet te veel drinken, moeten vaak naar 
het ziekenhuis en hebben een lagere levensverwachting. Voor veel patiënten met eindstadium 
nierfalen is daarom een niertransplantatie de beste behandeling. Bij een niertransplantatie 
wordt een nier van een levende of overleden donor in het lichaam van de patiënt geplaatst. 
De donornier neemt dan alle functies van de oude nieren over.
Een nadeel van niertransplantatie is dat het immuunsysteem van de patiënt de nier als 
lichaamsvreemd herkent en de nier kan afstoten. Hierbij spelen humane anti-leukocyten 
antigenen (HLA) een belangrijke rol. Deze HLA-eiwitten zijn aanwezig op het oppervlak van 
elke kernhoudende cel van het menselijk lichaam. Elk individu heeft een unieke “barcode” 
van deze HLA-eiwitten, die genetisch is vastgelegd in het DNA. Het immuunsysteem is 
in de normale situatie belangrijk voor de bestrijding van infecties met micro-organismen 
(bijvoorbeeld virussen, bacteriën of parasieten) en bestaat uit verschillende typen cellen zoals 
antigeen-presenterende cellen, T- cellen, B cellen, macrofagen, monocyten, natural killer 
(NK) cellen en neutrofiele granulocyten. Antigeen-presenterende cellen nemen delen van het 
micro-organisme op en presenteren het HLA van het micro-organisme aan T en B cellen. 
Deze immuuncellen bevinden zich in de bloedbaan, organen, weefsels en lymfeklieren 
van de patiënt en na activatie gaan deze cellen naar de plaats van de infectie, bijvoorbeeld 
naar de longen, darmen, huid of urinewegen, of worden lokaal geactiveerd om aldaar de 
infectie te bestrijden. Na niertransplantatie herkennen de immuuncellen de HLA-eiwitten 
van de donornier als lichaamsvreemd. Dit leidt tot een activatie van de immuuncellen en 
vervolgens tot beschadiging van het transplantaat. Een afstoting van een niertransplantaat 
lijkt dus erg op de normale reactie van het immuunsysteem op een infectie.
Er bestaan twee typen afstoting van een niertransplantaat, namelijk T cel-gemedieerde 
afstoting en antilichaam-gemedieerde afstoting. Deze twee typen kunnen acuut of chronisch 
zijn en afzonderlijk maar ook tegelijk voorkomen. Bij een T cel-gemedieerde afstoting 
worden T cellen geactiveerd na herkenning van lichaamsvreemd HLA van de donornier. 
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Hierdoor wordt het niertransplantaat direct (via het uitscheiden van cytokines en enzymen) 
en indirect (via activatie van monocyten, NK cellen en macrofagen) aangevallen door de T 
cellen waardoor de cellen van de donornier beschadigen. Bij een antilichaam-gemedieerde 
afstoting ontwikkelen geactiveerde B cellen zich tot plasmacellen. Deze plasmacellen 
kunnen antilichamen maken die gericht zijn tegen de cellen van het niertransplantaat 
(zogenoemde donor-specifieke antilichamen). Binding van deze antilichamen aan de cellen 
zet een cascade van ontstekingseiwitten in gang die leidt tot schade van de donornier.
Om afstoting van een niertransplantaat te voorkomen is het noodzakelijk om levenslang 
medicatie (immunosuppressiva) te gebruiken die het immuunsysteem onderdrukken. Het 
gebruik van deze immunosuppressiva gaat gepaard met bijwerkingen. Ondanks het gebruik 
van deze combinatie van immunosuppressiva komt afstoting van een donornier nog voor 
in ruim een kwart van de niertransplantatiepatiënten. Afstoting kan een kortere overleving 
van de donornier en een lagere levensverwachting van de patiënt tot gevolg hebben. In dit 
proefschrift wordt onderzocht hoe de preventie, diagnostiek en behandeling van acute 
afstoting van het niertransplantaat geoptimaliseerd kunnen worden.
Preventie van afstoting van het niertransplantaat
De immunosuppressieve behandeling na een niertransplantaat bestaat uit inductietherapie 
en onderhoudstherapie. Inductietherapie wordt rondom de operatie toegediend. 
Onderhoudstherapie wordt direct na de operatie gestart en moet levenslang gecontinueerd 
worden. De huidige onderhoudstherapie bestaat uit een combinatie van de geneesmiddelen 
tacrolimus, mycofenolzuur en prednisolon. Met deze combinatie is de overleving van een 
niertransplantaat op korte termijn goed, maar op de lange termijn komen afstotingreacties 
nog altijd voor. Daarnaast ervaren patiënten veel bijwerkingen van deze geneesmiddelen 
zoals infecties, kanker, diabetes mellitus (“suikerziekte”), hypertensie (“hoge bloeddruk”) 
en paradoxaal genoeg nierschade. Daarom is er behoefte naar nieuwe immunosuppressieve 
geneesmiddelen met minder bijwerkingen en een betere (langetermijn) effectiviteit. 
Een veelbelovende groep medicijnen die in de toekomst een rol kan gaan spelen als 
immunosuppressiva zijn middelen die de interactie tussen T cellen en antigeen-presenterende 
cellen blokkeren, ook wel costimulatie blokkers genoemd.
In hoofdstuk 2 wordt een overzicht gegeven van de costimulatie blokkers die nu gebruikt 
worden in de kliniek of nog in ontwikkeling zijn. Belatacept is de costimulatie blokker die 
aan transplantatie patiënten wordt voorgeschreven. Dit medicijn blokkeert de interactie 
tussen de CD28 en CD80/86 (eiwitten op de celwand van respectievelijk T cellen en 
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antigeen-presenterende cellen). Het gebruik van belatacept leidt tot een betere nierfunctie 
en minder aanmaak van donor-specifieke antilichamen. Het nadeel is dat er meer acute 
afstotingen van de donornier voorkomen in vergelijking met tacrolimus. Een beter begrip 
van het achterliggende mechanisme van de verhoogde kans op afstoting is belangrijk 
om het gebruik van belatacept gerichter te kunnen voorschrijven. Optimaal zou zijn 
om patiënten met een laag risico op afstoting te behandelen met belatacept en patiënten 
met een hoog risico met tacrolimus. In hoofdstuk 5 is dit mechanisme onderzocht. 
Niertransplantaatbiopten met acute afstoting van patiënten die zijn behandeld met 
belatacept of tacrolimus werden vergeleken. We hebben de expressie van 209 genen gemeten 
en de depositie van 9 eiwitten beoordeeld in die biopten. Er was geen verschil tussen de 
beide groepen te zien. Dit impliceert dat het afstotingsproces na belatacept behandeling via 
een vergelijkbaar mechanisme verloopt als na tacrolimus behandeling.
Vervolgens hebben we onderzocht of het mogelijk was om te voorspellen welke patiënten een 
laag risico hebben op afstoting tijdens belatacept behandeling (hoofdstuk 6). We hebben 
daarvoor de aanwezigheid van 92 eiwitten onderzocht in het bloed van patiënten die geen 
afstoting ontwikkelden en patiënten die wél een afstoting ontwikkelden. Er werd geen 
verschil gevonden tussen de beide groepen. Concluderend is met deze analyse niet mogelijk 
om in te schatten wat het risico op afstoting is tijdens een behandeling met belatacept.
In hoofdstuk 2 wordt de huidige positie van belatacept als onderhoudsbehandeling 
na niertransplantatie beschreven. De conclusie van dit hoofdstuk is dat belatacept een 
veelbelovende therapie is voor een subgroep van patiënten, namelijk patiënten met een 
laag risico op afstoting en patiënten met een contra-indicatie voor tacrolimus (bijvoorbeeld 
een slecht ingestelde diabetes mellitus). In hoofdstuk 7 beschrijven we een patiënt die een 
ernstige ontregeling van diabetes mellitus en neurotoxiciteit (trillen van de handen) had 
na start van tacrolimus therapie. Na het stoppen van tacrolimus en starten van belatacept 
had de patiënt een forse verbetering van de regulatie van de diabetes mellitus en het trillen 
verdween.
Diagnostiek van acute afstoting
Een afstoting van een niertransplantaat kan momenteel alleen met een microscopische 
beoordeling van een nierbiopsie worden vastgesteld. Het nemen van een nierbiopsie heeft 
een aantal nadelen, namelijk i) het afnemen van een nierbiopt is een invasieve belastende 
procedure waarbij een patiënt moet worden opgenomen in het ziekenhuis en complicaties, 
zoals een bloeding, kunnen ontstaan, ii) het is een kostbare procedure en iii) interobserver 
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variabiliteit tussen pathologen die nierbiopten beoordelen komt voor. Momenteel worden 
er meerdere studies gedaan om de diagnostiek van afstoting te verbeteren, zoals moleculaire 
analyse van nierbiopten en minimaal invasieve testen in het bloed en urine van patiënten. 
Dit hebben we ook onderzocht in hoofdstuk 5 en 6.
We hebben een genexpressieanalyse verricht van nierbiopten met en zonder een acute T 
cel-gemedieerde afstoting (hoofdstuk 5). Van de 209 geteste genen kwamen 78 genen 
meer tot expressie in biopten met een acute T cel-gemedieerde afstoting. Ook werd gezien 
dat de genexpressieanalyse een toevoeging kan zijn aan de microscopische beoordeling van 
een nierbiopt bij ingewikkelde casuïstiek. Bijvoorbeeld, bij één patiënt liet het nierbiopt 
een afstoting zien, maar er waren klinisch geen aanwijzingen voor een afstoting (stabiele 
nierfunctie). Het genexpressieprofiel toonde hetzelfde profiel als van de patiënten zonder een 
afstoting. Deze patiënt werd niet behandeld voor afstoting en de nierfunctie bleef hetzelfde. 
De genexpressieanalyse kan in zulke casus dus bijdragen aan een verbeterde diagnostiek 
van acute T cel-gemedieerde afstoting.
In hoofdstuk 6 beschrijven we een minimaal-invasieve test om acute T cel-gemedieerde 
afstoting in het bloed van niertransplantatiepatiënten die behandeld zijn met belatacept 
vast te stellen. Analyse van 92 eiwitten toonde dat de concentratie van 5 eiwitten hoger 
was in het bloed van patiënten op het moment van een acute T cel-gemedieerde afstoting. 
Dit resultaat laat zien dat deze zogenaamde proteomic extensie analyse techniek een 
veelbelovende methode is om patiënten te screenen op het ontstaan van een acute afstoting 
middels onderzoek van het bloed. Een belangrijke kanttekening bij dit onderzoek is dat het 
een studie betrof met een beperkt aantal patiënten. De waarde van deze minimaal-invasieve 
test wordt momenteel verder onderzocht in een grotere groep patiënten die behandeld 
worden met tacrolimus.
Behandeling van een acute afstoting
Indien een acute afstoting van een niertransplantaat plaatsvindt worden patiënten veelal als 
eerste behandeld met een hoge dosis prednison. Bij een ernstige afstoting of een afstoting die 
niet verbetert na prednison wordt een behandeling met anti-thymocyten globuline (ATG) 
geadviseerd in de internationale richtlijn. ATG is een medicijn dat zorgt voor afbraak van 
T- en B cellen gedurende enkele maanden. De richtlijn is gebaseerd op studies van meer dan 
25 jaar geleden toen het immunosuppressieve schema na niertransplantatie nog niet bestond 
uit tacrolimus en mycofenolzuur. Het doel van de studie beschreven in hoofdstuk 8 was om 
de effectiviteit van ATG te onderzoeken in patiënten met een acute afstoting die behandeld 
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worden met tacrolimus en mycofenolzuur. ATG blijkt een effectieve therapie te zijn bij een 
ernstige afstoting of een acute afstoting die niet verbetert na hoge dosering prednison in 
patiënten behandeld met tacrolimus en mycofenolzuur. Het was voornamelijk effectief in 
patiënten met een acute afstoting die binnen 1 maand na niertransplantatie plaatsvindt. Er 
waren wel frequente (ernstige) infusie-gerelateerde bijwerkingen na het gebruik van ATG.
Alemtuzumab is een ander medicijn wat zorgt voor afbraak van T- cellen en B cellen. 
Deze therapie is geregistreerd voor patiënten met multiple sclerose (een ziekte van het 
centraal zenuwstelsel) en wordt buiten deze indicatie gebruikt in niertransplantatiepatiënten 
als inductie- en anti-afstotingstherapie. In hoofdstuk 3 wordt een overzicht gegeven 
van de literatuur over het gebruik van alemtuzumab in niertransplantatiepatiënten. In 
het Erasmus MC worden sinds 2012 patiënten met een ernstige acute afstoting of een 
afstoting die niet verbetert na hoge dosering prednison behandeld met alemtuzumab. We 
hebben de uitkomsten van deze patiënten geanalyseerd en vergeleken met de hierboven 
beschreven uitkomsten van patiënten die met ATG werden behandeld. De patiënten- 
en niertransplantaat overleving bleek hetzelfde in beiden groepen. Het gebruik van 
alemtuzumab lijkt echter tot minder infusie-gerelateerde bijwerkingen en minder infecties 
te leiden in vergelijking met ATG. Bovendien was de duur van opname in het ziekenhuis 
van de met alemtuzumab behandelde patiënten 12 dagen korter dan die van de patiënten 
die ATG kregen voorgeschreven.
Het gebruik van alemtuzumab heeft dus voordelen ten opzichte van het gebruik van 
ATG. Een belangrijk nadeel is dat de toediening van alemtuzumab auto-immuunziekten 
kan veroorzaken, zoals schildklierziektes en immuun trombocytopenische purpura (ITP, 
een pathologische afbraak van bloedplaatjes). Dit hebben we ook gezien in de patiënten 
behandeld met alemtuzumab in het Erasmus MC. Drie patiënten ontwikkelden een zeldzame 
vorm van een inflammatoire polyneuropathie (Guillain-Barré syndroom en chronische 
inflammatoire demyeliniserende polyneuroradiculopathie) na alemtuzumab (hoofdstuk 
10). Verder kregen twee patiënten een verworven hemofilie A (bloedstollingsziekte) na 
toediening van alemtuzumab (hoofdstuk 11). Alemtuzumab heeft mogelijk een rol gespeeld 
in het ontstaan van deze auto-immuunziekten. Het is daarom belangrijk om alert te zijn op 
zeldzame bijwerkingen bij patiënten die behandeld zijn met alemtuzumab.
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CONCLUSIE
Acute niertransplantaat afstoting is een complex probleem met nadelige gevolgen voor de 
patiënt. Verbetering van de preventie, diagnostiek en behandeling van deze complicatie 
leidt tot een verbetering van de niertransplantaat- en patiënt overleving. De belangrijkste 
conclusies van dit proefschrift zijn: i) belatacept is een veelbelovend immunosuppressief 
geneesmiddel voor subgroepen van niertransplantaat patiënten, bijvoorbeeld patiënten met 
een contra-indicatie voor tacrolimus, ii) nieuwe technieken zoals genexpressie analyse van 
nierbiopten of eiwit analyse in het bloed, kunnen leiden tot een verbeterde diagnostiek van acute 
niertransplantaat afstoting, en iii) alemtuzumab en ATG zijn beiden effectieve geneesmiddelen 
om een ernstige of glucocorticoïd-resistente acute afstoting van een niertransplantaat te 
behandelen. Behandeling met alemtuzumab leidt tot minder infusie-gerelateerde bijwerkingen, 
een kortere opname in het ziekenhuis en lagere kosten in vergelijking met ATG maar tot meer 
auto-immuunziekten zoals inflammatoire polyneuropathie en verworven hemofilie. Mijn 
aanbevelingen voor toekomstig onderzoek zijn: 
1) Het optimaliseren van de genexpressie en eiwit analyse zoals onderzocht in dit proefschrift. 
De resultaten zoals beschreven in dit proefschrift dienen te worden gevalideerd in grotere 
groepen niertransplantatiepatiënten met verschillende types van afstoting. Validatie in 
andere groepen van orgaan transplantaatontvangers (anders dan een nier) is m.i. eveneens 
een vereiste alvorens deze technieken klinisch kunnen worden ingezet.
2) Het bijhouden van de uitkomsten en bijwerkingen na behandeling met alemtuzumab 
in een patiëntenregistratie. De ernstige, auto-immuun bijwerkingen van alemtuzumab zijn 
zeldzaam en het is niet precies duidelijk hoe vaak deze voorkomen en welke patiënten het 
meeste risico lopen. Een (landelijke) registratie van deze bijwerkingen zou hier meer inzicht 
in kunnen geven.
3) Het vaststellen van de meest optimale dosering van alemtuzumab. De huidige dosering 
van 30 mg subcutaan is gebaseerd op data uit de hematologie. Gezien de langdurige 
leukopenie is het denkbaar dat een lagere dosis wellicht net zo effectief is maar met minder 
bijwerkingen gepaard gaat. Een dose-finding studie zou hier antwoord op kunnen geven. 13
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LIST OF ABBREVIATIONS
3C study calcineurin, campath and chronic allograft nephropathy study
aABMR active ABMR
ABMR antibody-mediated rejection
ACR acute cellular rejection
aIRR adjusted incidence rate ratio
AHA acquired hemophilia A
Akt AKT8 virus oncogene cellular homolog
APCs antigen-presenting cells
aPTT activated partial thromboplastin time
AR acute kidney transplant rejection
aTCMR acute T cell-mediated rejection
AUC area under the curve
BAFF B- lymphocyte activating factor
b-aTCMR borderline aTCMR
BENEFIT Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression
BENEFIT-EXT BENEFIT-extended criteria donors
BPAR biopsy proven acute rejection
BU Bethesda Units
C0 pre-dose concentration
C4d complement 4d
c-aABMR chronic-active ABMR
CARE-MS comparison of alemtuzumab and Rebif ® efficacy
c-aTMCR chronic-active TCMR
CI confidence interval
CIDP chronic inflammatory demyelinating polyradiculoneuropathy
CKD chronic kidney disease
CKD–EPI chronic kidney disease Epidemiology Collaboration
CLL chronic lymphocytic leukemia
Cmax maximum concentration
CMV cytomegalovirus
CNI calcineurin inhibitor
CXCL chemokine (C-X-C motif ) ligand
CsA cyclosporin A
CTLA cytotoxic T lymphocyte antigen
DEG differentially expressed gene
DGF delayed graft function
DNA deoxyribonucleic acid
DM diabetes mellitus
DSA donor-specific anti-HLA antibodies
EBV Epstein-Barr virus
eGFR estimated glomerular filtration rate
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EMA European Medicines Agency
ESRD end-stage renal disease
ERK1/2 extracellular signal-Regulated Kinases 1 and 2
FVIII:C factor VIII coagulation activity
FDR false Discovery Rate
FDRPV false Discovery Rate p-value
Fc crystallizable fragment
FCγR IgG fragment C receptor
FDA United States Food and Drug Administration
FFPE formalin-fixed paraffin-embedded
FoxP3 forkhead box P3
GBS Guillain-Barré syndrome
HbA1c glycated hemoglobin
HCA hierarchical clustering analysis
HLA human leucocyte antigens
HR hazard ratio
ICOS inducible T cell costimulator
IFNγ interferon gamma
i-IF/TA inflammation in areas with interstitial fibrosis and tubular atrophy
Ig immunoglobulin
IgG1 immunoglobulin G1
IHC immunohistochemistry
IL interleukin
IQR interquartile range
IU international units
IVIg intravenous immunoglobulins
JAK Janus kinase
KDIGO Kidney Disease: Improving Global Outcomes
KTR kidney transplant recipients
LFA-3 lymphocyte function-associated antigen 3
MAPK mitogen-activated protein kinase
MMF mycophenolate mofetil
MPA mycophenolic acid
mRNA messenger ribosomal nucleic acid
MS multiple sclerosis
mTOR mammalian target of rapamycin inhibitors
NCR1 natural cytotoxicity triggering receptor 1
NK natural killer
NPX normalized protein expression
PCR polymerase chain reaction
PD-1 programmed death-1
PEA proximity extension immunoassay
PNF primary non-function
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PRA panel reactive antibodies
PTDM post-transplant diabetes mellitus
PTLD post-transplant lymphoproliferative disease
SLAM signaling lymphocytic activation molecule;
rATG rabbit anti-thymocyte globulin
RCT randomized controlled trial
RR relative risk
RRMS relapsing remitting multiple sclerosis
SPKT simultaneous pancreas-kidney transplantation
SOT solid organ transplantation
TAC tacrolimus
TCR T cell receptor
TIM T cell/transmembrane, immunoglobulin, and mucin
TNF tumor necrosis factor
TNFRSF TNF receptor superfamily
Treg regulatory T cells
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Memberships
Nederlandse Transplantatie Vereniging (NTV)
The European Society of Organ Transplantation (ESOT)
The Transplantation Society (TTS)
Nederlandse Internisten Vereniging
Nederlandse Federatie voor Nefrologie
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DANKWOORD
Nog geen vier jaar geleden deed zich de mogelijkheid voor om mijn opleiding tot nefroloog 
te onderbreken om een promotie onderzoek te doen. Met beide handen heb ik deze mooie 
kans aangepakt en ik ben erg trots op het resultaat. Graag wil ik op deze laatste pagina’s 
iedereen bedanken die heeft bijgedragen aan de totstandkoming van dit proefschrift.
Prof. Dr. C.C. Baan, beste Carla, ik ben je zeer dankbaar voor je begeleiding en steun de 
afgelopen jaren. Ik heb veel geleerd van jouw gedrevenheid, wetenschappelijke kwaliteiten, 
enthousiasme, en directheid. Al in een vroeg stadium gaf jij mij de vrijheid en het vertrouwen 
om mijn eigen weg in te slaan. Naast de wetenschappelijke discussies denk ik met veel plezier 
terug aan de vele gesprekken die wij hadden over (nieuwe) restaurants in Rotterdam, sporten 
en vakanties. Ik heb grote bewondering voor hoe je het transplantatielab runt en ik wens 
je veel succes met alle toekomstige onderzoeken.
Dr. D.A. Hesselink, beste Dennis, ik ben je zoveel dank verschuldigd voor de beslissing om 
voor mij een promotietraject te organiseren. Vijf jaar geleden vroeg je of ik geïnteresseerd 
was om klinische data op te zoeken van patiënten die met alemtuzumab behandeld waren. 
Na een paar maanden vroeg je mij een ‘koffietje’ te doen. Ik was bang dat je vond dat ik 
te weinig opgezocht had, maar tot mijn grote verbazing vroeg je mij of ik er een promotie-
traject van wilde maken. Je bent een zeer begaafde en pragmatische arts en onderzoeker. 
Dit proefschrift zou er niet zijn zonder jou. Je altijd scherpe blik, klinische kennis, precisie, 
geduld, langetermijnvisie en talent om alles korter en bondiger te verwoorden waren 
onmisbaar voor mij. Ik wens jou veel geluk in de toekomst op de werkvloer en natuurlijk 
thuis.
Dr. M.C. Clahsen-van Groningen, beste Marian, jouw optimisme, doortastendheid en 
onvermoeibaarheid werken aanstekelijk en hebben een mooie nefropathologische touch 
aan dit proefschrift gegeven. Je maakte altijd tijd om onder het genot van een cappuccino 
samen resultaten en (toekomst)plannen door te nemen. Ik vond het geweldig om samen de 
nefropathologie cursus in New York te bezoeken en later de ISN RenPath Quickcase samen 
te presenteren. Ik heb veel respect voor de manier waarop je werk met thuis combineert. 
Dank voor al je hulp en goede ideeën!
De leden van de kleine commissie, Prof. dr. T. van Gelder, Prof. dr. M.E.J. Reinders en Prof. 
dr. M. Naesens dank ik voor het kritisch lezen en beoordelen van het manuscript en het 
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deelnemen aan de oppositie. Daarnaast wil ik Prof. Dr. B.C. Jacobs en Prof Dr. R. Zietse 
bedanken voor hun bereidheid om zitting te nemen en aanwezig te zijn bij de promotie 
voor de inhoudelijke verdediging van het proefschrift. Ich möchte Dr. J.U. Beckers für die 
Teilnahme am Promotionsausschuss danken.
Mijn paranimfen, Hiske en Eefje, ik vind het super fijn dat jullie tijdens mijn verdediging 
achter mij willen staan. Als goede vriendinnen met ook een medische achtergrond, inclusief 
immunologische kennis over alemtuzumab (Eefje), kan er niets meer misgaan! Bedankt 
voor jullie hulp, maar ook voor de gezellige en sportieve uitjes met en zonder de kinderen.
Alle coauteurs wil ik bedanken voor de feedback op de onderzoeksvoorstellen en 
manuscripten. Dankzij alle waardevolle kritieken zijn de artikelen sterk verbeterd. I thank 
all coauthors for the collaboration and the solid comments that have greatly improved the 
manuscripts.
Beste (oud) collega’s van het transplantatielab, toen kwam er weer een dokter op het 
lab die niet zoveel had met pipetteren. Toch werd ik warm ontvangen en geduldig 
ingewerkt bij onder andere het ficollen. Jullie zijn een grote groep vol met enthousiaste 
en uiteenlopende persoonlijkheden. Ik heb een erg leuke tijd gehad met jullie. Bedankt 
voor alle wetenschappelijke input, gezelligheid, interesse, fijne gesprekken tijdens de lunch, 
borrels, etentjes, tenniswedstrijdjes (sorry Hector, Amy and Daphne, you will never win), en 
koffiemomenten de afgelopen jaren. Speciaal wil ik team Bela bedanken, Gretchen, Rens, 
Kitty, Marjolein, en Nynke. Ik sloot pas later aan bij de maandagmorgenbesprekingen, 
maar ik heb veel van jullie geleerd over alle mooie onderzoeksresultaten en discussies. Door 
al jullie inspanning om patiënten te includeren en materialen te verzamelen ben ik op een 
rijdende trein gesprongen en daar wil ik jullie ontzettend voor bedanken! Ik wens iedereen 
veel succes en geluk in de toekomst en wie weet kruisen onze paden nog wel een keer. For 
the non-Dutch speaking colleagues of the transplantation lab: Thank you all for the great 
support and happy moments. I wish you all the best in future with your careers.
Alle internist-nefrologen van het Erasmus MC wil ik bedanken voor hun hulp. Zonder 
jullie hulp waren deze klinische studies niet mogelijk geweest. In het bijzonder, Prof. Dr. 
R. Zietse, beste Bob, ik ben je dankbaar voor de leerzame opleiding nefrologie en de 
mogelijkheid om mijn opleiding te onderbreken om dit promotie onderzoek te doen. Verder 
waardeer ik het dat je mij de kans geeft om als chef de clinique aan de slag te gaan in het 
Erasmus MC.
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De (oud) NIO collega’s, bedankt voor de jullie collegialiteit, gezelligheid, het sparren met 
elkaar over ingewikkelde nefrologische casussen en aanhoren van frustraties.
Alle data managers en research nurses van de nefrologie wil ik bedanken voor hun hulp. 
Judith, als ik weer eens met een vraag kwam, vooral bij revisies van artikelen, had jij binnen 
de kortste tijd alweer een mooie database met gegevens voor mij tevoorschijn getoverd. 
Daardoor kon ik altijd weer snel verder en bleef het tempo hoog!
Collega’s van de pathologieafdeling, vooral Malou en Thierry, het was altijd fijn om met 
jullie samen te werken. Malou, ik vind het bijzonder dat wij precies tegelijk begonnen zijn 
met het promotietraject met dezelfde copromotoren en ook vlak na elkaar het proefschrift 
zullen verdedigen. Ik vond onze uitstapjes naar de winterschool van de Nierstichting en 
de nefropathologie cursus erg gezellig. Veel succes met je verdediging en je carrière als 
patholoog. Thierry, bedankt dat je altijd zo snel voor mij klaarstond om te helpen bij de 
kleuringen en inscannen van de coupes!
Al mijn lieve vrienden wil ik bedanken voor alle interesse, vriendschap, gezelligheid en 
afleiding buiten het werk om.
Mama en papa, jullie hebben ons laten opgroeien in een warm nest waar we onze eigen 
gang konden gaan. Jullie hebben ervoor gezorgd dat altijd alles mogelijk was en nog steeds 
staan jullie altijd voor ons klaar (inclusief voor Lieke en Julia). Mama, je hebt geen medische 
opleiding gedaan maar als je in een andere tijd was geboren was je vast en zeker dokter 
/ wetenschapper geworden. Als er een artikel van mij werd geaccepteerd voor publicatie 
stuurde ik het altijd meteen naar je op. De volgende dag kon ik dan een paar interessante 
vragen terugverwachten waaruit bleek dat je de essentie van het artikel echt had begrepen. 
Ook heb je geholpen met de Nederlandse samenvatting waardoor het stuk verbeterd is. Papa, 
je had het niet altijd makkelijk om met vier studerende familieleden aan de keukentafel te 
zitten, maar je verweerde je altijd kranig. Jouw befaamde uitspraak ‘Je kan wel gestudeerd 
hebben, maar dan hoef je nog niet slim te zijn’ heb ik dan ook bijna toegevoegd als stelling 
bij dit proefschrift. Bedankt voor jullie alle liefde en steun!
Nelleke en Jasper, jullie zijn een lieve zus en broer. Vroeger waren wij steevast te vinden 
op de tennisbaan en tegenwoordig hebben wij veel gezellige etentjes, spelletjesavonden en 
uitjes. Bedankt voor de vanzelfsprekendheid waarmee jullie mij altijd met raad en daad 
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bijstaan en meeleven met alle belangrijke en minder belangrijke momenten in mijn leven. 
Geraldine, wat fijn dat ik jou binnenkort mijn schoonzus kan noemen!
Schoonfamilie, bedankt voor alle support, belangstelling en afleiding. In het bijzonder wil 
ik Maria noemen. Bedankt dat je altijd voor ons klaar staat en voor de talloze oppasuurtjes. 
Elke week kom je naar ons toe om voor Lieke en Julia te zorgen. Je bent een lieve en 
zorgzame schoonmoeder en oma!
Lieve Lieke en Julia, mijn grote kleine meid en mijn kleine boef, jullie brengen mij zoveel 
liefde en geluk. Jullie zijn allebei geboren tijdens mijn promotieonderzoek. Door jullie 
komst heb ik mijn werk leren relativeren. Als je na een lange werkdag thuiskomt en er staat 
een prinses in blauwe jurk ‘Let it go’ te zingen, dan kan je daadwerkelijk alle stress direct 
laten gaan. Ik ben trots op jullie!
Als laatste wil ik Maarten natuurlijk bedanken. Zonder jouw vertrouwen, steun en 
onvoorwaardelijke liefde was ik niet zover gekomen. Ik hoorde je nooit klagen als ik weer 
eens ’s avonds de laptop pakte om te gaan typen. Wij zijn samen een team en ik heb nooit 
het gevoel dat ik er alleen voor sta. Ik hou van jou!
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